0001628280-19-006594.txt : 20190510 0001628280-19-006594.hdr.sgml : 20190510 20190510172836 ACCESSION NUMBER: 0001628280-19-006594 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 19816164 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-Q 1 gh-03312019x10q.htm 10-Q Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________
FORM 10-Q
_____________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2019
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                        to                        
Commission File Number: 001-38683
_____________________
GUARDANT HEALTH, INC.
(Exact Name of Registrant as Specified in its Charter)
_____________________
Delaware
 
45-4139254
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
505 Penobscot Dr.
Redwood City, California
 
94063
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (855) 698-8887
_______________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  o    No  x
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
o
Accelerated filer
o
 
 
 
 
Non-accelerated filer
x  (Do not check if a smaller reporting company)
Smaller reporting company
o
 
 
 
 
Emerging growth company
x
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x

Securities registered pursuant to Section 12(b) of the Act:




Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001
GH
  The Nasdaq Stock Market LLC

As of May 7, 2019, the registrant had 87,112,669 shares of common stock, $0.00001 par value per share, outstanding.
 




GUARDANT HEALTH, INC.
FORM 10-Q
TABLE OF CONTENTS
 
 
 
 
Page
Unaudited Condensed Consolidated Financial Statements
 
Condensed Consolidated Balance Sheets
 
Condensed Consolidated Statements of Operations
 
Condensed Consolidated Statements of Comprehensive Loss
 
Condensed Consolidated Statements of Noncontrolling Interest and Stockholders’ Equity
 
Condensed Consolidated Statements of Cash Flows
 
Notes to the Unaudited Condensed Consolidated Financial Statements
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Controls and Procedures
 
 
 
 
 
 
 
 
 

FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including the section titled “Managements Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections about our business, our results of operations, the industry in which we operate and the beliefs and assumptions of our management. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “would,” “could,” “should,” “intend” and “expect,” variations of these words, and similar expressions are intended to identify forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,“Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2018, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.

Each of the terms the “Company,” “we,” “our,” “us” and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated. 





PART I—FINANCIAL INFORMATION
Item 1. Unaudited Condensed Consolidated Financial Statements
Guardant Health, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share data)
 
March 31, 2019
 
December 31, 2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
153,790

 
$
140,544

Short-term marketable securities
313,069

 
278,417

Accounts receivable
28,989

 
35,690

Inventory
10,256

 
9,136

Prepaid expenses and other current assets
6,151

 
5,204

Total current assets
512,255

 
468,991

Long-term marketable securities
25,916

 
77,563

Property and equipment, net
30,581

 
31,003

Capitalized license fees
7,557

 
7,800

Other assets
2,862

 
2,046

Total Assets(1)
$
579,171

 
$
587,403

LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
7,163

 
$
10,642

Accrued compensation
14,683

 
12,986

Accrued expenses
9,137

 
7,081

Capital lease, current
96

 
97

Deferred revenue
17,113

 
16,138

Total current liabilities
48,192

 
46,944

Capital lease, net of current portion
100

 
119

Deferred rent, net of current portion
8,975

 
7,844

Obligation related to royalty
7,120

 
7,338

Other long-term liabilities
150

 
206

Total Liabilities(1)
64,537

 
62,451

Commitments and contingencies (Note 7)


 


Redeemable noncontrolling interest
46,500

 
41,800

Stockholders’ equity:
 
 
 
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 86,098,474 and 85,832,454 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively
1

 
1

Additional paid-in capital
771,009

 
764,033

Accumulated other comprehensive loss
333

 
(83
)
Accumulated deficit
(303,209
)
 
(280,799
)
Total Stockholders’ Equity
468,134

 
483,152

Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity
$
579,171

 
$
587,403





(1) As of March 31, 2019 and December 31, 2018, includes $47.0 million and $48.3 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $942,000 and $1.2 million of liabilities of the consolidated VIE and VIE’s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See Note 3.
The accompanying notes are an integral part of these condensed consolidated financial statements.

5


Guardant Health, Inc.
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
Revenue:
 
 
 
 
Precision oncology testing
 
$
28,837

 
$
14,191

Development services
 
7,818

 
2,501

Total revenue
 
36,655

 
16,692

Costs and operating expenses:
 
 
 
 
Cost of precision oncology testing
 
11,023

 
8,045

Cost of development services
 
2,512

 
1,208

Research and development expense
 
16,316

 
8,255

Sales and marketing expense
 
17,807

 
11,312

General and administrative expense
 
12,661

 
6,519

Total costs and operating expenses
 
60,319

 
35,339

Loss from operations
 
(23,664
)
 
(18,647
)
Interest income
 
2,485

 
985

Interest expense
 
(293
)
 
(331
)
Other income (expense), net
 
147

 
4,149

Loss before provision for income taxes
 
(21,325
)
 
(13,844
)
Provision for income taxes
 
26

 

Net loss
 
(21,351
)
 
(13,844
)
Fair value adjustment of redeemable noncontrolling interest
 
(4,700
)
 

Net loss attributable to Guardant Health, Inc. common stockholders
 
$
(26,051
)
 
$
(13,844
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.30
)
 
$
(1.16
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
85,935

 
11,920

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


Guardant Health, Inc.
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
(in thousands)
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
Net loss
 
$
(21,351
)
 
$
(13,844
)
Other comprehensive income (loss), net of tax impact:
 
 
 
 
Unrealized gain (loss) on available-for-sale securities
 
485
 
(298
)
Foreign currency translation adjustments
 
(69)
 

Other comprehensive income (loss)
 
416
 
(298)
Comprehensive loss
 
$
(20,935
)
 
$
(14,142
)
Comprehensive loss attributable to redeemable noncontrolling interest
 
(4,700
)
 

Comprehensive loss attributable to Guardant Health, Inc.
 
$
(25,635
)
 
$
(14,142
)
The accompanying notes are an integral part of these condensed consolidated financial statements.

7


Guardant Health, Inc.

Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity (unaudited)
(in thousands, except share data)
 
Redeemable Noncontrolling Interest

 
Common Stock 
 
 
Additional
Paid-in
Capital

 
Accumulated
Other
Comprehensive Loss

 
 
Accumulated
Deficit

 
Total Stockholders’ Equity

 
 
Shares

 
Amount

 
Balance as of December 31, 2018
$
41,800

 
85,832,454

 
$
1

 
$
764,033

 
$
(83
)
 
$
(280,799
)
 
$
483,152

Cumulative effect adjustment for Topic 606 adoption

 

 

 

 

 
4,907

 
4,907

Cumulative effect adjustment for ASU 2018-07 adoption

 

 

 
1,266

 

 
(1,266
)
 

Issuance of common stock upon exercise of stock options

 
146,318

 

 
538

 

 

 
538

Vesting of common stock exercised early

 

 

 
56

 

 

 
56

Common stock issued under employee stock purchase plan

 
119,702

 

 
1,933

 

 

 
1,933

Stock-based compensation

 

 

 
3,183

 

 

 
3,183

Fair value adjustment of redeemable noncontrolling interest
4,700

 

 

 

 

 
(4,700
)
 
(4,700
)
Other comprehensive gain, net of tax impact

 

 

 

 
416

 

 
416

Net loss

 

 

 

 

 
(21,351
)
 
(21,351
)
Balance as of March 31, 2019
$
46,500

 
86,098,474

 
$
1

 
$
771,009

 
$
333

 
$
(303,209
)
 
$
468,134

 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
Convertible
Preferred Stock 
 
 
Common Stock 
 
 
Additional
Paid-in
Capital

 
Accumulated
Other
Comprehensive Loss

 
 
Accumulated
Deficit

 
Total Stockholders’ Equity

 
Shares

 
Amount

 
Shares

 
Amount

 
Balance as of December 31, 2017
78,627,369

 
$
499,974

 
11,896,882

 
$

 
$
4,900

 
$
(532
)
 
$
(195,736
)
 
$
308,606

Issuance of common stock upon exercise of stock options

 

 
421,264

 

 
1,103

 

 

 
1,103

Issuance of common stock upon early exercise of stock options

 

 
44,268

 

 

 

 

 

Issuance of common stock upon exercise of warrants

 

 
31,713

 

 
4

 

 

 
4

Stock-based compensation

 

 

 

 
1,277

 

 

 
1,277

Other comprehensive loss, net of tax impact

 

 

 

 

 
(298
)
 

 
(298
)
Net loss

 

 

 

 

 

 
(13,844
)
 
(13,844
)
Balance as of March 31, 2018
78,627,369

 
$
499,974

 
12,394,127

 
$

 
$
7,284

 
$
(830
)
 
$
(209,580
)
 
$
296,848

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

8


Guardant Health, Inc.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
 
Three Months Ended March 31,
 
2019
 
2018
 
 
 
 
OPERATING ACTIVITIES:
 
Net loss
$
(21,351
)
 
$
(13,844
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
2,354

 
1,395

Unrealized translation (gains) losses on obligation related to royalty
(144
)
 
206

Non-cash stock-based compensation
3,182

 
1,277

Non-cash interest expense

 
(3
)
Amortization of discounts on marketable securities
(553
)
 
(78
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
11,608

 
623

Inventory
(1,120
)
 
321

Prepaid expenses and other current assets
(947
)
 
(1,312
)
Other assets
(833
)
 
255

Accounts payable
(2,610
)
 
1,989

Accrued compensation
1,697

 
(608
)
Accrued expenses and other current liabilities
2,308

 
1,108

Deferred rent
1,131

 
621

Deferred revenue
975

 
1,491

Net cash used in operating activities
(4,303
)
 
(6,559
)
 
 
 
 
INVESTING ACTIVITIES:
 
 
 
Purchase of marketable securities
(45,966
)
 
(19,634
)
Maturity of marketable securities
64,000

 
32,125

Purchase of property and equipment
(2,705
)
 
(4,021
)
Net cash provided by investing activities
15,329

 
8,470

 
 
 
 
FINANCING ACTIVITIES:
 
 
 
Payments made on royalty obligations
(73
)
 

Payments made on capital lease obligations
(21
)
 
(47
)
Proceeds from issuance of common stock upon exercise of stock options
538

 
1,310

Proceeds from issuance of common stock upon the exercise of warrants

 
4

Proceeds from issuances of common stock under employee stock purchase plan
1,933

 

Payment of offering costs related to initial public offering
(89
)
 

Net cash provided by financing activities
2,288

 
1,267

Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash
(69
)
 

Net increase in cash, cash equivalents and restricted cash
13,245

 
3,178

Cash, cash equivalents and restricted cash - Beginning of period
140,544

 
72,596

Cash, cash equivalents and restricted cash - End of period
$
153,789

 
$
75,774

Supplemental Disclosures of Cash Flow Information:
 
 
 
Cash paid for interest
$
293

 
$
30

Cash paid for income taxes
$
(48
)
 
$


9


Supplemental Disclosures of Noncash Investing and Financing Activities:
 
 
 
Purchases of property and equipment included in accounts payable and accrued expenses
$
490

 
$
3,351

The accompanying notes are an integral part of these condensed consolidated financial statements.

10


 Guardant Health, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
1.
Description of Business
Guardant Health, Inc. (the “Company”) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company’s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, it has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR early detection program to address the needs of early stage cancer patients with adjuvant treatment selection, cancer survivors with surveillance and asymptomatic individuals with screening.
The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the “Joint Venture”) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a 50% ownership interest in the Joint Venture. As of March 31, 2019, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3).
Reverse Stock Split
In September 2018, the Company’s Board of Directors and its stockholders approved a 0.7378-for-one reverse stock split of the Company’s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company's initial public offering (the “IPO”). All share and per share amounts in the accompanying condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to this reverse stock split.
2.
Summary of Significant Accounting Policies
Basis of Presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders’ interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.
The Company believes that its existing cash and cash equivalents and marketable securities as of March 31, 2019 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. If the Company’s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of

11


future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Unaudited Interim Condensed Financial Statements
The accompanying condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2019 and 2018, and cash flows for the three months ended March 31, 2019 and 2018, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.
The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
JOBS Act Accounting Election
The Company is an “emerging growth company” within the meaning of the Jumpstart Our Business Act of 2012 (the “JOBS Act”). Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. The Company has elected to use this extended transition period and, as a result, the consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company also intends to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.
Foreign Currency Translation
The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the three months ended March 31, 2019, foreign currency translation adjustment was immaterial.
Cash and Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less. Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.
Restricted cash consists of deposits related to the Company’s corporate credit card. Restricted cash balance was included in other assets in the accompanying condensed consolidated balance sheet, and was immaterial as of March 31, 2019 and December 31, 2018.
Concentration of Risk
The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.

12


The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.
The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.
Significant customers are those which represent more than 10% of the Company’s total revenue or accounts receivable balance at each respective condensed consolidated balance sheet date. For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:
 
 
Revenue
 
Accounts Receivable
 
 
Three Months Ended March 31,
 
March 31, 2019
 
December 31, 2018
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
(unaudited)
 
(unaudited)
 
 
Customer A
 
*

 
11
%
 
*

 
*

Customer B
 
24
%
 
*

 
35
%
 
65
%
Customer C
 
*

 
13
%
 
*

 
*

Customer D
 
*

 
*

 
13
%
 
*

*
less than 10%
Accounts Receivable
Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. Accounts receivable are written off when management determines a balance is uncollectible and no longer intends to actively pursue collection of the receivable. For the three months ended March 31, 2019 and 2018, the Company did not write off any material accounts receivable.
Upon the adoption of ASC 606 on January 1, 2019, contract assets are reported as part of accounts receivable on the condensed consolidated balance sheets and are discussed in "unbilled receivables".
Revenue Recognition
The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.
Effective January 1, 2019, the Company began recognizing revenue in accordance with FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Precision oncology testing
The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most

13


precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical patients. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.
The Company’s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.
Development services
The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.
The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company’s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.
Contracts with multiple performance obligations
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered

14


distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.
For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.
Unbilled receivables
Unbilled receivables, which is a contract asset, consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized prior to the establishment of billing rights or the achievement of performance-based milestones. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. 
Unbilled receivables are presented under accounts receivable on the Company's consolidated balance sheets. As of March 31, 2019, the Company had unbilled receivables of $3.9 million as compared to $4.9 million as of January 1, 2019. The Company did not record unbilled receivables for its contract assets prior to the adoption of ASC 606 on January 1, 2019.
Deferred revenue
Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized.
As of March 31, 2019 and December 31, 2018, the deferred revenue balance was $17.1 million and $16.1 million, respectively, which included $12.4 million and $10.5 million, respectively, related to collaboration development efforts with two pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the three months ended March 31, 2019 that was included in the deferred revenue balance as of January 1, 2019 was $7.0 million, which represented primarily revenue from provision of development services under the collaboration agreement with a biopharmaceutical company. 
Transaction price allocated to the remaining performance obligations
Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company applied the practical expedient in accordance with Topic 606 to forego disclosures related to the allocation of consideration to the remaining performance obligations and the timing in which revenues will be recognized from such performance obligations.
Costs of Precision Oncology Testing
Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology

15


calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.
Cost of Development Services
Cost of development service includes costs incurred for the performance of development services requested by the Company’s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.
Stock‑Based Compensation
Stock‑based compensation related to stock options granted to the Company’s employees and directors is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards.
In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.
The Company uses the Black‑Scholes option‑pricing model to estimate the fair value of its stock options. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.
Net Loss Per Share Attributable to Common Stockholders
The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.
Prior to the closing of the IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company’s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company’s losses.
Recent Adopted Accounting Pronouncements
The Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and all related amendments (collectively “ASC 606”) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. These differences are discussed below.
For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition.

16


For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.
Effective January 1, 2019, the Company recognizes revenue in accordance with ASC 606. Comparative information from prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.
The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:
 
Balance as of December 31, 2018
 
Adjustments Due to ASC 606
 
Balance as of January 1, 2019
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
35,690

 
$
4,907

 
$
40,597

Equity:
 
 
 
 
 
Accumulated deficit
$
(280,799
)
 
$
4,907

 
$
(275,892
)
In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:
 
Three Months Ended March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Revenue:
 
 
 
 
 
Precision oncology testing
$
28,837

 
$
994

 
$
29,831

Development services
7,818

 

 
7,818

 
 
March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
28,989

 
$
994

 
$
29,983

Equity:
 
 
 
 
 
Accumulated deficit
(303,209
)
 
994

 
(302,215
)
ASC 606 did not have an aggregate impact on the Company’s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above table.
In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company

17


adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of 1.3 million as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.
Recent Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The new guidance will be effective for the Company beginning in 2020, at which time, the new guidance will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements and anticipates the recognition of additional assets and corresponding liabilities on its condensed consolidated balance sheet related to leases. The adoption of the new standard is also expected to materially impact the Company’s condensed consolidated financial statement disclosures related to leases.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The new guidance is effective for the Company beginning in 2021, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements.
3.
Investment in Joint Venture
Variable Interest Entity (“VIE”)
In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the “Joint Venture”) for the sale, marketing and distribution of the Company’s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.
Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. The Joint Venture is deemed to be a variable interest entity ("VIE") and the Company has been identified as the VIE’s primary beneficiary. As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.
As of March 31, 2019 and December 31, 2018, the Joint Venture had total assets of approximately $47.0 million and $48.3 million, respectively, which were primarily comprised of cash, property and equipment and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company’s general credit or assets.  Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of March 31, 2019 and December 31, 2018, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.
Put-call arrangements
The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the “put right”), and the Company has a right to purchase all such shares (the “call right”). The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its common stock, or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.
The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company’s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the

18


formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.
As of March 31, 2019 and December 31, 2018, the fair value of the redeemable noncontrolling interest held by SoftBank approximated $46.5 million and $41.8 million, respectively. For the three months ended March 31, 2019, the Company recorded a fair value adjustment of $4.7 million in its condensed consolidated statements of operations.
As of March 31, 2019, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy.
4.
Condensed Consolidated Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Machinery and equipment
$
23,742

 
$
23,440

Computer hardware
5,293

 
4,949

Leasehold improvements
14,163

 
13,965

Furniture and fixtures
1,540

 
1,522

Computer software
741

 
643

Construction in progress
1,405

 
3,118

Property and equipment, gross
46,884

 
47,637

Less: accumulated depreciation and amortization
(16,303
)
 
(16,634
)
Property and equipment, net
$
30,581

 
$
31,003

Depreciation and amortization expense related to property and equipment was $2.1 million and $1.2 million for the three months ended March 31, 2019 and 2018, respectively.
As of March 31, 2019 and December 31, 2018, total property and equipment financed under capital leases was $504,000 and $504,000, net of accumulated amortization of $324,000 and $294,000, respectively. Amortization expense related to total property and equipment financed under capital leases was $30,000 and $64,000 for the three months ended March 31, 2019 and 2018, respectively.

19


Accrued Expenses
Accrued expenses consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Accrued royalty obligations
$
853

 
$
707

Accrued legal expenses
2,400

 
814

Accrued tax liabilities
1,410

 
1,470

Accrued professional services
1,988

 
1,791

Purchases of property and equipment included in accrued expenses
137

 
343

Other
2,349

 
1,956

Total accrued expenses
$
9,137

 
$
7,081

5.
Fair Value Measurements, Cash Equivalents and Marketable Securities
Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses and debt. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.
Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

20


 
March 31, 2019
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
10,093

 
$
10,093

 
$

 
$

Total cash equivalents
10,093

 
10,093

 

 

 
 
 
 
 
 
 
 
Corporate bonds
43,083

 

 
43,083

 

U.S. government debt securities
264,992

 

 
264,992

 

U.S. government agency bonds
4,994

 

 
4,994

 

Total short-term marketable securities
313,069

 

 
313,069

 

 
 
 
 
 
 
 
 
Corporate bonds
2,005

 

 
2,005

 

U.S. government debt securities
23,911

 

 
23,911

 

Total long-term marketable securities
25,916

 

 
25,916

 

Total
$
349,078

 
$
10,093

 
$
338,985

 
$

 
December 31, 2018
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
25,796

 
$
25,796

 
$

 
$

Total cash equivalents
25,796
 
25,796
 

 

 
 
 
 
 
 
 
 
Corporate bonds
38,397
 

 
38,397
 

U.S. government debt securities
235,016
 

 
235,016
 

U.S. government agency bonds
5,004
 

 
5,004
 

Total short-term marketable securities
278,417
 

 
278,417
 

 
 
 
 
 
 
 
 
Corporate bonds
3,805
 

 
3,805
 

U.S. government debt securities
73,758
 

 
73,758
 

Total long-term marketable securities
77,563
 

 
77,563
 

Total
$
381,776

 
$
25,796

 
$
355,980

 
$

The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
The significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.
There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.

21


Cash Equivalents and Marketable Securities
The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:
 
March 31, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Money market fund
$
10,093

 
$

 
$

 
$
10,093

Corporate bond
45,065

 
26

 
(3
)
 
45,088

U.S. government debt securities
288,522

 
455

 
(74
)
 
288,903

U.S. government agency bonds
4,995

 

 
(1
)
 
$
4,994

Total
$
348,675

 
$
481

 
$
(78
)
 
$
349,078

 
December 31, 2018
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(in thousands)
Money market fund
$
25,796

 
$

 
$

 
$
25,796

Corporate bond
42,273

 

 
(71
)
 
42,202

U.S. government debt securities
308,775

 
235

 
(236
)
 
308,774

U.S. government agency bonds
5,014

 

 
(10
)
 
5,004

Total
$
381,858

 
$
235

 
$
(317
)
 
$
381,776

There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company’s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the three months ended March 31, 2019 and 2018. The maturities of the Company’s long-term marketable securities range from 1.0 year to 1.2 years as of March 31, 2019.

22


6.
Patent License Agreement
In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The transaction was treated as an acquisition of an asset and the Company capitalized a total of $9.7 million under the arrangement.
As of March 31, 2019 and December 31, 2018, unamortized capitalized license fees were $7.6 million and $7.8 million, respectively, which will be amortized over the remaining useful life of 7.8 and 8.0 years, respectively. Amortization of capitalized license fees totaled $243,000 and $189,000 for the three months ended March 31, 2019 and 2018, respectively.
7.
Commitments and Contingencies
Operating Leases
As of March 31, 2019, future minimum payments under the non-cancelable operating lease were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
3,693

2020
7,276

2021
8,161

2022
8,388

2023
9,023

2024 and thereafter
26,076

Total
$
62,617

Rent expense for the facility leases was $1.3 million and $1.1 million for the three months ended March 31, 2019 and 2018, respectively.
Capital Leases
As of March 31, 2019, future minimum capital lease payments were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
107

2020
108

2021
36

Total minimum capital lease payments
251

Less: amount representing interest
(55
)
Present value of net minimum capital lease payments
196

Less: current installments of obligations under capital lease
(96
)
Obligations under capital lease, excluding current installments
$
100

License Agreements
The Company has patent license agreements with four different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.

23


Royalty expenses were included in cost of precision oncology testing on the accompanying condensed consolidated statements of operations. The Company recognized royalty expenses of $633,000 and $172,000, or 2% and 1% of precision oncology testing revenue in each period, for the three months ended March 31, 2019 and 2018, respectively.
As of March 31, 2019, future minimum royalty payments were due as follows regardless of sales amounts:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
1,052

2020
1,402

2021
1,402

2022
1,683

2023
1,683

2024 and thereafter
5,609

Total future minimum royalty payments
12,831

Less: amount representing interest
(5,711
)
Present value of future minimum royalty payments
$
7,120

Indemnification Agreements
The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of March 31, 2019.
Security Incidents
In July 2018, the Company experienced security incidents involving an unauthorized actor obtaining access to its email system and sending phishing messages. The Company has implemented and continues to implement additional security measures to help prevent future unauthorized access to its systems and the data it maintains, including promptly engaging an independent cybersecurity firm to support its investigation, assess its systems and bolster security thereof. The Company provided timely notices to the U.S. Department of Health and Human Services, or the HHS, certain state regulators and certain credit agencies, as applicable, as well as to the individuals affected. Following such security incidents, the Company received a request for information in January 2019 regarding the incidents from the HHS Office for Civil Rights, or OCR.  The Company has responded to that request in a timely manner but does not know whether OCR will request additional information or pursue any further action. The Company currently cannot predict the ultimate resolution of the security incidents or the OCR inquiry and cannot estimate the amounts or ranges of potential loss that could result therefrom. The Company has insurance coverage in place for certain potential claims, liabilities and costs relating to the security incidents, but this coverage is limited in amount and may not be adequate to protect against all claims, liabilities and costs arising from such incidents, including fines and penalties.

Legal Proceedings
The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.

24


Patent Disputes
In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (“Foundation Medicine”) and Personal Genome Diagnostics, Inc. (“Personal Genome Diagnostics”) in the United States District Court for the District of Delaware, alleging that each of the two companies has infringed a patent relating to the Company’s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys’ fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity, including subsequently unenforceabilty under the doctrine of inequitable conduct, and non-infringement. In addition, Personal Genome Diagnostics has alleged, as part of its subsequent counterclaims, that the Company’s actions related to obtaining and securing exclusive rights to the patents-in-suit violated provisions of Section 2 of the Sherman Antitrust Act.

In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the PTAB, challenging the patentability of two of the patents asserted by the Company. Prior to reaching a decision on the merits, the two post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.
License Dispute
In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (“Licensor”), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor’s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company’s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor’s counterclaims will succeed on the merits.
Other Disputes
In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of $4.25 million, which was reported as other income in the condensed consolidated statements of operations for the three months ended March 31, 2018.
8.
Common Stock
Common stockholders are entitled to dividends if and when declared by the Company’s Board of Directors (the “Board of Directors”). As of March 31, 2019 and December 31, 2018, no dividends on common stock had been declared by the Board of Directors.
Common stock has been reserved for the following potential future issuances:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)

 
 
Shares underlying outstanding stock options
7,378,068

 
7,588,405

Shares underlying unvested restricted stock units
102,498

 

Shares available for issuance under the 2018 Incentive Award Plan
3,436,451

 
3,556,507

Shares available for issuance under the 2018 Employee Stock Purchase Plan
802,548

 
922,250

Total
11,719,565
 
12,067,162
9.
Stock-Based Compensation
2012 Stock Plan and 2018 Incentive Award Plan

25


In June 2012 and September 2018, the Board of Directors adopted and its stockholders approved the Company’s 2012 Stock Plan (as amended and restated, the “2012 Plan”) and the Company’s 2018 Incentive Award Plan (the “2018 Plan”), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and nonemployees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and the 508,847 shares remaining available for future grant under the 2012 Plan were not made available for grant under the 2012 Plan or the 2018 Plan. Any outstanding awards granted under the 2012 Plan remained outstanding, subject to the terms of the 2012 Plan and applicable award agreement; and if any of those awards are forfeited or cancelled without payment therefor, the shares covered by those awards will not become available for future grant or issuance under the 2012 Plan or the 2018 Plan. No further grants will be made under the 2012 Plan. As of March 31, 2019 , 3,658,602 shares were approved and reserved for issuance under the 2018 Plan.
Stock Option Activity
A summary of the Company’s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
 
Options Outstanding
 
Shares
Available for Grant 
 
Shares Subject to Options Outstanding
 
Weighted-Average Exercise Price 
 
Weighted-Average Remaining Contractual Life (Years)
 
Aggregate Intrinsic Value
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands)
Balance as of December 31, 2018
3,556,507

 
7,588,405

 
$
4.58

 
8.3
 
$
250,495

Granted
(18,370
)
 
18,370

 
41.25

 
 
 
 
Exercised

 
(146,318
)
 
3.49

 
 
 
 
Canceled
812

 
(82,389
)
 
4.77

 
 
 
 
Restricted stock units granted
(120,835
)
 

 

 
 
 
 
Restricted stock units canceled
18,337

 

 

 
 
 
 
Balance as of March 31, 2019
3,436,451

 
7,378,068

 
$
4.69

 
8.0
 
$
531,281

Vested and Exercisable as of March 31, 2019
 
 
3,361,540

 
$
3.61

 
7.4
 
$
245,680

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $8.1 million and $1.3 million for the three months ended March 31, 2019 and 2018, respectively.
Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date. The weighted-average grant date fair value of options granted was $25.90 and $3.77 per share for the three months ended March 31, 2019 and 2018, respectively.
Future stock-based compensation for unvested options as of March 31, 2019 and December 31, 2018 was $16.6 million and $17.5 million, respectively, which is expected to be recognized over a weighted-average period of 2.5 years and 2.7 years, respectively.

26


Restricted Stock Units
A summary of the Company’s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
Restricted Stock Units Outstanding
 
Weighted-Average Grant Date Fair Value
 
 
 
 
 
Unvested balance as of December 31, 2018
 

 
$

Granted
 
120,835

 
44.02

Canceled
 
(18,337
)
 
41.30

Unvested balance as of March 31, 2019
 
102,498

 
$
44.50

Future stock-based compensation for unvested restricted stock units as of March 31, 2019 was $4.2 million, which is expected to be recognized over a weighted-average period of 3.6 years.
Stock‑Based Compensation Expense
The following table presents the effect of employee and non‑employee related stock‑based compensation expense:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Cost of precision oncology testing
 
$
170

 
$
63

Research and development expense
 
1,210

 
204

Sales and marketing expense
 
826

 
374

General and administrative expense
 
976

 
636

Total stock-based compensation expense
 
$
3,182

 
$
1,277

Valuation of Stock Options
The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
Expected term (in years)
 
6.22
 
5.01 – 10.00
Expected volatility
 
66.7%
 
81.6% – 86.5%
Risk-free interest rate
 
2.7%
 
2.5% – 2.7%
Expected dividend yield
 
—%
 
—%
The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:
Expected Term
The expected term represents the period that the options granted are expected to be outstanding. After the adoption of ASU 2018-07 on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. Prior to the adoption of ASU 2018-07, the expected term of stock options issued to

27


employees was determined using the simplified method, and the expected term of stock options issued to nonemployee consultants was based on the contractual term of the award.
Expected Volatility
Prior to the commencement of trading of the Company’s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock.

The Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
Risk-Free Interest Rate
The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.
Expected Dividend Yield
The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.
2018 Employee Stock Purchase Plan
In September 2018, the Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 922,250 shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP.
Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 10% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or last day of the offering period, whichever is lower. Except for the initial offering period, the ESPP provides for separate six-month offering periods beginning on February 1 and August 1 of each year. The initial offering period ran from October 2, 2018 through January 31, 2019.
For the three months ended March 31, 2019119,702 shares of common stock were purchased under the ESPP. The total compensation expense related to the ESPP for the three months ended March 31, 2019 was $566,000. As of March 31, 2019, the unrecognized stock-based compensation expense related to the ESPP was $646,000 which is expected to be recognized over the remaining term of the offering period of 0.3 years.
The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. For the three months ended March 31, 2019, the following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: a weighted-average expected life of 0.5 years; expected volatility of 60.2%; a risk-free interest rate of 2.5%; and a zero dividend yield.
Liabilities for Early Exercise of Employee Options
The Company allowed certain stock option holders to exercise unvested options to purchase shares of common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee’s employment termination, at the original issuance price, until the options are fully vested. As of March 31, 2019 and December 31, 2018, 32,279 and 44,268 shares of common stock were subject to repurchase at weighted-average prices of $4.66 and $4.66 per share, respectively. As of March 31, 2019 and December 31, 2018, the cash proceeds received for unvested shares of common stock of $150,000 and $206,000, respectively, were recorded within other long-term liabilities on the condensed consolidated balance sheet. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders’ equity as such shares are considered legally outstanding.

28


10.
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands, except per share data)
Net loss
 
$
(21,351
)
 
$
(13,844
)
Fair value adjustment of redeemable noncontrolling interest
 
(4,700
)
 

Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(26,051
)
 
$
(13,844
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.30
)
 
$
(1.16
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
85,935

 
11,920

Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Convertible preferred stock (on an as if converted basis)
 

 
58,265

Stock options issued and outstanding
 
7,503

 
7,457

Unvested restricted stock units
 
78

 

ESPP obligation
 
59

 

Preferred stock warrants (on an as if converted basis)
 

 
8

Common stock warrants
 

 
312

Common stock subject to repurchase
 
41

 
19

Total
 
7,681

 
66,061

11.
Segment and Geographic Information
The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
United States
 
$
31,245

 
$
12,902

International(1)
 
5,410

 
3,790

Total revenue

$
36,655

 
$
16,692

(1)
No single country outside of the United States accounted for more than 10% of total revenue during three months ended March 31, 2019 and 2018.
As of March 31, 2019 and December 31, 2018, substantially all of the Company’s long-lived assets are located in the United States.

29



12.
Related Party Transactions
As discussed in Note 3, in connection with Softbank’s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.
13.
Subsequent Events
Acquisition of Bellwether Bio
In April 2019, the Company completed its purchase of all of the outstanding shares of Bellwether Bio, Inc. ("Bellwether Bio"), a privately-held company developing a method for early blood-based cancer detection. The upfront consideration, after customary adjustments at closing, was approximately $10.1 million in cash. Subject to the achievement of certain commercialization milestones and, for certain milestones, the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio, the Company will pay additional contingent consideration of up to a total of $20.0 million, which may be paid, at the Company’s election, in cash or in the Company’s common stock. At the time of the issuance of the Company’s condensed consolidated financial statements as of and for the three months ended March 31, 2019, the initial accounting for the acquisition of Bellwether Bio, including purchase price allocation, had not been completed.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this his Quarterly Report on Form 10-Q contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,“Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2018.

Overview
We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we launched our Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers. Our GuardantOMNI test, launched in 2017, is specifically built for our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. Our LUNAR early detection program aims to address the needs of early stage cancer patients with adjuvant treatment selection, cancer survivors with surveillance and asymptomatic individuals with screening. In late 2018, we launched our LUNAR assay for research use by biopharmaceutical and academic researchers. In April 2019, at the American Association for Cancer Research, or AACR, annual meeting, we presented exploratory data around the use of our LUNAR assay for potential screening applications in a cohort of 229 recently diagnosed colorectal cancer patients and aged-matched cancer-free controls. This data demonstrated average LUNAR assay sensitivity exceeding 80% with specificity of 94% for patients with stage I/II colorectal cancer in this cohort (76% in stage I and 87% in stage II). To further pursue this potential market opportunity, we are planning to start a prospective colorectal screening study of over 10,000 patients in the second half of 2019.
Since our inception, we have devoted substantially all of our resources to research and development activities related to our Guardant360 and GuardantOMNI tests and our LUNAR program, including clinical and regulatory initiatives to obtain approval by the U.S. Food and Drug Administration, or the FDA, as well as sales and marketing activities. We have over 40 approved, completed or active clinical outcomes studies, more than 110 peer-reviewed publications and more than 300 scientific abstracts. We are pioneering the clinical comprehensive liquid biopsy market with our Guardant360 and GuardantOMNI tests, both of which analyze circulating tumor DNA in blood. Our Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes and has been used by clinicians to help inform which


30


therapy may be effective for advanced stage cancer patients with solid tumors and by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research, clinical trial enrollment, and drug development, and post-approval commercialization. Our GuardantOMNI test has a broader 500-gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability, and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including Merck MSD, Merck KGaA, Pfizer, AstraZeneca and Bristol-Myers Squibb.
The FDA granted designation as a breakthrough device for our Guardant360 test in January 2018 for companion diagnostic use, and for our GuardantOMNI test in December 2018 for companion diagnostic use. Breakthrough device designation, among other things, provides for priority review and more interactive communication with the FDA during the development process. Our Guardant360 and GuardantOMNI tests are both being developed as companion diagnostics under collaborations with biopharmaceutical companies.
We perform our Guardant360, GuardantOMNI and other tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states.
The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health and multiple Blue Cross Blue Shield plans, which have adopted reimbursement policies that specifically cover Guardant360 test for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers.
In July 2018, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare’s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for NSCLC patients who meet certain clinical criteria. We worked with Palmetto GBA to obtain this positive coverage decision through the submission of a detailed dossier of analytical and clinical data to substantiate that the test meets Medicare’s medical necessity requirements. We estimate that approximately 75% of Medicare patients tested for NSCLC are covered by the LCD. For the three months ended March 31, 2019 and 2018, approximately 47% and 46% of our U.S. clinical tests were for patients tested for NSCLC. Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in the MolDx, recently finalized its LCD for Guardant360 test. In September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for Medicare beneficiaries covered under the LCDs, and in October 2018, we began to receive payments from Medicare. In March 2019, Palmetto GBA posted a proposed LCD that, if finalized as written, would provide limited Medicare coverage for use of Guardant360 for patients diagnosed with solid cancers of non-central nervous system origin. The coverage requirements necessitate that patients are recurrent, relapsed, refractory, metastatic, or advanced cancer patients who are seeking further treatment and are potential candidates for an FDA-approved or NCCN-recommended (for Category 1 or 2A level of evidence) biomarker targeted therapy. Additionally, the patient must not have had a previous Guardant360 test and must be untreated or not responding on the patient’s current therapy. A patient who has previously been tested with Guardant360 and has progressed with new malignant growth since the patient’s prior test is considered to have a new primary cancer diagnosis and thus is eligible to have another test. Finally, for qualifying cancers other than NSCLC, tissue-based comprehensive genomic profiling must be infeasible for coverage. NSCLC patients would be eligible for coverage if tissue-based testing is infeasible or if previous tissue-based comprehensive genomic profiling returned no actionable results.
If finalized, we believe the proposed LCD will significantly expand coverage for Medicare patients based on historic physician ordering patterns. Palmetto GBA is accepting and evaluating public comments, after which the draft LCD may be finalized and implemented by MACs that follow MolDx coverage policies. We can provide no assurances, however, that the draft LCD will be finalized as written or implemented by Palmetto GBA or the California MAC.
We anticipate approval by the FDA, if obtained, may also support improvements in coverage and reimbursement for the Guardant360 test.
In the United States, we market our tests to clinical customers through our sales organization, which is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We also market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests throughout drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.

31


We generated total revenue of $36.7 million and $16.7 million for the three months ended March 31, 2019 and 2018, respectively. We also incurred net losses of $21.4 million and $13.8 million for the three months ended March 31, 2019 and 2018, respectively. We have funded our operations to date principally from the sale of our stock and revenue from our precision oncology testing and development services. In October 2018, we completed our initial public offering, or IPO, selling 14,375,000 shares of our common stock and raising $249.5 million net of underwriting discounts and commissions and other expenses payable by us. As of March 31, 2019, we had cash, cash equivalents and marketable securities of $492.8 million.
Factors affecting our performance
We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:
Testing volume, pricing and customer mix. Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average selling price for clinical tests since we are not a contracted provider for, or our tests are not covered by clinical patients’ insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Approximately 38% and 37% of our U.S. clinical tests for three months ended March 31, 2019 and 2018, respectively, were for Medicare beneficiaries. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical tests for certain Medicare beneficiaries, and in October 2018, we began to receive payments from Medicare for these clinical tests. In March 2019, Palmetto GBA posted a proposed LCD that, if finalized as written, would provide limited Medicare coverage for use of Guardant360 for qualifying patients diagnosed with solid cancers of non-central nervous system origin. We can provide no assurances, however, that the draft LCD will be finalized as written or implemented by Palmetto GBA or the California MAC.
Regulatory approval. Our Guardant360 test was the first comprehensive liquid biopsy test approved by NYSDOH. In addition, we believe our facility was the first comprehensive liquid biopsy laboratory to be CLIA-certified, CAP-accredited and NYSDOH-permitted. The FDA granted designation as a breakthrough device for our Guardant360 test as a companion diagnostic in January 2018 and for our GuardantOMNI test as a companion diagnostic in December 2018. Breakthrough Device designation, which, supersedes the EAP designation and, among other things, provides for priority review and more interactive communication with the FDA during the development process. While FDA approval is currently not required to market our tests in the United States, we intend to submit an application for a pre-market approval, or PMA, for each of our Guardant360 and GuardantOMNI tests for use as companion diagnostics. In March 2018, the Centers for Medicare and Medicaid Services, or CMS, published a Decision Memorandum for next-generation sequencing tests for patients with advanced cancer who meet certain clinical criteria, or the NGS Decision Memorandum. The NGS Decision Memorandum states that coverage would be available for next-generation sequencing FDA-approved tests offered within the FDA-approved labeling. FDA approval therefore provides a path to reimbursement by Medicare under the NGS Decision Memorandum. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad. We believe FDA approval, if obtained, will help increase adoption of our tests and facilitate favorable reimbursement decisions by Medicare and commercial payers. Any negative regulatory decisions or changes affecting our business could adversely impact our operations and financial results.
Payer coverage and reimbursement. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from commercial payers differs depending on whether we have entered into a contract with the payers as a “participating provider” or do not have a contract and are considered a “non-participating provider.” Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of commercial payers, most of which have not contracted with us to be a participating provider. We have received reimbursement for tests of patients with a variety of cancers, though for amounts that on average are significantly lower than for participating providers. Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have

32


sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider generally results in higher reimbursement for covered indications and lack of reimbursement for non-covered indications. As a result, the impact of becoming a participating provider with a specific payer will vary based on historical reimbursement as a non-participating provider for that payer, and in some situations, the benefit of increased reimbursement for covered testing could be offset by the loss of reimbursement on tests for non-covered indications previously received when we served as a non-participating provider. Current Procedural Terminology, or CPT, coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. Changes in how the Guardant360 test is coded may result in a significant change in its reimbursement amongst commercial payers. If our Guardant360 test receives approval from the FDA, we may be required to obtain a separate code for the Guardant360 test to bill U.S. based payers. If a coding change were to occur, payments for uncovered Guardant360 testing may be reduced or eliminated by commercial payers. The impact to our revenue may be in proportion to the volume of tests we performed as a non-participating provider. Cigna, Priority Health and multiple Blue Cross Blue Shield plans adopted reimbursement policies that cover our Guardant360 test for the majority of NSCLC patients we test. If their reimbursement policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In September 2018, we began to submit claims for reimbursement at the rate of $3,500 per test with respect to Guardant360 clinical testing performed for NSCLC patients covered under Medicare’s Molecular Diagnostic Services Program who meet certain clinical criteria, and in October 2018, we began to receive payments from Medicare. In addition, our Guardant360 test is expected to be a covered benefit for the members of the health plans associated with eviCore, a technology assessment company, as being considered medically necessary to assist in selecting therapy for patients with advanced lung cancer. When the eviCore policy becomes effective July 1, 2019, with added coverage for over 38 million Americans, we expect total lung cancer coverage in the United States for the Guardant360 test will increase to a total of more than 150 million lives, including Medicare beneficiaries and members of several health plans. If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments can also negatively impact our revenue and cause our financial results to fluctuate. We have experienced situations where commercial payers proactively reduce the amounts they were willing to reimburse for our tests or determine that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made.
Biopharmaceutical customers. Our revenue also depends on our ability to attract new, and to maintain and expand relationships with existing, biopharmaceutical customers, and we expect to increase our sales and marketing expense in furtherance of this goal. As we continue to develop these relationships, we expect to support a growing number of clinical trials both in the United States and internationally. If our relationships expand with biopharmaceutical customers, we believe we may continue to have opportunities to offer our platform to such customers for companion diagnostic development and for novel target discovery and validation, and to grow into other business opportunities. For example, we believe genomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and clinical trial enrollment.
Research and development. A significant aspect of our business is our investment in research and development, including the development of new products, such as those being developed as part of our LUNAR early detection program. In particular, we have invested heavily in clinical studies, including more than 40 clinical outcomes studies, the largest-ever liquid-to-tissue concordance study, and a prospective interventional clinical utility study demonstrating clinical overall response rates in line with tissue biopsy approaches. Our clinical research has resulted in over 110 peer-reviewed publications. For example, the positive results from the Noninvasive vs. Invasive Lung Evaluation (NILE) study, a head-to-head comparison of the Guardant360 assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced NSCLC patients, was published in Clinical Cancer Research. Beyond meeting its primary endpoint of demonstrating that the Guardant360 test was as accurate as standard-of-care tissue testing for the detection of guideline-recommended biomarkers in advanced NSCLC, the NILE study showed that (i) Guardant360 testing resulted in guideline-recommended testing for three times as many patients as standard-of-care tissue testing; (ii) when results for Guardant360 and tissue testing were both available for a patient, they were concordant in more than 90% of cases; (iii) the median time to results for Guardant360 was 9 days versus 15 days for standard-of-care tissue testing, and (iv) the Guardant360 test’s clinical sensitivity for EGFR L858R mutations was 90%. In addition, we are collaborating with investigators from multiple academic cancer centers, including MD Anderson Cancer Center, the University of Colorado, Memorial Sloan Kettering Cancer Center, Massachusetts General Cancer Center, Wake Forest Cancer Center and the University of California San Francisco, as well as several international institutions. We believe these studies are critical to

33


gaining physician adoption and driving favorable coverage decisions by payers, and expect our investments to increase. We expect to increase our research and development expense with the goal of fueling further innovation.
International expansion. A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the Americas and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with our initial focus being on Japan.
While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018 for more information.

Components of results of operations
Revenue
We derive our revenue from two sources: (i) precision oncology testing and (ii) development services.
Effective January 1, 2019, we adopted a new revenue recognition standard FASB ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, which primarily impacted our recognition of revenue related to patient claims paid by third-party commercial and governmental payors. We adopted ASC 606 using the modified retrospective method, which means that the cumulative effect of applying ASC 606 has been recognized to beginning accumulated deficit at January 1, 2019, the date of adoption of ASC 606, and prior comparative periods were not recast to reflect ASC 606. As a result, revenue for three months ended March 31, 2018 is presented in accordance with FASB ASC Topic 605, Revenue Recognition, or ASC 605, whereas revenue for the three months ended March 31, 2019 is presented under ASC 606. ASC 606 provides a five-step model for recognizing revenue that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Precision oncology testing. Precision oncology testing revenue is generated from sales of our Guardant 360 and GuardantOMNI tests. In the United States, through March 31, 2019, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement for these tests. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under Medicare’s Molecular Diagnostic Services Program who meet certain clinical criteria. Tests for patients covered by Medicare represented approximately 38% and 37% of U.S. tests processed for the three months ended March 31, 2019 and 2018, respectively. Due to the historical general lack of contracts with U.S. private payers and variability in payments received for claims submitted to them, as well as the limited claims experience to date with Medicare, from inception through the end of 2018 revenue had not been recognized by us at the time the service was performed as the price of the transaction was not fixed or determinable and collectability was not reasonably assured. As we provide precision oncology testing to biopharmaceutical customers under contracts for which all recognition criteria are met, we have recognized revenue on an accrual basis for those services.
Development services. Development services revenue represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial referrals and liquid biopsy testing development and support. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services revenue can vary over time as different projects start and complete.
Costs and operating expenses
Cost of precision oncology testing. Cost of precision oncology testing generally consists of cost of materials, direct labor, including bonus, benefit and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples, including sample accessioning, library preparation, sequencing, quality control

34


analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Cost of precision oncology testing revenue included royalty expense of $0.6 million and $0.2 million for the three months ended March 31, 2019 and 2018, respectively.
We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.
Cost of development services. Cost of development services includes costs incurred for the performance of development services requested by our customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services will vary depending on the nature, timing and scope of customer projects.
Research and development expense. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.
We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials. This expense is expected to increase, particularly to drive our LUNAR program. Long term we expect it to decrease modestly as a percentage of revenue, though it may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses.
Sales and marketing expense. Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.
We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our Guardant360 and GuardantOMNI tests. Development of products from our LUNAR program is expensive and we do not expect to generate profits from such products until they reach commercial scale. Sales and marketing expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses.
General and administrative expense. Our general and administrative expenses include costs for our executive, accounting and finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.
We expect that our general and administrative expenses will continue to increase in absolute dollars in 2019, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses.

35


Interest income
Interest income consists of interest earned on our cash, cash equivalents and marketable securities.
Interest expense
Interest expense consists primarily of interest from capital leases and royalty obligations.
Other income (expense), net
In the first quarter of 2018, we settled a commercial legal dispute. In connection with the settlement, we received a payment of $4.25 million, which was recognized as one-time other income for the three months ended March 31, 2018.
Other income (expense), net also consists of foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and asset and liability balances denominated in currencies other than the U.S. dollar, primarily comprised of a royalty obligation denominated in Euros. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.
Joint venture
In connection with SoftBank’s purchase of our Series E convertible preferred stock, we agreed to enter into a joint venture agreement with Softbank relating to the commercialization and distribution of products in in all areas worldwide outside of North America, Central, America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey, or the JV Territory. Upon the incorporation of the Joint Venture (Guardant Health AMEA, Inc.) in May 2018, SoftBank purchased 40,000 shares of common stock of the Joint Venture in exchange for $41.0 million in cash and we purchased 40,000 shares of common stock of the Joint Venture in exchange for $9.0 million in cash. We also entered into various ancillary agreements with the Joint Venture necessary to operate its business. Under the terms of the joint venture agreement, neither we nor SoftBank is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. In the event the Joint Venture requires any additional funding for its operations, the Joint Venture may seek debt financing from financial institutions or additional financing in debt or equity from its shareholders, which will be on a pro rata basis among such shareholders unless they agree otherwise.
Initial public offering
On October 9, 2018, we completed an initial public offering, or the IPO, in which we issued and sold 14,375,000 shares of our common stock at a price of $19.00 per share. We received net proceeds of $249.5 million after deducting underwriting discounts and commissions and offering expenses payable by us. All then-outstanding warrants to purchase our common stock were exercised prior to the completion of the IPO. In addition, in connection with the IPO, all shares of our then-outstanding convertible preferred stock were automatically converted into 58,264,577 shares of our common stock, and all then-outstanding warrants to purchase our convertible preferred stock were automatically converted into warrants to purchase 7,636 shares of our common stock.


36


Results of operations
The following table set forth the significant components of our results of operations for the periods presented.
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Revenue:
 
 
 
 
Precision oncology testing
 
$
28,837

 
$
14,191

Development services
 
7,818

 
2,501

Total revenue
 
36,655

 
16,692

Costs and operating expenses:
 
 
 
 
Cost of precision oncology testing(1)
 
11,023

 
8,045

Cost of development services
 
2,512

 
1,208

Research and development expense(1)
 
16,316

 
8,255

Sales and marketing expense(1)
 
17,807

 
11,312

General and administrative expense(1)
 
12,661

 
6,519

Total costs and operating expenses
 
60,319

 
35,339

Loss from operations
 
(23,664
)
 
(18,647
)
Interest income
 
2,485

 
985

Interest expense
 
(293
)
 
(331
)
Other income (expense), net
 
147

 
4,149

Loss before provision for income taxes
 
(21,325
)
 
(13,844
)
Provision for income taxes
 
26

 

Net loss
 
$
(21,351
)
 
$
(13,844
)
(1)
Amounts include stock-based compensation expense as follows:
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Cost of precision oncology testing
 
$
170

 
$
63

Research and development expense
 
1,210

 
204

Sales and marketing expense
 
826

 
374

General and administrative expense
 
976

 
636

Total stock-based compensation expense
 
$
3,182

 
$
1,277



37


Comparison of the Three Months Ended March 31, 2019 and 2018
Revenue
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Precision oncology testing
$
28,837

 
$
14,191

 
$
14,646

 
103
%
Development services
7,818

 
2,501

 
5,317

 
213
%
Total revenue
$
36,655

 
$
16,692

 
$
19,963

 
120
%
Total revenue was $36.7 million for the three months ended March 31, 2019 compared to $16.7 million for the three months ended March 31, 2018, an increase of $20.0 million, or 120%.
Precision oncology testing revenue increased to $28.8 million for the three months ended March 31, 2019 from $14.2 million for the three months ended March 31, 2018, an increase of $14.6 million, or 103%. This increase in precision oncology testing revenue was primarily due to an increase in tests processed. Tests for clinical customers increased to 9,521 for the three months ended March 31, 2019 from 7,246 for the three months ended March 31, 2018 mainly due to an increase in the number of physicians ordering Guardant360 tests. Precision oncology revenue from tests for clinical customers was $17.2 million in the three months ended March 31, 2019 and $7.3 million in the three months ended March 31, 2018, respectively. Precision oncology testing revenue increased due to increases in test volume for clinical customers, revenue earned from most tests of Medicare lung cancer patients starting in the fourth quarter of 2018 and increases in commercial payer payments that were beneficially affected by the Protecting Access to Medicare Act of 2014. The change to accrual basis revenue under ASC 606 also contributed to the increase in precision oncology revenue from clinical customers, as cash basis revenue under ASC 605 in the three months ended March 31, 2019 would have been approximately $18.2 million. Tests for biopharmaceutical customers increased to 3,762 for the three months ended March 31, 2019 from 2,334 for the three months ended March 31, 2018 due to an increase in the number of biopharmaceutical customers and their contracted projects. The average selling price of biopharmaceutical tests was $3,109 for the three months ended March 31, 2019, up from $2,966 for the three months ended March 31, 2018 due to a greater number of such tests being the GuardantOMNI test, which has a higher selling price than the Guardant360 test.
Development services revenue increased to $7.8 million for the three months ended March 31, 2019 from $2.5 million for the three months ended March 31, 2018, an increase of $5.3 million, or 213%. This increase in development services revenue was due to new projects in 2019 and was mainly received from biopharmaceutical customers for companion diagnostic development and regulatory approval services.
Costs and operating expenses
Cost of precision oncology testing
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Cost of precision oncology testing
$
11,023

 
$
8,045

 
$
2,978

 
37
%
Cost of precision oncology testing revenue was $11.0 million for the three months ended March 31, 2019 compared to $8.0 million for the three months ended March 31, 2018, an increase of $3.0 million, or 37%. This increase in cost of precision oncology testing was primarily due to a $1.7 million increase in material costs, a $0.9 million increase in other costs including freight, royalties and curation of test results for physicians and a $0.4 million increase in production labor and overhead costs.

38


Cost of development services
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Cost of development services
$
2,512

 
$
1,208

 
$
1,304

 
108
%
Cost of development services was $2.5 million for the three months ended March 31, 2019 compared to $1.2 million for the three months ended March 31, 2018, an increase of $1.3 million, or 108%. Costs include material and labor costs incurred after technological feasibility was achieved on the development programs.
Research and development expense
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Research and development
$
16,316

 
$
8,255

 
$
8,061

 
98
%
Research and development expenses were $16.3 million for the three months ended March 31, 2019 compared to $8.3 million for the three months ended March 31, 2018, an increase of $8.1 million, or 98%. This increase in research and development expense was primarily due to an increase of $4.8 million in personnel-related costs for employees in our research and development group, including a $1.0 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology. The increase is also attributable to an increase of $1.7 million in material costs incurred for the development of the LUNAR assay, and an increase of $0.5 million in development consulting fees, and an increase of $0.4 million related to allocated facilities and information technology infrastructure costs.
Sales and marketing expense
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Sales and marketing
$
17,807

 
$
11,312

 
$
6,495

 
57
%
Selling and marketing expenses were $17.8 million for the three months ended March 31, 2019 compared to $11.3 million for the three months ended March 31, 2018, an increase of $6.5 million, or 57%. This increase was primarily due to an increase of $4.8 million in personnel-related costs, including a $0.5 million increase in stock-based compensation, associated with the expansion of our commercial organization, an increase of $0.7 million in travel expense, an increase of $0.3 million related to allocated facilities and information technology infrastructure costs, and an increase of $0.3 million in professional service expenses related to marketing activities.
General and administrative expense
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
General and administrative
$
12,661

 
$
6,519

 
$
6,142

 
94
%

39


General and administrative expenses were $12.7 million for the three months ended March 31, 2019 compared to $6.5 million for the three months ended March 31, 2018, an increase of $6.1 million, or 94%. This increase was primarily due to an increase of $2.2 million in personnel-related costs, including a $0.3 million increase in stock-based compensation related to an increase in our headcount, an increase of $2.6 million in professional service expenses related to outside legal, accounting, consulting and IT services, and an increase of $0.8 million related to allocated facilities and information technology infrastructure costs.
Interest income
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Interest income
$
2,485

 
$
985

 
$
1,500

 
152
%
Interest income was $2.5 million for the three months ended March 31, 2019 compared to $1.0 million for the three months ended March 31, 2018, an increase of $1.5 million, or 152%. This increase was primarily due to a significant increase in cash, cash equivalents and marketable securities during the three months ended March 31, 2019 primarily as a result of cash proceeds from our initial public offering.
Interest expense
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Interest expense
$
293

 
$
331

 
$
(38
)
 
(11
)%
Interest expense was $0.3 million for the three months ended March 31, 2019 compared to $0.3 million for the three months ended March 31, 2018, a decrease of $38,000, or 11%. This decrease was primarily due to reduced outstanding balance of an obligation related to a royalty in connection with a license agreement entered into in January 2017.
Other income (expense), net
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Other income (expense), net
$
147

 
$
4,149

 
$
(4,002
)
 
(96
)%
Other income (expense), net included a gain of $4.25 million for settlement of a commercial legal dispute for the three months ended March 31, 2018. There was no similar charge or gain for the three months ended March 31, 2019.
Other income (expense), net also included foreign currency exchange gains of $147,000 for the three months ended March 31, 2019 and foreign currency exchange losses of $209,000 for the three months ended March 31, 2018. This increase was primarily due to an obligation denominated in Euros in connection with a license agreement entered into in January 2017.

40


Provision for income taxes
 
Three Months Ended March 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
(in thousands)
 
 
Provision for income taxes
$
26

 
$

 
$
26

 
*
*
Not meaningful
Provision for income taxes was very small for the three months ended March 31, 2019 and 2018 due to the losses incurred by us. The net change was insignificant.
Liquidity and capital resources
We have incurred losses and negative cash flows from operations since our inception, and as of March 31, 2019, we had an accumulated deficit of $303.2 million. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to expand our sales organization, increase our marketing efforts to drive market adoption of our Guardant360 and GuardantOMNI tests, invest in clinical trials and develop new product offerings from our research programs, including our LUNAR program. As demand for Guardant360 and GuardantOMNI tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements will also increase in order to build additional capacity. Moreover, we expect to continue to incur additional costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations.
We have funded our operations to date principally from the sale of stock, revenue from precision oncology testing and development service and the incurrence of indebtedness. As of March 31, 2019, we had cash and cash equivalents of $153.8 million and marketable securities of $339.0 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in marketable securities consisting of United States treasury securities and corporate bonds.
Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this report. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development service is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.
If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in this report, we may seek to sell additional common or preferred equity or convertible debt securities, enter into an additional credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available on reasonable terms, or at all.

41


Cash flows
The following table summarizes our cash flows for the periods presented:
 
Three Months Ended March 31,
 
2019
 
2018
 
 
 
 
 
(unaudited)
 
(in thousands)
Cash used in operating activities
$
(4,303
)
 
$
(6,559
)
Cash provided by investing activities
$
15,329

 
$
8,470

Cash provided by financing activities
$
2,288

 
$
1,267

Operating activities
Cash used in operating activities during the three months ended March 31, 2019 was $4.3 million, which resulted from a net loss of $21.4 million, partially offset by non-cash charges of $4.8 million and net change in our operating assets and liabilities of $12.2 million. Non-cash charges primarily consisted of $2.4 million of depreciation and amortization and $3.2 million of stock-based compensation, partially offset by $0.6 million of amortization of discount on investment. The net change in our operating assets and liabilities was primarily the result of a $11.6 million decrease in accounts receivable due to collection from our biopharmaceutical customers, a $2.3 million increase in accrued expenses and other current liabilities, a $1.7 million increase in accrued compensation due to increased personnel, a $1.1 million increase in deferred rent, and a $1.0 million increase in deferred revenue, partially offset by a $2.6 million decrease in accounts payable due to timing of payment, a $1.1 million increase in inventory due to higher testing volumes, a $0.9 million increase in prepaid and other current assets, and a $0.8 million increase in other assets.
Cash used in operating activities during the three months ended March 31, 2018 was $6.6 million, which resulted from a net loss of $13.8 million, partially offset by non-cash charges of $2.8 million and net change in our operating assets and liabilities of $4.5 million. Non-cash charges primarily consisted of $1.4 million of depreciation and amortization and $1.3 million of stock-based compensation. The net change in our operating assets and liabilities was primarily the result of a $2.0 million increase in accounts payable due to increases in operating activities to support growing revenue, a $1.5 million increase in deferred revenue, a $1.1 million increase in accrued expenses and other current liabilities, a $0.6 million decrease in accounts receivable due to timing of collection, and a $0.6 million increase in deferred rent; partially offset by a $1.3 million increase in prepaid and other current assets.
Investing activities
Cash provided by investing activities during the three months ended March 31, 2019 was $15.3 million, which resulted primarily from maturities of marketable securities of $64.0 million, partially offset by purchases of marketable securities of $46.0 million and purchases of property and equipment of $2.7 million.
Cash provided by investing activities during the three months ended March 31, 2018 was $8.5 million, which resulted primarily from maturities of marketable securities of $32.1 million, partially offset by purchases of marketable securities of $19.6 million and purchases of property and equipment of $4.0 million.
Financing activities
Cash provided by financing activities during the three months ended March 31, 2019 was $2.3 million, which was primarily due to proceeds from issuances of common stock under employee stock purchase plan and exercise of stock options.
Cash provided by financing activities during the three months ended March 31, 2018 was $1.3 million, which was primarily due to proceeds from issuances of common stock proceeds upon exercise of stock options.
Contractual obligations and commitments
Except as set forth in Note 7, Commitments and Contingencies, of the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management's Discussion

42


and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2018.
Off-balance sheet arrangements
As of March 31, 2019, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.
Critical accounting policies and estimates
We have prepared our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.
Revenue recognition
We derive revenue from the provision of precision oncology testing services provided to our ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to our biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from our platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. We currently receive payments from commercial third-party payors, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.
Effective January 1, 2019, we began recognizing revenue in accordance with ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Precision oncology testing
We recognize revenue from the sale of our precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, we determine an implied contract exists with our clinical patients. We identify each sale of our liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with our clinical customers represents variable consideration. We estimate the variable consideration under the portfolio approach and consider the historical reimbursement data from third-party payers and patients, as well as known current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. We identify our promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.

43


Our precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by us or billed to customers.
Development services
We perform development services for our biopharmaceutical customers utilizing our precision oncology information platform. Development services typically represent a single performance obligation as we perform a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage us for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.
We collaborate with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these collaborations, we generate revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, we are compensated through a combination of an upfront fee and performance-based non-refundable regulatory and other developmental milestone payments. The transaction price of our development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, we consider our historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than us. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
We recognize development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, we recognize revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in our condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.
Contracts with multiple performance obligations
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. We evaluate the terms and conditions included within our contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. We first identify material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, we consider whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, we consider whether we provide a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.
For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.
Variable interest entity
We review agreements we enter into with third party entities, pursuant to which we may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, we assess whether

44


or not we are the primary beneficiary of that entity. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If we determine we are the primary beneficiary of a VIE, we consolidate the statements of operations and financial condition of the VIE into our consolidated financial statements. Accounting for the consolidation is based on our determination if the VIE meets the definition of a business or and asset. Assets, liabilities and noncotnrolling interests, excluding goodwill, of VIEs that are not determined to be businesses are recorded at fair value in our financial statements upon consolidation. Assets and liabilities that we have transferred to a VIE, after, or shortly before the date we became the primary beneficiary are recorded at the same amount at which the assets and liabilities would have been measured if they had not been transferred. Our determination about whether we should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event.
In May 2018, we and SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of our tests in the JV Territory. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with an initial focus on Japan. As of March 31, 2018, the Joint Venture is deemed to be a VIE and we are identified as the primary beneficiary of the VIE. Consequently, we have consolidated the financial position, results of operations and cash flows of the Joint Venture in our financial statements and all intercompany balances have been eliminated in consolidation.
The joint venture agreement also includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares.
The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within our control and has been classified outside of permanent equity in our consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to us on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. We elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.
Stock-based compensation
After the adoption of Accounting Standards Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2019, we measure stock-based compensation expense for stock options granted to our employees, directors, and nonemployee consultants on the date of grant and recognize the corresponding compensation expense of those awards over the period that the related services are rendered, which is generally the vesting period of the respective award.
We estimate the fair value of stock options granted to our employees, directors and nonemployee consultants on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions used to calculate the fair value of our stock options were:
Expected term
Our expected term represents the period that our stock options are expected to be outstanding. After the adoption of Accounting Standards Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.
Expected volatility
Prior to the commencement of trading of our common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for our common stock. Due to limited historical data for the trading of our common stock, expected volatility is estimated based on the average volatility for comparable

45


publicly traded peer group companies in the same industry over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.
Risk-free interest rate
The risk-free interest rate is based on the U.S. treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock option grants.
Expected dividend yield
We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.
Black-Scholes assumptions
The weighted-average assumptions used in our Black-Scholes option-pricing model for stock options granted were as follows for the periods presented:
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
Expected term (in years)
 
6.22
 
5.01 – 10.00
Expected volatility
 
66.7%
 
81.6% – 86.5%
Risk-free interest rate
 
2.7%
 
2.5% – 2.7%
Expected dividend yield
 
—%
 
—%
We recognize stock-based compensation expense net of forfeitures as they occur in accordance with Accounting Standards Update 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.
We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future stock-based compensation expense.
As of March 31, 2019, we had unrecognized stock-based compensation of $20.7 million related to unvested employee stock options and restricted stock units which is expected to be recognized over a weighted-average period of 2.7 years.
JOBS Act accounting election
We are an “emerging growth company,” or EGC, within the meaning of the Jumpstart Our Business Act of 2012, or JOBS Act. Section 107(b) of the JOBS Act provides that an EGC can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We also intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.

We will remain an EGC until the earliest of (1) the last day of the fiscal year following the fifth anniversary of the consummation of the IPO, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. While we may otherwise remain an EGC until as late as December 31, 2023, if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30, 2019, we expect that we will cease to be an EGC and will need to comply with additional legal, financial and accounting requirements as of December 31, 2019, which could result in substantial costs and additional risks for us and divert management’s attention.


46



Recent accounting pronouncements
See Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.


47



Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.
Interest rate risk
We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of March 31, 2019, we had cash and cash equivalents of $153.8 million held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities, U.S. government agency bonds and corporate bonds. As of March 31, 2019, we had short-term marketable securities of $313.1 million and long-term marketable securities of $25.9 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of March 31, 2019, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate $1.8 million decline of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.
Our capital lease obligation bears a fixed interest rate. Therefore, we are not exposed to material risks from changes in interest rates on our outstanding indebtedness.
Foreign currency risk
The majority of our revenue is generated in the United States. Through March 31, 2019, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. Our obligation related to a royalty denominated in Euros is subject to foreign currency risk. As of March 31, 2019, the effect of a hypothetical 10% change in foreign currency exchange rates would result in a foreign exchange gains or losses of $0.7 million, on total cumulative balance of obligations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.


48


Item 4. Controls and Procedures
Evaluation of disclosure controls and procedures
Our management, with the participation of our chief executive officer, or CEO, and chief financial officer, or CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our CEO and CFO have concluded that as of March 31, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such required information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures.
Changes in internal control
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on effectiveness of controls and procedures
Our management, including our CEO and CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

49


PART II—OTHER INFORMATION
Item 1. Legal Proceedings
We may from time to time be involved in various legal proceedings and other matters arising in the normal course of business. For example, we have received, and may in the future continue to, receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute additional, legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.

The information under the caption “Commitments and Contingencies - Legal Proceedings” in Note 8 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.

Item 1A. Risk Factors
Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 19, 2019. The risks and uncertainties disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. While we believe there have been no material changes in our risk factors from those disclosed in the Annual Report, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.
 
These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Not applicable.

50



Item 6. Exhibits.
Exhibit Number
 
Description
 
Form
 
File No.
 
Exhibit
 
Filing Date
 
Filed/Furnished Herewith
3.1
 
 
8-K
 
001-38683
 
3.1
 
10/9/2018
 
 
3.2
 
 
8-K
 
001-38683
 
3.2
 
10/9/2018
 
 
10.1#
 
 
S-8
 
333-227762
 
99.3
 
10/10/2018
 
 
10.1(a)#
 
 
10-K
 
001-38683
 
10.4(a)
 
3/29/2019
 
 
10.2#
 
 
S-1/A
 
333-227206
 
10.13
 
9/21/2018
 
 
10.2(a)#
 
 
10-K
 
001-38683
 
10.5(a)
 
3/29/2019
 
 
10.3#
 
 
 
 
 
 
 
 
 
 
*
10.4#
 
 
10-K
 
001-38683
 
10.19
 
3/29/2019
 
 
10.5
 
 
 
 
 
 
 
 
 
 
*
10.6#
 
 
 
 
 
 
 
 
 
 
*
31.1
 
 
 
 
 
 
 
 
 
 
*
31.2
 
 
 
 
 
 
 
 
 
 
*
32.1
 
 
 
 
 
 
 
 
 
 
**
32.2
 
 
 
 
 
 
 
 
 
 
**
101.INS
 
XBRL Instance Document
 
 
 
 
 
 
 
 
 
*
101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
 
*
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 
*
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________
*    Filed herewith.
**    Furnished herewith.
#    Indicates management contract or compensatory plan.
§    Schedules and attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K.


51


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized
 
 
GUARDANT HEALTH, INC.
 
 
 
 
Dated:
May 10, 2019
By:
/s/ Derek Bertocci
 
 
Name:
Derek Bertocci
 
 
Title:
Chief Financial Officer (Principal Financial and Accounting Officer)

52
EX-10.3 2 guardanthealth-directorcom.htm EXHIBIT 10.3 Exhibit

Exhibit 10.3

GUARDANT HEALTH, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

(EFFECTIVE APRIL 1, 2019)

Eligible Directors (as defined below) on the board of directors (the “Board”) of Guardant Health, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any of its parents, affiliates or subsidiaries (each, an “Eligible Director”), who may be eligible to receive such cash or equity compensation, unless such Eligible Director declines the receipt of such cash or equity compensation by written notice to the Company.
This Program shall become effective upon the date set forth above (the “Effective Date”) and shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. No Eligible Director shall have any rights hereunder, except with respect to equity awards granted pursuant to Section 2 of this Program.
1.Cash Compensation.
a.    Annual Retainers. Effective upon the Effective Date, each Eligible Director shall be eligible to receive an annual cash retainer of $48,000 for service on the Board.
b.    Additional Annual Retainers. In addition, effective upon the Effective Date, an Eligible Director shall be eligible to receive the following additional annual retainers, as applicable:
(i)    Lead Independent Director. An Eligible Director serving as Lead Independent Director of the Board shall be eligible to receive an additional annual retainer of $10,000 for such service.
(ii)    Audit Committee. An Eligible Director serving as Chairperson of the Audit Committee shall be eligible to receive an additional annual retainer of $20,000 for such service. An Eligible Director serving as a member of the Audit Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $10,000 for such service.
(iii)    Compensation Committee. An Eligible Director serving as Chairperson of the Compensation Committee shall be eligible to receive an additional annual retainer of $15,000 for such service. An Eligible Director serving as a member of the Compensation Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $7,500 for such service.
(iv)     Nominating and Corporate Governance Committee. An Eligible Director serving as Chairperson of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $10,000 for such service. An Eligible Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall be eligible to receive an additional annual retainer of $5,000 for such service.
c.    Payment of Retainers. The annual cash retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than 30 days following the end of each calendar quarter. Annual cash retainers will not be pro-rated for any partial calendar quarter of service. For the avoidance of doubt, no Eligible Director will receive any annual cash retainer (or portion thereof) under Section 1(a) with respect to services provided to the Company prior to the Effective Date.

1




2.Equity Compensation.
a.    General. Eligible Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2018 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (such plan, as may be amended from time to time, the “Equity Plan”) and may be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms approved by the Board prior to or in connection with such grants. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of equity awards hereby are subject in all respects to the terms of the Equity Plan. Notwithstanding any provision to the contrary in this Program or the Equity Plan, the amount of any cash compensation and/or the grant date fair value (determined as of the date of the grant under Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all awards granted under this Program shall be subject to any limitations imposed under the Equity Plan or any other applicable Company agreement, program, policy or plan. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Equity Plan.
b.    Initial Awards. Each Eligible Director who is initially elected or appointed to serve on the Board after the Effective Date automatically shall be granted an Option with a value of $215,000 (the “Initial Option”) and a Restricted Stock Unit award with a value of $215,000 (the “Initial RSU Award” and, together with the Initial Option, the “Initial Award”). The number of Shares subject to an Initial Option shall be determined by dividing the value of the Initial Option by the per share Black-Scholes valuation as of the grant date, utilizing the same assumptions that the Company uses in preparation of its financial statements but using an average closing price for the Company’s common stock for the 30 consecutive calendar days prior to (and including) the date immediately preceding the applicable grant date. The number of Shares subject to an Initial RSU Award shall be determined by dividing the value of the Initial RSU Award by the average closing price for the Company’s common stock for the 30 consecutive calendar days prior to (and including) the date immediately preceding the applicable grant date. Each Initial Award shall be granted on the date on which such Eligible Director is appointed or elected to serve on the Board (the “Election Date”), and each such award shall vest and become exercisable, as applicable, as to one-third of the Shares subject to such award on each of the first three anniversaries of such Election Date, subject to continued service through the applicable vesting date. The Initial Option shall have an exercise price per Share equal to the Fair Market Value of a Share on the applicable grant date, and shall have a maximum term of ten years from the applicable grant date.
c.    Annual Awards. An Eligible Director who has served on the Board for at least six months as of the date of the annual meeting of the Company’s stockholders beginning with the annual meeting in calendar year 2019 shall be granted, on such annual meeting date, an Option with a value of $107,500 (the “Annual Option”) and a Restricted Stock Unit award with a value of $107,500 (the “Annual RSU Award” and, together with the Annual Option, the “Annual Award”). The number of Shares subject to an Annual Option shall be determined by dividing the value of the Annual Option by the per share Black-Scholes valuation as of the grant date, utilizing the same assumptions that the Company uses in preparation of its financial statements but using an average closing price for the Company’s common stock for the 30 consecutive calendar days prior to (and including) the date immediately preceding the applicable grant date. The number of Shares subject to an Annual RSU Award shall be determined by dividing the value by the average closing price for the Company’s common stock for the 30 consecutive calendar days prior to (and including) the date immediately preceding the applicable grant date. Each Annual Award shall vest in full on the earlier to occur of (i) the one-year anniversary of the applicable grant date and (ii) the date of the next annual meeting of the Company’s stockholders following the grant date, subject to continued service through the applicable vesting date. The Annual Option shall have an exercise price per Share equal to the Fair Market Value of a Share on the applicable grant date, and shall have a maximum term of ten years from the applicable grant date.
d.    Accelerated Vesting Events. Notwithstanding the foregoing, an Eligible Director’s Initial Award and Annual Award(s) shall vest in full immediately prior to (i) such Eligible Director’s Termination of Service by the Company without Cause (as defined below) or due to his/her death or Disability (as defined below) or (ii) the occurrence of a Change in Control, in each case, to the extent outstanding at such time.

2




3.Certain Defined Terms.
a.    “Cause” means the occurrence of any one or more of the following events unless, to the extent capable of correction, the Eligible Director fully corrects the circumstances constituting Cause within 15 days after receipt of written notice thereof:
i.    the Eligible Director’s willful failure to substantially perform his or her duties with the Company (other than any such failure resulting from the Eligible Director’s incapacity due to physical or mental illness), after a written demand for performance is delivered to the Eligible Director by the Board, which demand specifically identifies the manner in which the Board believes that the Eligible Director has not performed his or her duties;

ii.    the Eligible Director’s commission of an act of fraud or material dishonesty resulting in reputational, economic or financial injury to the Company;

iii.    the Eligible Director’s material misappropriation or embezzlement of the property of the Company or any of its affiliates;

iv.    the Eligible Director’s commission of, including any entry by the Eligible Director of a guilty or no contest plea to, a felony (other than a traffic violation) or other crime involving moral turpitude, or the Eligible Director’s commission of unlawful harassment or discrimination;

v.    the Eligible Director’s willful misconduct or gross negligence with respect to any material aspect of the Company’s business or a material breach by the Eligible Director of his or her fiduciary duty to the Company, which willful misconduct, gross negligence or material breach has a material and demonstrable adverse effect on the Company; or

vi.    (f)    the Eligible Director’s material breach of the Eligible Director’s obligations under a written agreement between the Company and the Eligible Director.
b.    “Disability” means a permanent and total disability under Section 22(e)(3) of the Code.

3


EX-10.5 3 a10-qexhibitghleenasignedo.htm EXHIBIT 10.5 Exhibit

    


Exhibit 10.5
May 13, 2018

Leena Das-Young
15638 Via Santa Pradera
San Diego, CA 92131



Dear Leena:

On behalf of Guardant Health, Inc. (the “Company”), I am pleased to offer you the position of General Manager and Chief Lunar Officer for the Company working in our office located at 505 Penobscot Dr., Redwood City, CA. You will be working under the guidance of and reporting to AmirAli Talasaz, President & COO.
When you join Guardant Health, you will be an exempt salaried employee. Your initial base salary will be $398,000 less applicable deductions and withholdings, which will be paid semi-monthly in accordance to the Company’s normal payroll procedures. As an exempt employee, you will not be entitled to payment of overtime.

Bonus: You are eligible to participate in the yearly Incentive Compensation bonus plan, and your target bonus is up to 35% bonus of your base salary. This is payable each year and contingent upon factors including individual and Company performance. Your initial annualized bonus target amount will be prorated from your hire date (subject to the satisfactory achievement of the above stated objectives). 
Sign On: You will receive a one-time signing bonus of $120,000 subject to applicable taxes, payable on your first or second payroll date. Please note that if you voluntarily terminate your employment with the Company prior to completing 24 months of service, you will be required to repay the sign-on bonus on a prorated basis. It will be based upon the number of months of employment with the Company.
Stock Options: We will recommend that the Board of Directors grant you a stock option (the “Option”) to purchase 300,000 shares of the Company’s Common Stock with an exercise price equal to the fair market value on the date of the grant. The Option shares will vest and become exercisable at the rate of 25% of the total number of shares on the twelve (12) month anniversary of your Vesting Commencement Date (as defined in the Stock Option Agreement to be executed between you and the Company, which date will be your Start Date, as defined below) and 1/48th of the total number of shares each month thereafter on the monthly anniversary of the Vesting Commencement Date. Vesting will, of course, depend on your continued employment with the Company. The Option will be an incentive stock option to the maximum extent allowed by the tax code and will be subject to the terms of the Company’s 2012 Stock Plan (the “Plan”) and the Stock Option Agreement between you and the Company, including but not limited to a “lock-up” provision and a right of first refusal in favor of the Company. The Company will also recommend to the Board of Directors that your Stock Option Agreement be approved to contain standard double trigger acceleration similar to that of other executives in the Company. This will include the following definition of “Constructive Termination”. Constructive Termination” shall mean (1) any reduction of your base compensation without your written consent (except an equal, across-the-board reduction in the compensation of all similarly-situated employees of the Company or the surviving entity that is approved by the board of directors); or (2) a requirement that you relocate by more than 50 miles.

Relocation: We are offering you a one-time relocation payment of$250,000 to assist with your move from San Diego to the Bay Area (including to cover any realtor fees you incur upon sale of your home), subject to applicable taxes, payable promptly following your start date.   Your move must be completed by December 31st, 2018 and should be considered part of a “permanent move.”    If before the completion of two years of employment, you voluntarily leave Guardant Health, you must repay to Guardant health the relocation payment. The percentage of relocation payment to be repaid is based on the following schedule:
 
100% if employed for less than 12 months
75% if employed for between 12 months but less than 15 months
50% if employed between 12 months but less than 18 months 
25% if employed between 18 months but less than 24 months

Paid Time Off: You will be eligible to accrue paid time off of 15 days for your first year and then 20 days from your first anniversary, accrued per pay period. Details of our paid time off policy will be provided in our Company’s handbook.
Group Benefits Plans: You will be eligible to participate in the standard benefits plans currently available to other similarly situated employees, including medical, dental, vision and life insurance, subject to any eligibility requirements imposed by such plans. Eligibility for these plans will start on your first day of employment. Details of the plans will be provided prior to your start date and you will be able to select benefits during your first 30 days of employment.
Confidentiality Agreement: Your acceptance of this offer and commencement of employment with the Company is contingent upon the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and Invention Assignment Agreement, a copy of which is enclosed for your review and execution (the “Confidentiality Agreement”), prior to your Start Date.
Work Authorization: This offer is contingent upon your obtaining the requisite employment authorization. If you require assistance obtaining work authorization or transferring a visa, please contact Gail Jacobs (gjacobs@guardanthealth.com) to initiate the process with our attorneys. The Company will submit a petition on your behalf to obtain employment authorization, as well as file visa applications for your immediate dependent family members. The Company will pay the legal fees and costs related to these filings. Because the number of work visas available each year is limited by the U.S. Government, Guardant Health reserves the right to withdraw or suspend this offer of employment if it is not able to obtain work authorization for you in a reasonable period of time. Please note that if you currently have employment authorization such as practical, curricular or academic training (F-1 or J-1) you must contact us before beginning employment.
Federal immigration law requires that we verify your right to work legally in the United States. You will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your Start Date, or our employment relationship with you may be terminated.
Your offer of employment is also contingent upon the successful verification of the information you provided to the Company during your application process, as well as a general background check performed by the Company.  By accepting this offer of employment, you warrant that all information provided by you is true and correct to the best of your knowledge. Please make sure to fill out the necessary forms as soon as you receive them.
Lastly, we pride ourselves having a supportive and open environment, however, as a Guardant Health employee, you will be expected to abide by the Company rules and standards. You will be required to read and sign the ‘Acknowledgment of Receipt’ from the Guardant Health Employee Handbook.

No Conflicting Obligations: By accepting this offer of employment, you understand and agree that your performance will not breach any other agreement to which you are a party and that you have not, and will not during the term of your employment with the Company, enter into any oral or written agreement in conflict with any of the provisions of this letter or the Company’s policies. You are not to bring with you to Guardant Health, or use or disclose to any person associated with the Company, any confidential or proprietary information belonging to any former employer or other person or entity with respect to which you owe an obligation of confidentiality under any agreement or otherwise. The Company does not need and will not use such information and we will assist you in any way possible to preserve and protect the confidentiality of proprietary information belonging to third parties. Also, we expect you to abide by any obligations to refrain from soliciting any person employed by or otherwise associated with any former employer (to the extent you have any such obligations) and suggest that you refrain from having any contact with such persons until such time as any non-solicitation obligation expires.
General Obligations: Guardant Health is proud of its culture that it’s developed and as an employee, you will be expected to adhere to the Company’s standards of professionalism, loyalty, integrity, honesty, reliability and respect for all. Please note that we are an equal opportunity employer. The Company does not permit, and will not tolerate, the unlawful discrimination or harassment of any employees, consultants, or related third parties on the basis of sex, race, color, religion, age, national origin or ancestry, family care status, marital or domestic partner status, veteran or military status, mental or physical disability or legally protected medical condition, genetic information, sexual orientation, gender identity, gender expression, pregnancy, childbirth or related medical condition, or any other status protected by applicable law.
At Will Employment: Guardant Health is excited about your joining and looks forward to a mutually beneficial relationship. Nevertheless, you should be aware that your employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason without further obligation or liability. Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without notice. The Company also reserves the right to modify or amend the terms of your employment at any time for any reason. This policy of at-will employment is the final and entire agreement as to how your employment may be terminated and may only be modified in an express written agreement signed by the Chief Executive Officer of the Company that expressly changes your at-will status.
This letter, together with the Confidentiality Agreement, set forth the terms of your employment with the Company and supersede any prior representations or agreements, whether written or oral. This letter will be governed by the laws of California, without regard to its conflict of laws and provisions.

We are all delighted to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the offer, please sign and date this letter in the space provided below and return it to me May 14, 2018. We request that you begin full-time work in this new position on June 18, 2018.

Leena, we are very excited about having you join Guardant Health and look forward to working with you.

Very truly yours,
Guardant Health, Inc.

/s/ Amelia Merrill              
Amelia Merrill, VP of People
ACCEPTED AND AGREED:
Leena Das-Young

/s/ Leena Das-Young    
Signature

May 13, 2018    
Date

Attachment A: Confidential Information and Invention Assignment Agreement



EX-10.6 4 a10-qexhibitghlanmansigned.htm EXHIBIT 10.6 Exhibit
 

    

Exhibit 10.6

July 29, 2014
Rick Lanman, MD
556 Van Buren Street
Los Altos, CA 94022
Dear Rick:
On behalf of Guardant Health, Inc. (the “Company”), I am pleased to offer you the position of Chief Medical Officer for the Company. You will be working under the guidance of, and reporting to AmirAli Talasaz, President for the Company.
1.Compensation.
(a)    Base Wage. In this exempt position, you will earn a starting salary of $325,000 per year, subject to applicable tax withholding. Your salary will be payable two times each month (semi-monthly) pursuant to the Company’s regular payroll policy.
(b)    Signing Bonus. The Company will pay you a one-time bonus of $45,000 as a sign-on bonus with your first payroll. Should your employment end before the one-year anniversary of your Start Date (defined below), you will be required to forfeit this entire amount.
(c)    Incentive Compensation. You will also be eligible to receive an annualized incentive bonus of up to $50,000 payable each year after your annual review, determined based upon achievement of mutually agreed upon milestones.
2.    Employee Benefits.
(a)    Paid Time Off. You will be eligible to accrue paid time off in accordance with the policies set forth in the Company’s handbook.
(b)    Group Plans. The Company will provide you with the opportunity to participate in the standard benefits plans currently available to other similarly situated employees, including medical, dental, vision and life insurance, subject to any eligibility requirements imposed by such plans.
3.    Pre-employment Conditions.
(a)    Confidentiality Agreement. Your acceptance of this offer and commencement of employment with the Company is contingent upon the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and Invention Assignment Agreement, a copy of which is enclosed for your review and execution (the “Confidentiality Agreement”), prior to or on your Start Date.
(b)    Right to Work. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your Start Date, or our employment relationship with you may be terminated.
(c)    Verification of Information. This offer of employment is also contingent upon the successful verification of the information you provided to the Company during your application process, as well as a general background check performed by the Company to confirm your suitability for employment. By accepting this offer of employment, you warrant that all information provided by you is true and correct to the best of your knowledge, and you expressly release the Company from any claim or cause of action arising out of the Company’s verification of such information. You have a right to review copies of any public records obtained by the Company in conducting this verification process unless you check the box below.
4.    No Conflicting Obligations. You understand and agree that by accepting this offer of employment, you represent to the Company that your performance will not breach any other agreement to which you are a party and that you have not, and will not during the term of your employment with the Company, enter into any oral or written agreement in conflict with any of the provisions of this letter or the Company’s policies. You are not to bring with you to the Company, or use or disclose to any person associated with the Company, any confidential or proprietary information belonging to any former employer or other person or entity with respect to which you owe an obligation of confidentiality under any agreement or otherwise. The Company does not need and will not use such information and we will assist you in any way possible to preserve and protect the confidentiality of proprietary information belonging to third parties. Also, we expect you to abide by any obligations to refrain from soliciting any person employed by or otherwise associated with any former employer and suggest that you refrain from having any contact with such persons until such time as any non-solicitation obligation expires.
5.    General Obligations. As an employee, you will be expected to adhere to the Company’s standards of professionalism, loyalty, integrity, honesty, reliability and respect for all. Please note that the Company is an equal opportunity employer. The Company does not permit, and will not tolerate, the unlawful discrimination or harassment of any employees, consultants, or related third parties on the basis of sex, race, color, religion, age, national origin or ancestry, marital status, veteran status, mental or physical disability or medical condition, sexual orientation, pregnancy, childbirth or related medical condition, or any other status protected by applicable law. Any questions regarding this EEO statement should be directed to Human Resources.
6.    At-Will Employment. Your employment with the Company will be on an “at will” basis, meaning that either you or the Company may terminate your employment at any time for any reason or no reason, without further obligation or liability. The Company also reserves the right to modify or amend the terms of your employment at any time for any reason. This policy of at-will employment is the entire agreement as to the duration of your employment and may only be modified in an express written agreement signed by the Chief Executive Officer of the Company.
7.    Stock Option. The Company will recommend that the Board of Directors grant you a stock option (the “Option”) to purchase 400,000 shares of the Company’s Common Stock (equal to approximately 1% of the Company’s fully-diluted capital stock as of the date of this letter) with an exercise price equal to the fair market value on the date of the grant. The Option shares will vest and become exercisable at the rate of 25% of the total number of shares on the twelve (12) month anniversary of your Vesting Commencement Date (as defined in the Stock Option Agreement to be executed between you and the Company, which date will be your Start Date, as defined below) and 1/48th of the total number of shares each month thereafter on the monthly anniversary of the Vesting Commencement Date. Vesting will, of course, depend on your continued employment with the Company. The Option will be an incentive stock option to the maximum extent allowed by the tax code and will be subject to the terms of the Company’s 2012 Stock Plan (the “Plan”) and the Stock Option Agreement between you and the Company, including but not limited to a “lock-up” provision and a right of first refusal in favor of the Company. The Company will also recommend to the Board of Directors that your Stock Option Agreement be approved to contain standard double trigger acceleration similar to that of other executives in the Company.
We are all delighted to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below and return it to me on or before July 29, 2014. The Company requests that you begin full-time work in this new position on or about August 30, 2014 (the “Start Date”). This letter, together with the Confidentiality Agreement, set forth the terms of your employment with the Company and supersede any prior representations or agreements, whether written or oral. This letter will be governed by the laws of California, without regard to its conflict of laws provisions. This letter may not be modified or amended except by a written agreement, signed by an officer of the Company.
Very truly yours,
Guardant Health, Inc.
/s/ AmirAli Talasaz    
AmirAli Talasaz, President
ACCEPTED AND AGREED:
Rick Lanman, M.D.
/s/ Rick Lanman    
Signature
July 29, 2014    
Date


EX-31.1 5 gh-0331x2019x10qxexhibit311.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Helmy Eltoukhy, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
May 10, 2019
/s/ Helmy Eltoukhy
 
Helmy Eltoukhy
 
Chief Executive Officer
 
(Principal Executive Officer)

EX-31.2 6 gh-0331x2019x10qxexhibit312.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Derek Bertocci, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
May 10, 2019
/s/ Derek Bertocci
 
Derek Bertocci
 
Chief Financial Officer
 
(Principal Financial Officer and
Principal Accounting Officer)

EX-32.1 7 gh-0331x2019x10qxexhibit321.htm EXHIBIT 32.1 Exhibit
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Guardant Health, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:
May 10, 2019
/s/ Helmy Eltoukhy
 
Helmy Eltoukhy
 
Chief Executive Officer
 
(Principal Executive Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-32.2 8 gh-0331x2019x10qxexhibit322.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Guardant Health, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:
May 10, 2019
/s/ Derek Bertocci
 
Derek Bertocci
 
Chief Financial Officer
 
(Principal Financial Officer and
Principal Accounting Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.INS 9 gh-20190331.xml XBRL INSTANCE DOCUMENT 0001576280 2019-01-01 2019-03-31 0001576280 2019-05-07 0001576280 2019-03-31 0001576280 2018-12-31 0001576280 2018-01-01 2018-03-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001576280 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001576280 us-gaap:PreferredStockMember 2018-03-31 0001576280 us-gaap:CommonStockMember 2017-12-31 0001576280 2017-12-31 0001576280 2018-03-31 0001576280 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001576280 us-gaap:PreferredStockMember 2017-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001576280 us-gaap:RetainedEarningsMember 2017-12-31 0001576280 us-gaap:CommonStockMember 2018-03-31 0001576280 us-gaap:RetainedEarningsMember 2018-03-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001576280 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001576280 gh:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 0001576280 gh:RedeemableNoncontrollingInterestMember 2019-03-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2019-01-01 0001576280 us-gaap:RetainedEarningsMember 2018-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001576280 us-gaap:CommonStockMember 2018-12-31 0001576280 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001576280 us-gaap:CommonStockMember 2019-03-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2018-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001576280 us-gaap:RetainedEarningsMember 2019-03-31 0001576280 gh:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2019-01-01 0001576280 gh:RedeemableNoncontrollingInterestMember 2019-01-01 2019-03-31 0001576280 gh:GuardantHealthAMEAIncMember 2018-04-30 0001576280 2018-09-01 2018-09-30 0001576280 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-03-31 0001576280 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-03-31 0001576280 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-03-31 0001576280 us-gaap:CollaborativeArrangementMember 2019-03-31 0001576280 2019-01-01 0001576280 us-gaap:CollaborativeArrangementMember 2018-12-31 0001576280 gh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001576280 gh:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001576280 gh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001576280 gh:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0001576280 gh:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001576280 gh:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001576280 gh:SoftBankMember gh:GuardantHealthAMEAIncMember 2018-05-31 0001576280 gh:GuardantHealthAMEAIncMember 2018-05-31 0001576280 gh:SoftBankMember gh:GuardantHealthAMEAIncMember 2018-05-01 2018-05-31 0001576280 gh:GuardantHealthAMEAIncMember 2018-05-01 2018-05-31 0001576280 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001576280 us-gaap:LeaseholdImprovementsMember 2019-03-31 0001576280 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001576280 us-gaap:FurnitureAndFixturesMember 2019-03-31 0001576280 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-03-31 0001576280 us-gaap:ConstructionInProgressMember 2019-03-31 0001576280 us-gaap:ComputerEquipmentMember 2019-03-31 0001576280 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001576280 us-gaap:ConstructionInProgressMember 2018-12-31 0001576280 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001576280 us-gaap:ComputerEquipmentMember 2018-12-31 0001576280 us-gaap:MachineryAndEquipmentMember 2019-03-31 0001576280 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001576280 us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:USGovernmentDebtSecuritiesMember 2019-03-31 0001576280 us-gaap:MoneyMarketFundsMember 2019-03-31 0001576280 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001576280 srt:MinimumMember 2019-01-01 2019-03-31 0001576280 srt:MaximumMember 2019-01-01 2019-03-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 2017-01-01 2017-01-31 0001576280 2018-01-01 2018-12-31 0001576280 gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member 2018-03-01 2018-03-31 0001576280 us-gaap:OtherIncomeMember 2018-01-01 2018-03-31 0001576280 gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember 2018-03-01 2018-03-31 0001576280 gh:PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember 2017-11-01 2017-11-30 0001576280 us-gaap:EmployeeStockMember 2018-12-31 0001576280 us-gaap:EmployeeStockMember 2019-03-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001576280 gh:A2018IncentiveAwardPlanMember 2019-03-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-03-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-12-31 0001576280 gh:A2018IncentiveAwardPlanMember 2018-12-31 0001576280 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001576280 gh:NonemployeeStockOptionMember 2019-01-01 2019-03-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001576280 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0001576280 gh:NonemployeeStockOptionMember 2018-12-31 0001576280 gh:NonemployeeStockOptionMember 2018-01-01 2018-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001576280 gh:NonemployeeStockOptionMember 2019-03-31 0001576280 2018-10-01 2018-10-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001576280 gh:PrecisionOncologyTestingMember 2019-01-01 2019-03-31 0001576280 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-03-31 0001576280 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001576280 gh:PrecisionOncologyTestingMember 2018-01-01 2018-03-31 0001576280 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001576280 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001576280 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-03-31 0001576280 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001576280 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001576280 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001576280 us-gaap:WarrantMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001576280 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001576280 us-gaap:WarrantMember us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001576280 us-gaap:TreasuryStockCommonMember 2018-01-01 2018-03-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001576280 us-gaap:EmployeeStockMember 2018-01-01 2018-03-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001576280 us-gaap:WarrantMember us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001576280 us-gaap:WarrantMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001576280 us-gaap:TreasuryStockCommonMember 2019-01-01 2019-03-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001576280 us-gaap:NonUsMember 2019-01-01 2019-03-31 0001576280 country:US 2019-01-01 2019-03-31 0001576280 us-gaap:NonUsMember 2018-01-01 2018-03-31 0001576280 country:US 2018-01-01 2018-03-31 0001576280 gh:BellweatherBioInc.Member us-gaap:SubsequentEventMember 2019-04-01 2019-04-30 0001576280 gh:BellweatherBioInc.Member us-gaap:SubsequentEventMember 2019-04-30 xbrli:pure gh:patent xbrli:shares gh:party iso4217:USD xbrli:shares iso4217:USD false --12-31 Q1 2019 2019-03-31 10-Q 0001576280 87112669 true false Non-accelerated Filer Guardant Health, Inc. false GH 343000 137000 7338000 7120000 381776000 349078000 44268 32279 5711000 7120000 1208000 2512000 8045000 11023000 381858000 348675000 40000 40000 814000 2400000 3351000 490000 P1Y2M0D P1Y0M0D 3000 0 3 2 4 4 2 6 9700000 0 73000 2501000 7818000 0 7818000 14191000 28837000 994000 29831000 0.01 0.02 508847 812 18337 18370 120835 44268 31713 4000 4000 56000 56000 -206000 144000 4.66 4.66 10642000 7163000 35690000 28989000 994000 29983000 40597000 4907000 78000 553000 1470000 1410000 7081000 9137000 1791000 1988000 707000 853000 16634000 16303000 -83000 333000 764033000 771009000 1277000 1277000 3183000 3183000 1277000 63000 636000 204000 374000 3182000 566000 170000 976000 1210000 826000 189000 243000 64000 30000 66061000 58265000 0 7457000 0 19000 312000 8000 7681000 0 59000 7503000 78000 41000 0 0 587403000 579171000 468991000 512255000 25796000 355980000 0 381776000 10093000 338985000 0 349078000 235000 0 0 235000 481000 26000 0 455000 317000 71000 10000 236000 78000 3000 1000 74000 42273000 5014000 308775000 45065000 4995000 288522000 42202000 5004000 308774000 45088000 4994000 288903000 20000000 97000 96000 119000 100000 504000 504000 251000 36000 108000 55000 196000 107000 294000 324000 140544000 25796000 153790000 10093000 25796000 0 0 25796000 25796000 0 0 25796000 25796000 10093000 0 0 10093000 10093000 0 0 10093000 10093000 72596000 75774000 140544000 153789000 3178000 13245000 12067162 3556507 922250 7588405 0 11719565 3436451 802548 7378068 102498 0.0000001 0.0000001 350000000 350000000 85832454 86098474 85832454 86098474 1000 1000 -14142000 -25635000 -14142000 -20935000 0.11 0.65 0.13 0.35 0.24 0.13 16100000 10500000 17100000 12400000 7000000 12831000 5609000 1683000 1683000 1402000 1402000 1052000 35339000 60319000 1266000 -1266000 4907000 4907000 0 0 0 0 278417000 38397000 5004000 235016000 0 0 0 0 278417000 38397000 5004000 235016000 0 0 0 0 313069000 43083000 4994000 264992000 0 0 0 0 313069000 43083000 4994000 264992000 0 0 0 77563000 3805000 73758000 0 0 0 77563000 3805000 73758000 0 0 0 25916000 2005000 23911000 0 0 0 25916000 2005000 23911000 12986000 14683000 206000 150000 7844000 8975000 16138000 17113000 1200000 2100000 1395000 2354000 -1.16 -0.30 0 -69000 P2Y8M21D P2Y5M27D P0Y4M0D P3Y7M24D 646000 4200000 17500000 16600000 0.50 0.50 0.50 P8Y0M0D P7Y9M0D 7800000 7800000 7600000 7557000 6519000 12661000 -13844000 -21325000 0 26000 0 -48000 1989000 -2610000 -623000 -11608000 1108000 2308000 -621000 -1131000 1491000 975000 -608000 1697000 -321000 1120000 -255000 833000 1312000 947000 331000 293000 30000 293000 9136000 10256000 985000 2485000 1100000 1300000 62451000 64537000 587403000 579171000 46944000 48192000 4250000 278417000 313069000 77563000 25916000 1267000 2288000 8470000 15329000 -6559000 -4303000 0 4700000 -13844000 -26051000 -18647000 -23664000 62617000 3693000 9023000 8388000 8161000 7276000 26076000 1956000 2349000 2046000 2862000 0 -69000 -298000 -298000 416000 416000 0 4700000 -298000 485000 206000 150000 4149000 147000 0 89000 10100000 9000000 19634000 45966000 4021000 2705000 5204000 6151000 32125000 64000000 1310000 538000 0 1933000 4000 0 -13844000 -13844000 -21351000 -21351000 47637000 4949000 3118000 1522000 13965000 23440000 643000 46884000 5293000 1405000 1540000 14163000 23742000 741000 31003000 30581000 -4700000 4700000 -4700000 41800000 46500000 41000000 47000 21000 8255000 16316000 -280799000 -303209000 994000 -302215000 -275892000 4907000 16692000 12902000 3790000 36655000 31245000 5410000 172000 633000 11312000 17807000 1277000 3182000 18337 41.30 120835 44.02 0.00 44.50 0 102498 0 0 0 0.865 0.816 0.667 0.602 0.027 0.025 0.027 0.025 0.1 922250 3658602 3556507 3436451 3.61 1300000 8100000 82389 18370 3.77 25.90 250495000 531281000 7588405 7378068 4.58 4.69 3361540 3.49 4.77 41.25 P10Y P5Y4D P6Y2M21D P0Y5M29D 245680000 P7Y4M17D P8Y3M6D P8Y0M14D 0.85 11896882 78627369 12394127 78627369 85832454 86098474 119702 119702 421264 146318 146318 1933000 1933000 1103000 1103000 538000 538000 308606000 -532000 4900000 0 499974000 -195736000 296848000 -830000 7284000 0 499974000 -209580000 483152000 -83000 764033000 1000 -280799000 468134000 333000 771009000 1000 -303209000 0.7378 41800000 46500000 3900000 4900000 48300000 47000000 1200000 942000 11920000 85935000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs of Precision Oncology Testing</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market fund </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bond </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,088</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market fund </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bond </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Act of 2012 (the &#8220;JOBS Act&#8221;). Section&#160;107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section&#160;102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. The Company has elected to use this extended transition period and, as a result, the consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company also intends to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Condensed Consolidated Balance Sheet Components</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense related to property and equipment was </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, total property and equipment financed under capital leases was </font><font style="font-family:inherit;font-size:10pt;">$504,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$504,000</font><font style="font-family:inherit;font-size:10pt;">, net of accumulated amortization of </font><font style="font-family:inherit;font-size:10pt;">$324,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$294,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense related to total property and equipment financed under capital leases was </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$64,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalty obligations </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued tax liabilities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional services </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment included in accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that its existing cash and cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments under the non-cancelable operating lease were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,617</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for the facility leases was </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capital Leases</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum capital lease payments were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum capital lease payments </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of net minimum capital lease payments </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current installments of obligations under capital lease </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obligations under capital lease, excluding current installments </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has patent license agreements with&#160;</font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty expenses were included in cost of precision oncology testing on the accompanying condensed consolidated statements of operations. The Company recognized royalty expenses of </font><font style="font-family:inherit;font-size:10pt;">$633,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$172,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of precision oncology testing revenue in each period, for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum royalty payments were due as follows regardless of sales amounts:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum royalty payments </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,711</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of future minimum royalty payments </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Incidents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2018, the Company experienced security incidents involving an unauthorized actor obtaining access to its email system and sending phishing messages. The Company has implemented and continues to implement additional security measures to help prevent future unauthorized access to its systems and the data it maintains, including promptly engaging an independent cybersecurity firm to support its investigation, assess its systems and bolster security thereof. The Company provided timely notices to the U.S. Department of Health and Human Services, or the HHS, certain state regulators and certain credit agencies, as applicable, as well as to the individuals affected. Following such security incidents, the Company received a request for information in January 2019 regarding the incidents from the HHS Office for Civil Rights, or OCR.&#160; The Company has responded to that request in a timely manner but does not know whether OCR will request additional information or pursue any further action. The Company currently cannot predict the ultimate resolution of the security incidents or the OCR inquiry and cannot estimate the amounts or ranges of potential loss that could result therefrom. The Company has insurance coverage in place for certain potential claims, liabilities and costs relating to the security incidents, but this coverage is limited in amount and may not be adequate to protect against all claims, liabilities and costs arising from such incidents, including fines and penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.</font></div><div style="line-height:174%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Disputes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;) in the United States District Court for the District of Delaware, alleging that each of the&#160;two&#160;companies has infringed a patent relating to the Company&#8217;s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys&#8217; fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity, including subsequently unenforceabilty under the doctrine of inequitable conduct, and non-infringement. In addition, Personal Genome Diagnostics has alleged, as part of its subsequent counterclaims, that the Company&#8217;s actions related to obtaining and securing exclusive rights to the patents-in-suit violated provisions of Section 2 of the Sherman Antitrust&#160;Act. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, Personal Genome Diagnostics filed </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> petitions for post-grant review with the PTAB, challenging the patentability of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of the patents asserted by the Company. Prior to reaching a decision on the merits, the&#160;</font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;post-grant review petitions were dismissed with prejudice in July 2018. Subsequently,&#160;Foundation Medicine filed&#160;</font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#160;petitions for inter partes review with the PTAB, challenging the patentability of all </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions.&#160;At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.</font></div><div style="line-height:174%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Dispute</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (&#8220;Licensor&#8221;), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor&#8217;s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company&#8217;s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor&#8217;s counterclaims will succeed on the merits.</font></div><div style="line-height:174%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Disputes</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of </font><font style="font-family:inherit;font-size:10pt;">$4.25 million</font><font style="font-family:inherit;font-size:10pt;">, which was reported as other income in the condensed consolidated statements of operations for the three months ended March 31, 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment&#8209;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#8209;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum royalty payments were due as follows regardless of sales amounts:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum royalty payments </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,711</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of future minimum royalty payments </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2012 Stock Plan and 2018 Incentive Award Plan</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2012 and September 2018, the Board of Directors adopted and its stockholders approved the Company&#8217;s 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the Company&#8217;s 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and nonemployees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and&#160;the </font><font style="font-family:inherit;font-size:10pt;">508,847</font><font style="font-family:inherit;font-size:10pt;">&#160;shares remaining available for future grant under the 2012 Plan were not made available for grant under the 2012 Plan or the 2018 Plan. Any outstanding awards granted under the 2012 Plan remained outstanding, subject to the terms of the 2012 Plan and applicable award agreement; and if any of those awards are forfeited or cancelled without payment therefor, the shares covered by those awards will not become available for future grant or issuance under the 2012 Plan or the 2018 Plan. No further grants will be made under the 2012 Plan. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> , </font><font style="font-family:inherit;font-size:10pt;">3,658,602</font><font style="font-family:inherit;font-size:10pt;">&#160;shares were approved and reserved for issuance under the 2018 Plan.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Grant&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Subject to Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,588,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,436,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,378,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Exercisable as of March 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,361,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date. The weighted-average grant date fair value of options granted was </font><font style="font-family:inherit;font-size:10pt;">$25.90</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.77</font><font style="font-family:inherit;font-size:10pt;"> per share for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested options as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.7 years</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restricted Stock Units Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested balance as of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future stock-based compensation for unvested restricted stock units as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">3.6 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the effect of employee and non&#8209;employee related stock&#8209;based compensation expense:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expense </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Stock Options</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years) </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.01 &#8211; 10.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.6% &#8211; 86.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5% &#8211; 2.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#8217;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected term represents the period that the options granted are expected to be outstanding. After the adoption of ASU 2018-07 on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. Prior to the adoption of ASU 2018-07, the expected term of stock options issued to employees was determined using the simplified method, and the expected term of stock options issued to nonemployee consultants was based on the contractual term of the award.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Yield</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of&#160;</font><font style="font-family:inherit;font-size:10pt;">922,250</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;</font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;</font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the fair market value of the Company's common stock on the first or last day of the offering period, whichever is lower. Except for the initial offering period, the ESPP provides for separate&#160;six-month offering periods beginning on February 1 and August 1 of each year. The initial offering period ran from October&#160;2, 2018 through January 31, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;</font><font style="font-family:inherit;font-size:10pt;">119,702</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock were purchased under the ESPP. The total compensation expense related to the ESPP for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#160;was&#160;</font><font style="font-family:inherit;font-size:10pt;">$566,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized stock-based compensation expense related to the ESPP was </font><font style="font-family:inherit;font-size:10pt;">$646,000</font><font style="font-family:inherit;font-size:10pt;"> which is expected to be recognized over the remaining term of the offering period of </font><font style="font-family:inherit;font-size:10pt;">0.3 years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: a weighted-average expected life of&#160;</font><font style="font-family:inherit;font-size:10pt;">0.5 years</font><font style="font-family:inherit;font-size:10pt;">; expected volatility of&#160;</font><font style="font-family:inherit;font-size:10pt;">60.2%</font><font style="font-family:inherit;font-size:10pt;">; a risk-free interest rate of&#160;</font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">; and a&#160;zero&#160;dividend yield.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities for Early Exercise of Employee Options</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allowed certain stock option holders to exercise unvested options to purchase shares of common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#8217;s employment termination, at the original issuance price, until the options are fully vested. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">32,279</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">44,268</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were subject to repurchase at weighted-average prices of </font><font style="font-family:inherit;font-size:10pt;">$4.66</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.66</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the cash proceeds received for unvested shares of common stock of </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$206,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, were recorded within other long-term liabilities on the condensed consolidated balance sheet. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders&#8217; equity as such shares are considered legally outstanding.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Attributable to Common Stockholders</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the closing of the IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#8217;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustment of redeemable noncontrolling interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock (on an as if converted basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants (on an as if converted basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,681</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment in Joint Venture</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Variable Interest Entity (&#8220;VIE&#8221;)</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the joint venture agreement, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, or </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, or the other </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. The Joint Venture is deemed to be a variable interest entity ("VIE") and the Company has been identified as the VIE&#8217;s primary beneficiary. As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Joint Venture had total assets of approximately </font><font style="font-family:inherit;font-size:10pt;">$47.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$48.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which were primarily comprised of cash, property and equipment and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Put-call arrangements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;). The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its common stock, or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the redeemable noncontrolling interest held by SoftBank approximated </font><font style="font-family:inherit;font-size:10pt;">$46.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$41.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a fair value adjustment of </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> in its condensed consolidated statements of operations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term marketable securities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term marketable securities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,397</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,397</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term marketable securities </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,758</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,758</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term marketable securities </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355,980</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Fair Value Measurements, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses and debt. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term marketable securities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term marketable securities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,397</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,397</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term marketable securities </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,758</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,758</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term marketable securities </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355,980</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant unobservable inputs used in the fair value measurement of the Company&#8217;s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market fund </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bond </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,088</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market fund </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bond </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. government agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The maturities of the Company&#8217;s long-term marketable securities range from </font><font style="font-family:inherit;font-size:10pt;">1.0 year</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.2 years</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, foreign currency translation adjustment was immaterial. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patent License Agreement</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The transaction was treated as an acquisition of an asset and the Company capitalized a total of </font><font style="font-family:inherit;font-size:10pt;">$9.7 million</font><font style="font-family:inherit;font-size:10pt;"> under the arrangement.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, unamortized capitalized license fees were </font><font style="font-family:inherit;font-size:10pt;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which will be amortized over the remaining useful life of </font><font style="font-family:inherit;font-size:10pt;">7.8</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">8.0 years</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization of capitalized license fees totaled </font><font style="font-family:inherit;font-size:10pt;">$243,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$189,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">and all related amendments (collectively &#8220;ASC 606&#8221;) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. These differences are discussed below.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company recognizes revenue in accordance with ASC 606. Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments Due to ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,799</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275,892</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precision oncology testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,209</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302,215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 did not have an aggregate impact on the Company&#8217;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#8217;s condensed consolidated statement of cash flows, as reflected in the above table.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of </font><font style="font-family:inherit;font-size:10pt;">1.3 million</font><font style="font-family:inherit;font-size:10pt;"> as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The new guidance will be effective for the Company beginning in 2020, at which time, the new guidance will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements and anticipates the recognition of additional assets and corresponding liabilities on its condensed consolidated balance sheet related to leases. The adoption of the new standard is also expected to materially impact the Company&#8217;s condensed consolidated financial statement disclosures related to leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The new guidance is effective for the Company beginning in 2021, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, it has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR early detection program to address the needs of early stage cancer patients with adjuvant treatment selection, cancer survivors with surveillance and asymptomatic individuals with screening.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in the Joint Venture. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company&#8217;s Board of Directors and its stockholders approved a </font><font style="font-family:inherit;font-size:10pt;">0.7378</font><font style="font-family:inherit;font-size:10pt;">-for-one reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company's initial public offering (the &#8220;IPO&#8221;). All share and per share amounts in the accompanying condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to this reverse stock split.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. Accounts receivable are written off when management determines a balance is uncollectible and no longer intends to actively pursue collection of the receivable.&#160;For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company did not write off any material accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the adoption of ASC 606 on January 1, 2019, contract assets are reported as part of accounts receivable on the condensed consolidated balance sheets and are discussed in "unbilled receivables". </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 3, in connection with Softbank&#8217;s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Development Services</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company began recognizing revenue in accordance with FASB ASC Topic 606,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;ASC 606&#8221;). Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical patients. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unbilled receivables</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, which is a contract asset, consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized prior to the establishment of billing rights or the achievement of performance-based milestones. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables are presented under accounts receivable on the Company's consolidated balance sheets. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had unbilled receivables of&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2019. The Company did not record unbilled receivables for its contract assets prior to the adoption of ASC 606 on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the deferred revenue balance was </font><font style="font-family:inherit;font-size:10pt;">$17.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which included </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to collaboration development efforts with two pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> that was included in the deferred revenue balance as of January 1, 2019 was </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which represented primarily revenue from&#160;provision of development services under the collaboration agreement with a biopharmaceutical company.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction price allocated to the remaining performance obligations</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company applied the practical expedient in accordance with Topic 606 to forego disclosures related to the allocation of consideration to the remaining performance obligations and the timing in which revenues will be recognized from such performance obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalty obligations </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued tax liabilities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional services </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,988</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment included in accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued expenses </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock (on an as if converted basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants (on an as if converted basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,681</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the effect of employee and non&#8209;employee related stock&#8209;based compensation expense:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expense </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustment of redeemable noncontrolling interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum capital lease payments were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum capital lease payments </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of net minimum capital lease payments </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current installments of obligations under capital lease </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obligations under capital lease, excluding current installments </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments under the non-cancelable operating lease were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,617</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments Due to ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,799</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275,892</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precision oncology testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,209</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302,215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Restricted Stock Units Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested balance as of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">No single country outside of the United States accounted for more than 10% of total revenue during </font><font style="font-family:inherit;font-size:7.5pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:7.5pt;"> and </font><font style="font-family:inherit;font-size:7.5pt;">2018</font><font style="font-family:inherit;font-size:7.5pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Grant&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares Subject to Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,588,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,370</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,436,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,378,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Exercisable as of March 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,361,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years) </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.01 &#8211; 10.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.6% &#8211; 86.5%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5% &#8211; 2.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock has been reserved for the following potential future issuances:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,378,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,588,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares underlying unvested restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Incentive Award Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,436,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,719,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,067,162</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accounts Receivable</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7.5pt;">*</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">less than 10%</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Segment and Geographic Information</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">No single country outside of the United States accounted for more than 10% of total revenue during </font><font style="font-family:inherit;font-size:7.5pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:7.5pt;"> and </font><font style="font-family:inherit;font-size:7.5pt;">2018</font><font style="font-family:inherit;font-size:7.5pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, substantially all of the Company&#8217;s long-lived assets are located in the United States.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock&#8209;based compensation related to stock options granted to the Company&#8217;s employees and directors is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black&#8209;Scholes option&#8209;pricing model to estimate the fair value of its stock options. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that its existing cash and cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Act of 2012 (the &#8220;JOBS Act&#8221;). Section&#160;107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section&#160;102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. The Company has elected to use this extended transition period and, as a result, the consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company also intends to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, foreign currency translation adjustment was immaterial. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less.&#160;Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. Restricted cash balance was included in other assets in the accompanying condensed consolidated balance sheet, and was immaterial as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment&#8209;grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after&#8209;tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue or accounts receivable balance at each respective condensed consolidated balance sheet date. For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accounts Receivable</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7.5pt;">*</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">less than 10%</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. Accounts receivable are written off when management determines a balance is uncollectible and no longer intends to actively pursue collection of the receivable.&#160;For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company did not write off any material accounts receivable.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the adoption of ASC 606 on January 1, 2019, contract assets are reported as part of accounts receivable on the condensed consolidated balance sheets and are discussed in "unbilled receivables". </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company began recognizing revenue in accordance with FASB ASC Topic 606,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;ASC 606&#8221;). Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Precision oncology testing</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical patients. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Development services</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts with multiple performance obligations</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unbilled receivables</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, which is a contract asset, consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized prior to the establishment of billing rights or the achievement of performance-based milestones. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables are presented under accounts receivable on the Company's consolidated balance sheets. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had unbilled receivables of&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2019. The Company did not record unbilled receivables for its contract assets prior to the adoption of ASC 606 on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the deferred revenue balance was </font><font style="font-family:inherit;font-size:10pt;">$17.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which included </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to collaboration development efforts with two pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> that was included in the deferred revenue balance as of January 1, 2019 was </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which represented primarily revenue from&#160;provision of development services under the collaboration agreement with a biopharmaceutical company.&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction price allocated to the remaining performance obligations</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company applied the practical expedient in accordance with Topic 606 to forego disclosures related to the allocation of consideration to the remaining performance obligations and the timing in which revenues will be recognized from such performance obligations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs of Precision Oncology Testing</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Development Services</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock&#8209;Based Compensation</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock&#8209;based compensation related to stock options granted to the Company&#8217;s employees and directors is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black&#8209;Scholes option&#8209;pricing model to estimate the fair value of its stock options. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Attributable to Common Stockholders</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the closing of the IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company&#8217;s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company&#8217;s losses. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">and all related amendments (collectively &#8220;ASC 606&#8221;) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. These differences are discussed below.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company recognizes revenue in accordance with ASC 606. Comparative information from prior periods has not been restated and&#160;continues to be reported under the accounting standards in effect for those periods.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments Due to ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance as of January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,799</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275,892</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:17px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precision oncology testing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Reported Under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Effect of Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balances Without Adoption of ASC606</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,209</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302,215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 did not have an aggregate impact on the Company&#8217;s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company&#8217;s condensed consolidated statement of cash flows, as reflected in the above table.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of </font><font style="font-family:inherit;font-size:10pt;">1.3 million</font><font style="font-family:inherit;font-size:10pt;"> as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The new guidance will be effective for the Company beginning in 2020, at which time, the new guidance will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements and anticipates the recognition of additional assets and corresponding liabilities on its condensed consolidated balance sheet related to leases. The adoption of the new standard is also expected to materially impact the Company&#8217;s condensed consolidated financial statement disclosures related to leases.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The new guidance is effective for the Company beginning in 2021, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, no dividends on common stock had been declared by the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock has been reserved for the following potential future issuances:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares underlying outstanding stock options </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,378,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,588,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares underlying unvested restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Incentive Award Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,436,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for issuance under the 2018 Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,719,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,067,162</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Bellwether Bio</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2019, the Company completed its purchase of all of the outstanding shares of Bellwether Bio, Inc. ("Bellwether Bio"), a privately-held company developing a method for early blood-based cancer detection. The upfront consideration, after customary adjustments at closing, was approximately </font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. Subject to the achievement of certain commercialization milestones and,&#160;for certain milestones,&#160;the continued provision of services to the Company by certain former employees&#160;and consultants&#160;of Bellwether Bio, the Company&#160;will&#160;pay additional contingent consideration of up to a total of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, which may be paid, at the Company&#8217;s election, in cash or in the Company&#8217;s common stock. At the time of the issuance of the Company&#8217;s condensed consolidated financial statements as of and for the three months ended March 31, 2019, the initial accounting for the acquisition of Bellwether Bio, including purchase price allocation, had not been completed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</font></div></div> As of March 31, 2019 and December 31, 2018, includes $47.0 million and $48.3 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $942,000 and $1.2 million of liabilities of the consolidated VIE and VIE’s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See Note 3. EX-101.SCH 10 gh-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments For Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments For Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments For Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Condensed Consolidated Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Investment in Joint Venture link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Investment in Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders link:presentationLink link:calculationLink link:definitionLink 2437403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2437402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2337301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Patent License Agreement link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Patent License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2143100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Segment and Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2434402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2434406 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2434404 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2434403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2334301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2434405 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2144100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2444401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Summary of Significant Accounting Policies - Adoption of ACS 606 (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2304302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 gh-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 gh-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 gh-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Schedule of Stock by Class Schedule of Stock by Class [Table Text Block] Balance Sheet Related Disclosures [Abstract] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Segment Reporting [Abstract] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Finite-Lived Intangible Assets, Net [Abstract] Payment in connection with patent licensing agreement Payment In Connection With a License Agreement Payment In Connection With a License Agreement Capitalized license fees Finite-Lived Intangible Assets, Net Useful life (years) Finite-Lived Intangible Asset, Useful Life Amortization of intangible assets Amortization of Intangible Assets Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] SoftBank SoftBank [Member] SoftBank [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Guardant Health AMEA, Inc Guardant Health AMEA, Inc [Member] Guardant Health AMEA, Inc [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Payments to acquire interest in joint venture Payments to Acquire Interest in Joint Venture Equity method investment, shares purchased Equity Method Investment, Shares Purchased Equity Method Investment, Shares Purchased Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Redeemable noncontrolling interest, redemption value Redeemable Noncontrolling Interest, Equity, Redemption Value Variable interest entity, assets Variable Interest Entity, Consolidated, Carrying Amount, Assets Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Patent License Agreement Intangible Assets Disclosure [Text Block] Income Statement [Abstract] Revenue: Revenues [Abstract] Precision oncology testing Revenue from Precision Oncology Testing Revenue from Precision Oncology Testing Development services Revenue from Development Services Revenue from Development Services Total revenue Revenues Costs and operating expenses: Costs and Expenses [Abstract] Cost of precision oncology testing Costs of Precision Oncology Testing Costs of Precision Oncology Testing Cost of development services Cost of Development Services Cost of Development Services Research and development expense Research and Development Expense Sales and marketing expense Selling and Marketing Expense General and administrative expense General and Administrative Expense Total costs and operating expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest income Investment Income, Interest Interest expense Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Fair value adjustment of redeemable noncontrolling interest Net loss attributable to Guardant Health, Inc. common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net loss per share attributable to common stockholders, basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Lease Payments for Capital Leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of Future Minimum Royalty Payments Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Remainder of 2019 Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year 2020 Contractual Obligation, Due in Second Year 2021 Contractual Obligation, Due in Third Year 2022 Contractual Obligation, Due in Fourth Year 2023 Contractual Obligation, Due in Fifth Year 2024 and thereafter Contractual Obligation, Due after Fifth Year Total future minimum royalty payments Contractual Obligation Less: amount representing interest Contractual Obligation, Future Minimum Payments, Interest Included in Payments Contractual Obligation, Future Minimum Payments, Interest Included in Payments Present value of future minimum royalty payments Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Convertible preferred stock (on an as if converted basis) Convertible Preferred Stock [Member] Stock options Employee Stock Option [Member] Unvested restricted stock units Restricted Stock Units (RSUs) [Member] ESPP obligation Employee Stock [Member] Stock warrants Warrant [Member] Common stock subject to repurchase Treasury Stock, Common [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Ownership interest in joint venture Stock split conversion rate Stockholders' Equity Note, Stock Split, Conversion Ratio Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Compensation, Stock Options, Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Restricted Stock Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Remainder of 2019 Capital Leases, Future Minimum Payments, Remainder of Fiscal Year 2020 Capital Leases, Future Minimum Payments Due in Two Years 2021 Capital Leases, Future Minimum Payments Due in Three Years Total minimum capital lease payments Capital Leases, Future Minimum Payments Due Less: amount representing interest Capital Leases, Future Minimum Payments, Interest Included in Payments Present value of net minimum capital lease payments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Less: current installments of obligations under capital lease Capital Lease Obligations, Current Capital lease, net of current portion Capital Lease Obligations, Noncurrent Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Deficit Retained Earnings [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Effect of Change Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Balances Without Adoption of ASC606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Topic 606 adoption Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Accounts receivable Accounts Receivable, Net, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Depreciation and amortization expense Depreciation Capital leases, balance sheet, assets, net Capital Leases, Balance Sheet, Assets by Major Class, Net Capital leases, balance sheet, assets, accumulated depreciation Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Amortization expense Amortization of Leased Asset Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Maturity period (years) Marketable Securities, Maturity Period Marketable Securities, Maturity Period Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders Earnings Per Share [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Machinery and equipment Machinery and Equipment [Member] Computer hardware Computer Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Computer software Software and Software Development Costs [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of the Cumulative Effect on Financial Information Related to the Adoption of ACS 606 Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Other Commitments [Table] Other Commitments [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Income Other Income [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member] Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member] Other Commitments [Line Items] Other Commitments [Line Items] Operating leases, rent expense Operating Leases, Rent Expense Number of parties with patent license agreement Number of Parties With Patent License Agreement Number of Parties With Patent License Agreement Royalty expense Royalty Expense Percentage of precision oncology testing revenue Royalty Expense, Percentage of Precision Oncology Testing Revenue Royalty Expense, Percentage of Precision Oncology Testing Revenue Number of asserted patents Number of Asserted Patents Number of Asserted Patents Number of petitions filed Number of Petitions Filed Number of Petitions Filed Amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] Convertible Preferred Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] ASU 2018-07 adoption Accounting Standards Update 2018-07 [Member] Accounting Standards Update 2018-07 [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Beginning balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Fair value adjustment of redeemable noncontrolling interest Reclassifications of Temporary to Permanent Equity Ending balance Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Beginning balance, shares Shares, Outstanding Cumulative effect adjustment for new ASU's Cumulative Effect of New Accounting Principle in Period of Adoption Issuance of common stock upon exercise of stock options, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Vesting of common stock exercised early Stock Issued During Period, Value, Stock Options Exercised Early Stock Issued During Period, Value, Stock Options Exercised Early Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Common stock issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon early exercise of stock options, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period Issuance of common stock upon exercise of warrants, shares Stock Issued During Period, Shares, Exercise of Warrants Stock Issued During Period, Shares, Exercise of Warrants Issuance of common stock upon exercise of warrants Stock Issued During Period, Value, Exercise of Warrants Stock Issued During Period, Value, Exercise of Warrants Other comprehensive gain (loss), net of tax impact Other Comprehensive Income (Loss), Net of Tax Net loss Ending balance, shares Ending balance Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Unbilled receivables Unbilled Receivables, Current Deferred revenue Contract with Customer, Liability Deferred revenue recognized Contract with Customer, Liability, Revenue Recognized Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] 2018 Employee Stock Purchase Plan Restricted stock units Nonemployee stock option Nonemployee Stock Option [Member] Nonemployee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares canceled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross Exercises in period, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average grant date fair value, grants in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock based compensation not recognized, options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Stock based compensation not recognized, other than options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Stock based compensation not recognized, period for recognition (years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Number of shares outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock-based compensation Allocated Share-based Compensation Expense Stock subject to repurchase (in shares) Common Stock Subject to Repurchase or Cancellation Common Stock Subject to Repurchase or Cancellation Stock subject to repurchase, per share (in dollars per share) Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share Cash proceeds received for unvested shares Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent Shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum employee subscription rate, ESPP Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate ESPP purchase price of common stock (as a percent of the fair value of common stock) Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Weighted-average expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Fair Value Measurements, Recurring and Nonrecurring Fair Value, Assets Measured on Recurring Basis [Table Text Block] Debt Securities, Available-for-sale Debt Securities [Table Text Block] Debt Securities [Table Text Block] Fair value adjustment of redeemable noncontrolling interest Net loss attributable to Guardant Health, Inc. common stockholders Restricted Stock Units Restricted Stock [Member] Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] Beginning number of shares, available for grant (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Canceled (shares) Ending number of shares, available for grant (shares) Shares Subject to Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Beginning number of shares, outstanding (shares) Granted (shares) Exercised (shares) Canceled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Ending number of shares, outstanding (shares) Options vested and exercisable, number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Beginning balance of options outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (unaudited) (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (unaudited) (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled (unaudited) (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Ending balance of options outstanding (in dollars per share) Options vested and exercisable, weighted average exercise price per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options outstanding, Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options outstanding, Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options vested and exercisable, Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable, Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Statement of Financial Position [Abstract] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Common stock, shares issued (shares) Common Stock, Shares, Issued Variable interest entity, liabilities Variable Interest Entity, Consolidated, Carrying Amount, Liabilities Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Money market funds Money Market Funds [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate bonds Corporate Debt Securities [Member] U.S. government debt securities US Government Debt Securities [Member] U.S. government agency bonds US Government Agencies Debt Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Debt securities, short-term Debt Securities, Current Debt securities, long-term Debt Securities, Noncurrent Total assets Assets, Fair Value Disclosure Investment in Joint Venture Equity Method Investments and Joint Ventures Disclosure [Text Block] Beginning unvested balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Canceled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Ending unvested balance (shares) Beginning balance of options outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Granted (unaudited) (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Canceled (unaudited) (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Ending balance of options outstanding (in dollars per share) Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Remainder of 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term marketable securities Marketable Securities, Current Accounts receivable Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Long-term marketable securities Marketable Securities, Noncurrent Property and equipment, net Other assets Other Assets, Noncurrent Total Assets Assets LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Deferred Compensation Liability, Current Accrued expenses Accrued Liabilities, Current Capital lease, current Deferred revenue Deferred Revenue, Current Total current liabilities Liabilities, Current Deferred rent, net of current portion Deferred Rent Credit, Noncurrent Obligation related to royalty Accrued Royalties, Noncurrent Accrued Royalties, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total Liabilities Liabilities Commitments and contingencies (Note 7) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 86,098,474 and 85,832,454 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively Common Stock, Value, Outstanding Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Stockholders’ Equity Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity Liabilities and Equity Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents Amortized cost, debt securities, available-for-sale Debt Securities, Available-for-sale, Amortized Cost Amortized cost, cash and cash equivalents and debt securities available-for-sale Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost Gross Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value, Cash and Cash Equivalents Estimated Fair Value, Debt Securities Debt Securities, Available-for-sale Cash, Cash Equivalents and Debt Securities, Fair Value Cash, Cash Equivalents and Debt Securities, Fair Value Cash, Cash Equivalents and Debt Securities, Fair Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total revenue Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Unaudited Interim Condensed Financial Statements Unaudited Interim Condensed Financial Statements [Policy Text Block] Unaudited Interim Condensed Financial Statements [Policy Text Block] JOBS Act Accounting Election JOBS Act Accounting Election [Policy Text Block] JOBS Act Accounting Election [Policy Text Block] Foreign Currency Translations Foreign Currency Transactions and Translations Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Costs of Precision Oncology Testing Costs of Precision Oncology Testing [Policy Text Block] Costs of Precision Oncology Testing [Policy Text Block] Cost of Development Services Research and Development Expense, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Loss Per Share Attributable to Common Shareholders Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Condensed Consolidated Balance Sheet Components Additional Financial Information Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), net of tax impact: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other comprehensive income (loss) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to redeemable noncontrolling interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to Guardant Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk [Table] Concentration Risk [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Customer A Customer A [Member] Customer A [Member] Customer B Customer B [Member] Customer B Customer C Customer C [Member] Customer C Customer D Customer D [Member] Customer D [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Credit Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Fair Value Measurements. Cash Equivalents and Marketable Securities Fair Value Disclosures [Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Unrealized translation (gains) losses on obligation related to royalty Unrealized Translations Gain (Loss) On Obligation Related To Royalty Unrealized Translations Gain (Loss) On Obligation Related To Royalty Non-cash stock-based compensation Share-based Compensation Non-cash interest expense Noncash Interest Expense Paid Noncash Interest Expense Paid Amortization of discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Employee Related Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred rent Increase (Decrease) in Deferred Charges Deferred revenue Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of marketable securities Payments to Acquire Marketable Securities Maturity of marketable securities Proceeds from Sale and Maturity of Marketable Securities Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Payments made on royalty obligations Payment Related to Settlement of Debt and Buyout of Royalty Obligations Payment Related to Settlement of Debt and Buyout of Royalty Obligations Payments made on capital lease obligations Repayments of Long-term Capital Lease Obligations Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Proceeds from issuance of common stock upon the exercise of warrants Proceeds from Warrant Exercises Proceeds from issuances of common stock under employee stock purchase plan Proceeds from Stock Plans Payment of offering costs related to initial public offering Payments of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash - Beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash - End of period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income taxes Income Taxes Paid, Net Supplemental Disclosures of Noncash Investing and Financing Activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Purchases of property and equipment included in accounts payable and accrued expenses Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid Subsequent Event [Table] Subsequent Event [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Bellweather Bio, Inc. Bellweather Bio, Inc. [Member] Bellweather Bio, Inc. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Payments to acquire business Payments to Acquire Businesses, Gross Contingent payment payable Business Combination, Contingent Consideration, Liability Accrued royalty obligations Accrued Royalties, Current Accrued legal expenses Estimated Litigation Liability, Legal Fees, Current Estimated Litigation Liability, Legal Fees, Current Accrued tax liabilities Accrued Income Taxes, Current Accrued professional services Accrued Professional Fees, Current Purchases of property and equipment included in accrued expenses Accrued Expenses, Property and Equipment, Current Accrued Expenses, Property and Equipment, Current Other Other Accrued Liabilities, Current Total accrued expenses Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] 2018 Incentive Award Plan 2018 Incentive Award Plan [Member] 2018 Incentive Award Plan [Member] Class of Stock [Line Items] Class of Stock [Line Items] Common stock, shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Common Stock Stockholders' Equity Note Disclosure [Text Block] Precision oncology testing Precision Oncology Testing [Member] Precision Oncology Testing [Member] Research and development expense Research and Development Expense [Member] Sales and marketing expense Selling and Marketing Expense [Member] General and administrative expense General and Administrative Expense [Member] Total stock-based compensation expense Expected term (years) Risk-free interest rate EX-101.PRE 14 gh-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2019
May 07, 2019
Document and Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Trading Symbol GH  
Entity Registrant Name Guardant Health, Inc.  
Entity Central Index Key 0001576280  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Common Stock, Shares Outstanding   87,112,669
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 153,790 $ 140,544
Short-term marketable securities 313,069 278,417
Accounts receivable 28,989 35,690
Inventory 10,256 9,136
Prepaid expenses and other current assets 6,151 5,204
Total current assets 512,255 468,991
Long-term marketable securities 25,916 77,563
Property and equipment, net 30,581 31,003
Capitalized license fees 7,557 7,800
Other assets 2,862 2,046
Total Assets [1] 579,171 587,403
Current liabilities:    
Accounts payable 7,163 10,642
Accrued compensation 14,683 12,986
Accrued expenses 9,137 7,081
Capital lease, current 96 97
Deferred revenue 17,113 16,138
Total current liabilities 48,192 46,944
Capital lease, net of current portion 100 119
Deferred rent, net of current portion 8,975 7,844
Obligation related to royalty 7,120 7,338
Other long-term liabilities 150 206
Total Liabilities [1] 64,537 62,451
Commitments and contingencies (Note 7)
Redeemable noncontrolling interest 46,500 41,800
Stockholders’ equity:    
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 86,098,474 and 85,832,454 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 1 1
Additional paid-in capital 771,009 764,033
Accumulated other comprehensive loss 333 (83)
Accumulated deficit (303,209) (280,799)
Total Stockholders’ Equity 468,134 483,152
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity $ 579,171 $ 587,403
[1] As of March 31, 2019 and December 31, 2018, includes $47.0 million and $48.3 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $942,000 and $1.2 million of liabilities of the consolidated VIE and VIE’s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See Note 3.
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenue:    
Precision oncology testing $ 28,837 $ 14,191
Development services 7,818 2,501
Total revenue 36,655 16,692
Costs and operating expenses:    
Cost of precision oncology testing 11,023 8,045
Cost of development services 2,512 1,208
Research and development expense 16,316 8,255
Sales and marketing expense 17,807 11,312
General and administrative expense 12,661 6,519
Total costs and operating expenses 60,319 35,339
Loss from operations (23,664) (18,647)
Interest income 2,485 985
Interest expense (293) (331)
Other income (expense), net 147 4,149
Loss before provision for income taxes (21,325) (13,844)
Provision for income taxes 26 0
Net loss (21,351) (13,844)
Fair value adjustment of redeemable noncontrolling interest (4,700) 0
Net loss attributable to Guardant Health, Inc. common stockholders $ (26,051) $ (13,844)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) $ (0.30) $ (1.16)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) 85,935 11,920
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Common stock, par value (in usd per share) $ 0.0000001 $ 0.0000001
Common stock, shares authorized (shares) 350,000,000 350,000,000
Common stock, shares outstanding (shares) 86,098,474 85,832,454
Common stock, shares issued (shares) 86,098,474 85,832,454
Variable interest entity, assets $ 47,000 $ 48,300
Variable interest entity, liabilities $ 942 $ 1,200
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Statement of Comprehensive Income [Abstract]    
Net loss $ (21,351) $ (13,844)
Other comprehensive income (loss), net of tax impact:    
Unrealized gain (loss) on available-for-sale securities 485 (298)
Foreign currency translation adjustments (69) 0
Other comprehensive income (loss) 416 (298)
Comprehensive loss (20,935) (14,142)
Comprehensive loss attributable to redeemable noncontrolling interest (4,700) 0
Comprehensive loss attributable to Guardant Health, Inc. $ (25,635) $ (14,142)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (unaudited) - USD ($)
$ in Thousands
Total
Redeemable Noncontrolling Interest
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance at Dec. 31, 2017 $ 308,606   $ 499,974 $ 0 $ 4,900 $ (532) $ (195,736)
Beginning balance, shares at Dec. 31, 2017     78,627,369 11,896,882      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options, shares       421,264      
Issuance of common stock upon exercise of stock options 1,103       1,103    
Stock-based compensation 1,277       1,277    
Issuance of common stock upon early exercise of stock options, shares       44,268      
Issuance of common stock upon exercise of warrants, shares       31,713      
Issuance of common stock upon exercise of warrants (4)       (4)    
Other comprehensive gain (loss), net of tax impact (298)         (298)  
Net loss (13,844)           (13,844)
Ending balance, shares at Mar. 31, 2018     78,627,369 12,394,127      
Ending balance at Mar. 31, 2018 296,848   $ 499,974 $ 0 7,284 (830) (209,580)
Beginning balance at Dec. 31, 2018   $ 41,800          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Fair value adjustment of redeemable noncontrolling interest (4,700) 4,700         (4,700)
Ending balance at Mar. 31, 2019   $ 46,500          
Beginning balance at Dec. 31, 2018 $ 483,152     $ 1 764,033 (83) (280,799)
Beginning balance, shares at Dec. 31, 2018       85,832,454      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options, shares 146,318     146,318      
Issuance of common stock upon exercise of stock options $ 538       538    
Vesting of common stock exercised early 56       56    
Stock-based compensation 3,183       3,183    
Common stock issued under employee stock purchase plan (in shares)       119,702      
Common stock issued under employee stock purchase plan 1,933       1,933    
Other comprehensive gain (loss), net of tax impact 416         416  
Net loss (21,351)           (21,351)
Ending balance, shares at Mar. 31, 2019       86,098,474      
Ending balance at Mar. 31, 2019 $ 468,134     $ 1 $ 771,009 $ 333 $ (303,209)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
OPERATING ACTIVITIES:    
Net loss $ (21,351) $ (13,844)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,354 1,395
Unrealized translation (gains) losses on obligation related to royalty (144) 206
Non-cash stock-based compensation 3,182 1,277
Non-cash interest expense 0 (3)
Amortization of discounts on marketable securities (553) (78)
Changes in operating assets and liabilities:    
Accounts receivable 11,608 623
Inventory (1,120) 321
Prepaid expenses and other current assets (947) (1,312)
Other assets (833) 255
Accounts payable (2,610) 1,989
Accrued compensation 1,697 (608)
Accrued expenses and other current liabilities 2,308 1,108
Deferred rent 1,131 621
Deferred revenue 975 1,491
Net cash used in operating activities (4,303) (6,559)
INVESTING ACTIVITIES:    
Purchase of marketable securities (45,966) (19,634)
Maturity of marketable securities 64,000 32,125
Purchase of property and equipment (2,705) (4,021)
Net cash provided by investing activities 15,329 8,470
FINANCING ACTIVITIES:    
Payments made on royalty obligations (73) 0
Payments made on capital lease obligations (21) (47)
Proceeds from issuance of common stock upon exercise of stock options 538 1,310
Proceeds from issuance of common stock upon the exercise of warrants 0 4
Proceeds from issuances of common stock under employee stock purchase plan 1,933 0
Payment of offering costs related to initial public offering (89) 0
Net cash provided by financing activities 2,288 1,267
Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash (69) 0
Net increase in cash, cash equivalents and restricted cash 13,245 3,178
Cash, cash equivalents and restricted cash - Beginning of period 140,544 72,596
Cash, cash equivalents and restricted cash - End of period 153,789 75,774
Supplemental Disclosures of Cash Flow Information:    
Cash paid for interest 293 30
Cash paid for income taxes (48) 0
Supplemental Disclosures of Noncash Investing and Financing Activities:    
Purchases of property and equipment included in accounts payable and accrued expenses $ 490 $ 3,351
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Description of Business
3 Months Ended
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business
Description of Business
Guardant Health, Inc. (the “Company”) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company’s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, it has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR early detection program to address the needs of early stage cancer patients with adjuvant treatment selection, cancer survivors with surveillance and asymptomatic individuals with screening.
The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the “Joint Venture”) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a 50% ownership interest in the Joint Venture. As of March 31, 2019, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3).
Reverse Stock Split
In September 2018, the Company’s Board of Directors and its stockholders approved a 0.7378-for-one reverse stock split of the Company’s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company's initial public offering (the “IPO”). All share and per share amounts in the accompanying condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to this reverse stock split.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Basis of Presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders’ interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.
The Company believes that its existing cash and cash equivalents and marketable securities as of March 31, 2019 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. If the Company’s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Unaudited Interim Condensed Financial Statements
The accompanying condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2019 and 2018, and cash flows for the three months ended March 31, 2019 and 2018, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.
The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
JOBS Act Accounting Election
The Company is an “emerging growth company” within the meaning of the Jumpstart Our Business Act of 2012 (the “JOBS Act”). Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. The Company has elected to use this extended transition period and, as a result, the consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company also intends to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.
Foreign Currency Translation
The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the three months ended March 31, 2019, foreign currency translation adjustment was immaterial.
Cash and Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less. Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.
Restricted cash consists of deposits related to the Company’s corporate credit card. Restricted cash balance was included in other assets in the accompanying condensed consolidated balance sheet, and was immaterial as of March 31, 2019 and December 31, 2018.
Concentration of Risk
The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.
The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.
The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.
Significant customers are those which represent more than 10% of the Company’s total revenue or accounts receivable balance at each respective condensed consolidated balance sheet date. For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:
 
 
Revenue
 
Accounts Receivable
 
 
Three Months Ended March 31,
 
March 31, 2019
 
December 31, 2018
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
(unaudited)
 
(unaudited)
 
 
Customer A
 
*

 
11
%
 
*

 
*

Customer B
 
24
%
 
*

 
35
%
 
65
%
Customer C
 
*

 
13
%
 
*

 
*

Customer D
 
*

 
*

 
13
%
 
*

*
less than 10%
Accounts Receivable
Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. Accounts receivable are written off when management determines a balance is uncollectible and no longer intends to actively pursue collection of the receivable. For the three months ended March 31, 2019 and 2018, the Company did not write off any material accounts receivable.
Upon the adoption of ASC 606 on January 1, 2019, contract assets are reported as part of accounts receivable on the condensed consolidated balance sheets and are discussed in "unbilled receivables".
Revenue Recognition
The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.
Effective January 1, 2019, the Company began recognizing revenue in accordance with FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Precision oncology testing
The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical patients. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.
The Company’s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.
Development services
The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.
The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company’s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.
Contracts with multiple performance obligations
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.
For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.
Unbilled receivables
Unbilled receivables, which is a contract asset, consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized prior to the establishment of billing rights or the achievement of performance-based milestones. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. 
Unbilled receivables are presented under accounts receivable on the Company's consolidated balance sheets. As of March 31, 2019, the Company had unbilled receivables of $3.9 million as compared to $4.9 million as of January 1, 2019. The Company did not record unbilled receivables for its contract assets prior to the adoption of ASC 606 on January 1, 2019.
Deferred revenue
Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized.
As of March 31, 2019 and December 31, 2018, the deferred revenue balance was $17.1 million and $16.1 million, respectively, which included $12.4 million and $10.5 million, respectively, related to collaboration development efforts with two pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the three months ended March 31, 2019 that was included in the deferred revenue balance as of January 1, 2019 was $7.0 million, which represented primarily revenue from provision of development services under the collaboration agreement with a biopharmaceutical company. 
Transaction price allocated to the remaining performance obligations
Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company applied the practical expedient in accordance with Topic 606 to forego disclosures related to the allocation of consideration to the remaining performance obligations and the timing in which revenues will be recognized from such performance obligations.
Costs of Precision Oncology Testing
Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.
Cost of Development Services
Cost of development service includes costs incurred for the performance of development services requested by the Company’s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.
Stock‑Based Compensation
Stock‑based compensation related to stock options granted to the Company’s employees and directors is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards.
In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.
The Company uses the Black‑Scholes option‑pricing model to estimate the fair value of its stock options. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.
Net Loss Per Share Attributable to Common Stockholders
The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.
Prior to the closing of the IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company’s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company’s losses.
Recent Adopted Accounting Pronouncements
The Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and all related amendments (collectively “ASC 606”) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. These differences are discussed below.
For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition.
For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.
Effective January 1, 2019, the Company recognizes revenue in accordance with ASC 606. Comparative information from prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.
The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:
 
Balance as of December 31, 2018
 
Adjustments Due to ASC 606
 
Balance as of January 1, 2019
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
35,690

 
$
4,907

 
$
40,597

Equity:
 
 
 
 
 
Accumulated deficit
$
(280,799
)
 
$
4,907

 
$
(275,892
)
In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:
 
Three Months Ended March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Revenue:
 
 
 
 
 
Precision oncology testing
$
28,837

 
$
994

 
$
29,831

Development services
7,818

 

 
7,818

 
 
March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
28,989

 
$
994

 
$
29,983

Equity:
 
 
 
 
 
Accumulated deficit
(303,209
)
 
994

 
(302,215
)
ASC 606 did not have an aggregate impact on the Company’s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above table.
In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of 1.3 million as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.
Recent Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The new guidance will be effective for the Company beginning in 2020, at which time, the new guidance will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements and anticipates the recognition of additional assets and corresponding liabilities on its condensed consolidated balance sheet related to leases. The adoption of the new standard is also expected to materially impact the Company’s condensed consolidated financial statement disclosures related to leases.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The new guidance is effective for the Company beginning in 2021, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.19.1
Investment in Joint Venture
3 Months Ended
Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]  
Investment in Joint Venture
Investment in Joint Venture
Variable Interest Entity (“VIE”)
In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the “Joint Venture”) for the sale, marketing and distribution of the Company’s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.
Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. The Joint Venture is deemed to be a variable interest entity ("VIE") and the Company has been identified as the VIE’s primary beneficiary. As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.
As of March 31, 2019 and December 31, 2018, the Joint Venture had total assets of approximately $47.0 million and $48.3 million, respectively, which were primarily comprised of cash, property and equipment and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company’s general credit or assets.  Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of March 31, 2019 and December 31, 2018, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.
Put-call arrangements
The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the “put right”), and the Company has a right to purchase all such shares (the “call right”). The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its common stock, or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.
The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company’s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.
As of March 31, 2019 and December 31, 2018, the fair value of the redeemable noncontrolling interest held by SoftBank approximated $46.5 million and $41.8 million, respectively. For the three months ended March 31, 2019, the Company recorded a fair value adjustment of $4.7 million in its condensed consolidated statements of operations.
As of March 31, 2019, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheet Components
3 Months Ended
Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Condensed Consolidated Balance Sheet Components
Condensed Consolidated Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Machinery and equipment
$
23,742

 
$
23,440

Computer hardware
5,293

 
4,949

Leasehold improvements
14,163

 
13,965

Furniture and fixtures
1,540

 
1,522

Computer software
741

 
643

Construction in progress
1,405

 
3,118

Property and equipment, gross
46,884

 
47,637

Less: accumulated depreciation and amortization
(16,303
)
 
(16,634
)
Property and equipment, net
$
30,581

 
$
31,003


Depreciation and amortization expense related to property and equipment was $2.1 million and $1.2 million for the three months ended March 31, 2019 and 2018, respectively.
As of March 31, 2019 and December 31, 2018, total property and equipment financed under capital leases was $504,000 and $504,000, net of accumulated amortization of $324,000 and $294,000, respectively. Amortization expense related to total property and equipment financed under capital leases was $30,000 and $64,000 for the three months ended March 31, 2019 and 2018, respectively.
Accrued Expenses
Accrued expenses consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Accrued royalty obligations
$
853

 
$
707

Accrued legal expenses
2,400

 
814

Accrued tax liabilities
1,410

 
1,470

Accrued professional services
1,988

 
1,791

Purchases of property and equipment included in accrued expenses
137

 
343

Other
2,349

 
1,956

Total accrued expenses
$
9,137

 
$
7,081

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements. Cash Equivalents and Marketable Securities
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements. Cash Equivalents and Marketable Securities
Fair Value Measurements, Cash Equivalents and Marketable Securities
Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses and debt. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.
Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
 
March 31, 2019
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
10,093

 
$
10,093

 
$

 
$

Total cash equivalents
10,093

 
10,093

 

 

 
 
 
 
 
 
 
 
Corporate bonds
43,083

 

 
43,083

 

U.S. government debt securities
264,992

 

 
264,992

 

U.S. government agency bonds
4,994

 

 
4,994

 

Total short-term marketable securities
313,069

 

 
313,069

 

 
 
 
 
 
 
 
 
Corporate bonds
2,005

 

 
2,005

 

U.S. government debt securities
23,911

 

 
23,911

 

Total long-term marketable securities
25,916

 

 
25,916

 

Total
$
349,078

 
$
10,093

 
$
338,985

 
$

 
December 31, 2018
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
25,796

 
$
25,796

 
$

 
$

Total cash equivalents
25,796
 
25,796
 

 

 
 
 
 
 
 
 
 
Corporate bonds
38,397
 

 
38,397
 

U.S. government debt securities
235,016
 

 
235,016
 

U.S. government agency bonds
5,004
 

 
5,004
 

Total short-term marketable securities
278,417
 

 
278,417
 

 
 
 
 
 
 
 
 
Corporate bonds
3,805
 

 
3,805
 

U.S. government debt securities
73,758
 

 
73,758
 

Total long-term marketable securities
77,563
 

 
77,563
 

Total
$
381,776

 
$
25,796

 
$
355,980

 
$


The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
The significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.
There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.
Cash Equivalents and Marketable Securities
The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:
 
March 31, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Money market fund
$
10,093

 
$

 
$

 
$
10,093

Corporate bond
45,065

 
26

 
(3
)
 
45,088

U.S. government debt securities
288,522

 
455

 
(74
)
 
288,903

U.S. government agency bonds
4,995

 

 
(1
)
 
$
4,994

Total
$
348,675

 
$
481

 
$
(78
)
 
$
349,078

 
December 31, 2018
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(in thousands)
Money market fund
$
25,796

 
$

 
$

 
$
25,796

Corporate bond
42,273

 

 
(71
)
 
42,202

U.S. government debt securities
308,775

 
235

 
(236
)
 
308,774

U.S. government agency bonds
5,014

 

 
(10
)
 
5,004

Total
$
381,858

 
$
235

 
$
(317
)
 
$
381,776


There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company’s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the three months ended March 31, 2019 and 2018. The maturities of the Company’s long-term marketable securities range from 1.0 year to 1.2 years as of March 31, 2019.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Patent License Agreement
3 Months Ended
Mar. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]  
Patent License Agreement
Patent License Agreement
In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The transaction was treated as an acquisition of an asset and the Company capitalized a total of $9.7 million under the arrangement.
As of March 31, 2019 and December 31, 2018, unamortized capitalized license fees were $7.6 million and $7.8 million, respectively, which will be amortized over the remaining useful life of 7.8 and 8.0 years, respectively. Amortization of capitalized license fees totaled $243,000 and $189,000 for the three months ended March 31, 2019 and 2018, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Operating Leases
As of March 31, 2019, future minimum payments under the non-cancelable operating lease were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
3,693

2020
7,276

2021
8,161

2022
8,388

2023
9,023

2024 and thereafter
26,076

Total
$
62,617

Rent expense for the facility leases was $1.3 million and $1.1 million for the three months ended March 31, 2019 and 2018, respectively.
Capital Leases
As of March 31, 2019, future minimum capital lease payments were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
107

2020
108

2021
36

Total minimum capital lease payments
251

Less: amount representing interest
(55
)
Present value of net minimum capital lease payments
196

Less: current installments of obligations under capital lease
(96
)
Obligations under capital lease, excluding current installments
$
100


License Agreements
The Company has patent license agreements with four different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.
Royalty expenses were included in cost of precision oncology testing on the accompanying condensed consolidated statements of operations. The Company recognized royalty expenses of $633,000 and $172,000, or 2% and 1% of precision oncology testing revenue in each period, for the three months ended March 31, 2019 and 2018, respectively.
As of March 31, 2019, future minimum royalty payments were due as follows regardless of sales amounts:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
1,052

2020
1,402

2021
1,402

2022
1,683

2023
1,683

2024 and thereafter
5,609

Total future minimum royalty payments
12,831

Less: amount representing interest
(5,711
)
Present value of future minimum royalty payments
$
7,120


Indemnification Agreements
The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of March 31, 2019.
Security Incidents
In July 2018, the Company experienced security incidents involving an unauthorized actor obtaining access to its email system and sending phishing messages. The Company has implemented and continues to implement additional security measures to help prevent future unauthorized access to its systems and the data it maintains, including promptly engaging an independent cybersecurity firm to support its investigation, assess its systems and bolster security thereof. The Company provided timely notices to the U.S. Department of Health and Human Services, or the HHS, certain state regulators and certain credit agencies, as applicable, as well as to the individuals affected. Following such security incidents, the Company received a request for information in January 2019 regarding the incidents from the HHS Office for Civil Rights, or OCR.  The Company has responded to that request in a timely manner but does not know whether OCR will request additional information or pursue any further action. The Company currently cannot predict the ultimate resolution of the security incidents or the OCR inquiry and cannot estimate the amounts or ranges of potential loss that could result therefrom. The Company has insurance coverage in place for certain potential claims, liabilities and costs relating to the security incidents, but this coverage is limited in amount and may not be adequate to protect against all claims, liabilities and costs arising from such incidents, including fines and penalties.

Legal Proceedings
The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.
Patent Disputes
In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (“Foundation Medicine”) and Personal Genome Diagnostics, Inc. (“Personal Genome Diagnostics”) in the United States District Court for the District of Delaware, alleging that each of the two companies has infringed a patent relating to the Company’s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys’ fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity, including subsequently unenforceabilty under the doctrine of inequitable conduct, and non-infringement. In addition, Personal Genome Diagnostics has alleged, as part of its subsequent counterclaims, that the Company’s actions related to obtaining and securing exclusive rights to the patents-in-suit violated provisions of Section 2 of the Sherman Antitrust Act.

In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the PTAB, challenging the patentability of two of the patents asserted by the Company. Prior to reaching a decision on the merits, the two post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.
License Dispute
In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (“Licensor”), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor’s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company’s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor’s counterclaims will succeed on the merits.
Other Disputes
In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of $4.25 million, which was reported as other income in the condensed consolidated statements of operations for the three months ended March 31, 2018.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Common Stock
Common Stock
Common stockholders are entitled to dividends if and when declared by the Company’s Board of Directors (the “Board of Directors”). As of March 31, 2019 and December 31, 2018, no dividends on common stock had been declared by the Board of Directors.
Common stock has been reserved for the following potential future issuances:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)

 
 
Shares underlying outstanding stock options
7,378,068

 
7,588,405

Shares underlying unvested restricted stock units
102,498

 

Shares available for issuance under the 2018 Incentive Award Plan
3,436,451

 
3,556,507

Shares available for issuance under the 2018 Employee Stock Purchase Plan
802,548

 
922,250

Total
11,719,565
 
12,067,162
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
2012 Stock Plan and 2018 Incentive Award Plan
In June 2012 and September 2018, the Board of Directors adopted and its stockholders approved the Company’s 2012 Stock Plan (as amended and restated, the “2012 Plan”) and the Company’s 2018 Incentive Award Plan (the “2018 Plan”), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and nonemployees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and the 508,847 shares remaining available for future grant under the 2012 Plan were not made available for grant under the 2012 Plan or the 2018 Plan. Any outstanding awards granted under the 2012 Plan remained outstanding, subject to the terms of the 2012 Plan and applicable award agreement; and if any of those awards are forfeited or cancelled without payment therefor, the shares covered by those awards will not become available for future grant or issuance under the 2012 Plan or the 2018 Plan. No further grants will be made under the 2012 Plan. As of March 31, 2019 , 3,658,602 shares were approved and reserved for issuance under the 2018 Plan.
Stock Option Activity
A summary of the Company’s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
 
Options Outstanding
 
Shares
Available for Grant 
 
Shares Subject to Options Outstanding
 
Weighted-Average Exercise Price 
 
Weighted-Average Remaining Contractual Life (Years)
 
Aggregate Intrinsic Value
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands)
Balance as of December 31, 2018
3,556,507

 
7,588,405

 
$
4.58

 
8.3
 
$
250,495

Granted
(18,370
)
 
18,370

 
41.25

 
 
 
 
Exercised

 
(146,318
)
 
3.49

 
 
 
 
Canceled
812

 
(82,389
)
 
4.77

 
 
 
 
Restricted stock units granted
(120,835
)
 

 

 
 
 
 
Restricted stock units canceled
18,337

 

 

 
 
 
 
Balance as of March 31, 2019
3,436,451

 
7,378,068

 
$
4.69

 
8.0
 
$
531,281

Vested and Exercisable as of March 31, 2019
 
 
3,361,540

 
$
3.61

 
7.4
 
$
245,680


Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $8.1 million and $1.3 million for the three months ended March 31, 2019 and 2018, respectively.
Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date. The weighted-average grant date fair value of options granted was $25.90 and $3.77 per share for the three months ended March 31, 2019 and 2018, respectively.
Future stock-based compensation for unvested options as of March 31, 2019 and December 31, 2018 was $16.6 million and $17.5 million, respectively, which is expected to be recognized over a weighted-average period of 2.5 years and 2.7 years, respectively.
Restricted Stock Units
A summary of the Company’s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
Restricted Stock Units Outstanding
 
Weighted-Average Grant Date Fair Value
 
 
 
 
 
Unvested balance as of December 31, 2018
 

 
$

Granted
 
120,835

 
44.02

Canceled
 
(18,337
)
 
41.30

Unvested balance as of March 31, 2019
 
102,498

 
$
44.50


Future stock-based compensation for unvested restricted stock units as of March 31, 2019 was $4.2 million, which is expected to be recognized over a weighted-average period of 3.6 years.
Stock‑Based Compensation Expense
The following table presents the effect of employee and non‑employee related stock‑based compensation expense:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Cost of precision oncology testing
 
$
170

 
$
63

Research and development expense
 
1,210

 
204

Sales and marketing expense
 
826

 
374

General and administrative expense
 
976

 
636

Total stock-based compensation expense
 
$
3,182

 
$
1,277


Valuation of Stock Options
The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
Expected term (in years)
 
6.22
 
5.01 – 10.00
Expected volatility
 
66.7%
 
81.6% – 86.5%
Risk-free interest rate
 
2.7%
 
2.5% – 2.7%
Expected dividend yield
 
—%
 
—%

The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:
Expected Term
The expected term represents the period that the options granted are expected to be outstanding. After the adoption of ASU 2018-07 on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. Prior to the adoption of ASU 2018-07, the expected term of stock options issued to employees was determined using the simplified method, and the expected term of stock options issued to nonemployee consultants was based on the contractual term of the award.
Expected Volatility
Prior to the commencement of trading of the Company’s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock.

The Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
Risk-Free Interest Rate
The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.
Expected Dividend Yield
The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.
2018 Employee Stock Purchase Plan
In September 2018, the Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 922,250 shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP.
Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 10% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or last day of the offering period, whichever is lower. Except for the initial offering period, the ESPP provides for separate six-month offering periods beginning on February 1 and August 1 of each year. The initial offering period ran from October 2, 2018 through January 31, 2019.
For the three months ended March 31, 2019119,702 shares of common stock were purchased under the ESPP. The total compensation expense related to the ESPP for the three months ended March 31, 2019 was $566,000. As of March 31, 2019, the unrecognized stock-based compensation expense related to the ESPP was $646,000 which is expected to be recognized over the remaining term of the offering period of 0.3 years.
The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. For the three months ended March 31, 2019, the following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: a weighted-average expected life of 0.5 years; expected volatility of 60.2%; a risk-free interest rate of 2.5%; and a zero dividend yield.
Liabilities for Early Exercise of Employee Options
The Company allowed certain stock option holders to exercise unvested options to purchase shares of common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee’s employment termination, at the original issuance price, until the options are fully vested. As of March 31, 2019 and December 31, 2018, 32,279 and 44,268 shares of common stock were subject to repurchase at weighted-average prices of $4.66 and $4.66 per share, respectively. As of March 31, 2019 and December 31, 2018, the cash proceeds received for unvested shares of common stock of $150,000 and $206,000, respectively, were recorded within other long-term liabilities on the condensed consolidated balance sheet. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders’ equity as such shares are considered legally outstanding.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands, except per share data)
Net loss
 
$
(21,351
)
 
$
(13,844
)
Fair value adjustment of redeemable noncontrolling interest
 
(4,700
)
 

Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(26,051
)
 
$
(13,844
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.30
)
 
$
(1.16
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
85,935

 
11,920


Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Convertible preferred stock (on an as if converted basis)
 

 
58,265

Stock options issued and outstanding
 
7,503

 
7,457

Unvested restricted stock units
 
78

 

ESPP obligation
 
59

 

Preferred stock warrants (on an as if converted basis)
 

 
8

Common stock warrants
 

 
312

Common stock subject to repurchase
 
41

 
19

Total
 
7,681

 
66,061

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Segment and Geographic Information
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Segment and Geographic Information
Segment and Geographic Information
The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
United States
 
$
31,245

 
$
12,902

International(1)
 
5,410

 
3,790

Total revenue

$
36,655

 
$
16,692

(1)
No single country outside of the United States accounted for more than 10% of total revenue during three months ended March 31, 2019 and 2018.
As of March 31, 2019 and December 31, 2018, substantially all of the Company’s long-lived assets are located in the United States.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Related Party Transactions
3 Months Ended
Mar. 31, 2019
Related Party Transactions [Abstract]  
Related Party Transactions
Related Party Transactions
As discussed in Note 3, in connection with Softbank’s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events
3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
Acquisition of Bellwether Bio
In April 2019, the Company completed its purchase of all of the outstanding shares of Bellwether Bio, Inc. ("Bellwether Bio"), a privately-held company developing a method for early blood-based cancer detection. The upfront consideration, after customary adjustments at closing, was approximately $10.1 million in cash. Subject to the achievement of certain commercialization milestones and, for certain milestones, the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio, the Company will pay additional contingent consideration of up to a total of $20.0 million, which may be paid, at the Company’s election, in cash or in the Company’s common stock. At the time of the issuance of the Company’s condensed consolidated financial statements as of and for the three months ended March 31, 2019, the initial accounting for the acquisition of Bellwether Bio, including purchase price allocation, had not been completed.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders’ interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.
The Company believes that its existing cash and cash equivalents and marketable securities as of March 31, 2019 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. If the Company’s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Unaudited Interim Condensed Financial Statements
Unaudited Interim Condensed Financial Statements
The accompanying condensed consolidated balance sheet as of March 31, 2019, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2019 and 2018, and cash flows for the three months ended March 31, 2019 and 2018, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.
The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
JOBS Act Accounting Election
JOBS Act Accounting Election
The Company is an “emerging growth company” within the meaning of the Jumpstart Our Business Act of 2012 (the “JOBS Act”). Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. The Company has elected to use this extended transition period and, as a result, the consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company also intends to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.
Foreign Currency Translations
Foreign Currency Translation
The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the three months ended March 31, 2019, foreign currency translation adjustment was immaterial.
Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less. Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.
Concentration of Risk
Concentration of Risk
The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.
The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.
The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.
Accounts Receivable
Accounts Receivable
Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. Accounts receivable are written off when management determines a balance is uncollectible and no longer intends to actively pursue collection of the receivable. For the three months ended March 31, 2019 and 2018, the Company did not write off any material accounts receivable.
Upon the adoption of ASC 606 on January 1, 2019, contract assets are reported as part of accounts receivable on the condensed consolidated balance sheets and are discussed in "unbilled receivables".
Revenue Recognition
Revenue Recognition
The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.
Effective January 1, 2019, the Company began recognizing revenue in accordance with FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Precision oncology testing
The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical patients. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. Revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.
The Company’s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.
Development services
The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, in certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.
The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company’s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.
Contracts with multiple performance obligations
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.
For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.
Unbilled receivables
Unbilled receivables, which is a contract asset, consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized prior to the establishment of billing rights or the achievement of performance-based milestones. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. 
Unbilled receivables are presented under accounts receivable on the Company's consolidated balance sheets. As of March 31, 2019, the Company had unbilled receivables of $3.9 million as compared to $4.9 million as of January 1, 2019. The Company did not record unbilled receivables for its contract assets prior to the adoption of ASC 606 on January 1, 2019.
Deferred revenue
Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized.
As of March 31, 2019 and December 31, 2018, the deferred revenue balance was $17.1 million and $16.1 million, respectively, which included $12.4 million and $10.5 million, respectively, related to collaboration development efforts with two pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the three months ended March 31, 2019 that was included in the deferred revenue balance as of January 1, 2019 was $7.0 million, which represented primarily revenue from provision of development services under the collaboration agreement with a biopharmaceutical company. 
Transaction price allocated to the remaining performance obligations
Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company applied the practical expedient in accordance with Topic 606 to forego disclosures related to the allocation of consideration to the remaining performance obligations and the timing in which revenues will be recognized from such performance obligations.
Costs of Precision Oncology Testing
Costs of Precision Oncology Testing
Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.
Cost of Development Services
Cost of Development Services
Cost of development service includes costs incurred for the performance of development services requested by the Company’s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.
Stock-Based Compensation
Stock‑Based Compensation
Stock‑based compensation related to stock options granted to the Company’s employees and directors is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards.
In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.
The Company uses the Black‑Scholes option‑pricing model to estimate the fair value of its stock options. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.
Net Loss Per Share Attributable to Common Shareholders
Net Loss Per Share Attributable to Common Stockholders
The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.
Prior to the closing of the IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company’s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company’s losses.
Recent Accounting Pronouncements Not Yet Adopted
Recent Adopted Accounting Pronouncements
The Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and all related amendments (collectively “ASC 606”) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. These differences are discussed below.
For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition.
For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition.
Effective January 1, 2019, the Company recognizes revenue in accordance with ASC 606. Comparative information from prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.
The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:
 
Balance as of December 31, 2018
 
Adjustments Due to ASC 606
 
Balance as of January 1, 2019
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
35,690

 
$
4,907

 
$
40,597

Equity:
 
 
 
 
 
Accumulated deficit
$
(280,799
)
 
$
4,907

 
$
(275,892
)
In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:
 
Three Months Ended March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Revenue:
 
 
 
 
 
Precision oncology testing
$
28,837

 
$
994

 
$
29,831

Development services
7,818

 

 
7,818

 
 
March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
28,989

 
$
994

 
$
29,983

Equity:
 
 
 
 
 
Accumulated deficit
(303,209
)
 
994

 
(302,215
)
ASC 606 did not have an aggregate impact on the Company’s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above table.
In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of 1.3 million as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.
Recent Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The new guidance will be effective for the Company beginning in 2020, at which time, the new guidance will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements and anticipates the recognition of additional assets and corresponding liabilities on its condensed consolidated balance sheet related to leases. The adoption of the new standard is also expected to materially impact the Company’s condensed consolidated financial statement disclosures related to leases.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The new guidance is effective for the Company beginning in 2021, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
For each significant customer, revenue as a percentage of revenue and accounts receivable as a percentage of accounts receivable are as follows:
 
 
Revenue
 
Accounts Receivable
 
 
Three Months Ended March 31,
 
March 31, 2019
 
December 31, 2018
 
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
(unaudited)
 
(unaudited)
 
 
Customer A
 
*

 
11
%
 
*

 
*

Customer B
 
24
%
 
*

 
35
%
 
65
%
Customer C
 
*

 
13
%
 
*

 
*

Customer D
 
*

 
*

 
13
%
 
*

*
less than 10%
Schedule of the Cumulative Effect on Financial Information Related to the Adoption of ACS 606
The cumulative effect of changes made to the condensed consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:
 
Balance as of December 31, 2018
 
Adjustments Due to ASC 606
 
Balance as of January 1, 2019
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
35,690

 
$
4,907

 
$
40,597

Equity:
 
 
 
 
 
Accumulated deficit
$
(280,799
)
 
$
4,907

 
$
(275,892
)
In accordance with ASC 606 requirements under the modified retrospective method of adoption, the disclosure of the impact of adoption on the Company's condensed consolidated statement of operations and condensed consolidated balance sheet was as follows:
 
Three Months Ended March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Revenue:
 
 
 
 
 
Precision oncology testing
$
28,837

 
$
994

 
$
29,831

Development services
7,818

 

 
7,818

 
 
March 31, 2019
 
As Reported Under ASC 606
 
Effect of Change
 
Balances Without Adoption of ASC606
 
(in thousands)
Assets:
 
 
 
 
 
Accounts receivable
$
28,989

 
$
994

 
$
29,983

Equity:
 
 
 
 
 
Accumulated deficit
(303,209
)
 
994

 
(302,215
)
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Property, Plant and Equipment
Property and equipment, net consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Machinery and equipment
$
23,742

 
$
23,440

Computer hardware
5,293

 
4,949

Leasehold improvements
14,163

 
13,965

Furniture and fixtures
1,540

 
1,522

Computer software
741

 
643

Construction in progress
1,405

 
3,118

Property and equipment, gross
46,884

 
47,637

Less: accumulated depreciation and amortization
(16,303
)
 
(16,634
)
Property and equipment, net
$
30,581

 
$
31,003

Schedule of Accrued Liabilities
Accrued expenses consisted of the following:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)
 
 
 
(in thousands)
Accrued royalty obligations
$
853

 
$
707

Accrued legal expenses
2,400

 
814

Accrued tax liabilities
1,410

 
1,470

Accrued professional services
1,988

 
1,791

Purchases of property and equipment included in accrued expenses
137

 
343

Other
2,349

 
1,956

Total accrued expenses
$
9,137

 
$
7,081

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements, Recurring and Nonrecurring
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
 
March 31, 2019
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
10,093

 
$
10,093

 
$

 
$

Total cash equivalents
10,093

 
10,093

 

 

 
 
 
 
 
 
 
 
Corporate bonds
43,083

 

 
43,083

 

U.S. government debt securities
264,992

 

 
264,992

 

U.S. government agency bonds
4,994

 

 
4,994

 

Total short-term marketable securities
313,069

 

 
313,069

 

 
 
 
 
 
 
 
 
Corporate bonds
2,005

 

 
2,005

 

U.S. government debt securities
23,911

 

 
23,911

 

Total long-term marketable securities
25,916

 

 
25,916

 

Total
$
349,078

 
$
10,093

 
$
338,985

 
$

 
December 31, 2018
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
25,796

 
$
25,796

 
$

 
$

Total cash equivalents
25,796
 
25,796
 

 

 
 
 
 
 
 
 
 
Corporate bonds
38,397
 

 
38,397
 

U.S. government debt securities
235,016
 

 
235,016
 

U.S. government agency bonds
5,004
 

 
5,004
 

Total short-term marketable securities
278,417
 

 
278,417
 

 
 
 
 
 
 
 
 
Corporate bonds
3,805
 

 
3,805
 

U.S. government debt securities
73,758
 

 
73,758
 

Total long-term marketable securities
77,563
 

 
77,563
 

Total
$
381,776

 
$
25,796

 
$
355,980

 
$

Debt Securities, Available-for-sale
The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:
 
March 31, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(unaudited)
 
(in thousands)
Money market fund
$
10,093

 
$

 
$

 
$
10,093

Corporate bond
45,065

 
26

 
(3
)
 
45,088

U.S. government debt securities
288,522

 
455

 
(74
)
 
288,903

U.S. government agency bonds
4,995

 

 
(1
)
 
$
4,994

Total
$
348,675

 
$
481

 
$
(78
)
 
$
349,078

 
December 31, 2018
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(in thousands)
Money market fund
$
25,796

 
$

 
$

 
$
25,796

Corporate bond
42,273

 

 
(71
)
 
42,202

U.S. government debt securities
308,775

 
235

 
(236
)
 
308,774

U.S. government agency bonds
5,014

 

 
(10
)
 
5,004

Total
$
381,858

 
$
235

 
$
(317
)
 
$
381,776

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases
As of March 31, 2019, future minimum payments under the non-cancelable operating lease were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
3,693

2020
7,276

2021
8,161

2022
8,388

2023
9,023

2024 and thereafter
26,076

Total
$
62,617

Schedule of Future Minimum Lease Payments for Capital Leases
As of March 31, 2019, future minimum capital lease payments were as follows:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
107

2020
108

2021
36

Total minimum capital lease payments
251

Less: amount representing interest
(55
)
Present value of net minimum capital lease payments
196

Less: current installments of obligations under capital lease
(96
)
Obligations under capital lease, excluding current installments
$
100

Schedule of Future Minimum Royalty Payments
As of March 31, 2019, future minimum royalty payments were due as follows regardless of sales amounts:
Year Ending December 31,
 
 
(unaudited)
 
(in thousands)
Remainder of 2019
$
1,052

2020
1,402

2021
1,402

2022
1,683

2023
1,683

2024 and thereafter
5,609

Total future minimum royalty payments
12,831

Less: amount representing interest
(5,711
)
Present value of future minimum royalty payments
$
7,120

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock (Tables)
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Schedule of Stock by Class
Common stock has been reserved for the following potential future issuances:
 
March 31, 2019
 
December 31, 2018
 
(unaudited)

 
 
Shares underlying outstanding stock options
7,378,068

 
7,588,405

Shares underlying unvested restricted stock units
102,498

 

Shares available for issuance under the 2018 Incentive Award Plan
3,436,451

 
3,556,507

Shares available for issuance under the 2018 Employee Stock Purchase Plan
802,548

 
922,250

Total
11,719,565
 
12,067,162
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based Compensation, Stock Options, Activity
A summary of the Company’s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
 
Options Outstanding
 
Shares
Available for Grant 
 
Shares Subject to Options Outstanding
 
Weighted-Average Exercise Price 
 
Weighted-Average Remaining Contractual Life (Years)
 
Aggregate Intrinsic Value
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands)
Balance as of December 31, 2018
3,556,507

 
7,588,405

 
$
4.58

 
8.3
 
$
250,495

Granted
(18,370
)
 
18,370

 
41.25

 
 
 
 
Exercised

 
(146,318
)
 
3.49

 
 
 
 
Canceled
812

 
(82,389
)
 
4.77

 
 
 
 
Restricted stock units granted
(120,835
)
 

 

 
 
 
 
Restricted stock units canceled
18,337

 

 

 
 
 
 
Balance as of March 31, 2019
3,436,451

 
7,378,068

 
$
4.69

 
8.0
 
$
531,281

Vested and Exercisable as of March 31, 2019
 
 
3,361,540

 
$
3.61

 
7.4
 
$
245,680

Schedule of Restricted Stock Activity
A summary of the Company’s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
Restricted Stock Units Outstanding
 
Weighted-Average Grant Date Fair Value
 
 
 
 
 
Unvested balance as of December 31, 2018
 

 
$

Granted
 
120,835

 
44.02

Canceled
 
(18,337
)
 
41.30

Unvested balance as of March 31, 2019
 
102,498

 
$
44.50

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
The following table presents the effect of employee and non‑employee related stock‑based compensation expense:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Cost of precision oncology testing
 
$
170

 
$
63

Research and development expense
 
1,210

 
204

Sales and marketing expense
 
826

 
374

General and administrative expense
 
976

 
636

Total stock-based compensation expense
 
$
3,182

 
$
1,277

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
Expected term (in years)
 
6.22
 
5.01 – 10.00
Expected volatility
 
66.7%
 
81.6% – 86.5%
Risk-free interest rate
 
2.7%
 
2.5% – 2.7%
Expected dividend yield
 
—%
 
—%
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands, except per share data)
Net loss
 
$
(21,351
)
 
$
(13,844
)
Fair value adjustment of redeemable noncontrolling interest
 
(4,700
)
 

Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(26,051
)
 
$
(13,844
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.30
)
 
$
(1.16
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
85,935

 
11,920

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Convertible preferred stock (on an as if converted basis)
 

 
58,265

Stock options issued and outstanding
 
7,503

 
7,457

Unvested restricted stock units
 
78

 

ESPP obligation
 
59

 

Preferred stock warrants (on an as if converted basis)
 

 
8

Common stock warrants
 

 
312

Common stock subject to repurchase
 
41

 
19

Total
 
7,681

 
66,061

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Segment and Geographic Information (Tables)
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:
 
 
Three Months Ended
March 31,
 
 
2019
 
2018
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
United States
 
$
31,245

 
$
12,902

International(1)
 
5,410

 
3,790

Total revenue

$
36,655

 
$
16,692

(1)
No single country outside of the United States accounted for more than 10% of total revenue during three months ended March 31, 2019 and 2018.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Description of Business (Details)
1 Months Ended
Sep. 30, 2018
May 31, 2018
Apr. 30, 2018
Subsidiary, Sale of Stock [Line Items]      
Stock split conversion rate 0.7378    
Guardant Health AMEA, Inc      
Subsidiary, Sale of Stock [Line Items]      
Ownership interest in joint venture   50.00% 50.00%
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Unbilled receivables $ 3,900 $ 4,900  
Accumulated deficit (303,209) (275,892) $ (280,799)
Deferred revenue 17,100   16,100
Deferred revenue recognized 7,000    
Collaborative Arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 12,400   $ 10,500
ASU 2018-07 adoption | Accumulated Deficit      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Cumulative effect adjustment for new ASU's   $ (1,266)  
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Customer A | Revenue    
Concentration Risk [Line Items]    
Concentration risk, percentage   11.00%
Customer B | Revenue    
Concentration Risk [Line Items]    
Concentration risk, percentage 24.00%  
Customer B | Accounts Receivable    
Concentration Risk [Line Items]    
Concentration risk, percentage 35.00% 65.00%
Customer C | Revenue    
Concentration Risk [Line Items]    
Concentration risk, percentage   13.00%
Customer D | Accounts Receivable    
Concentration Risk [Line Items]    
Concentration risk, percentage 13.00%  
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Adoption of ACS 606 (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Jan. 01, 2019
Dec. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Accounts receivable $ 28,989   $ 40,597 $ 35,690
Accumulated deficit (303,209)   (275,892) $ (280,799)
Precision oncology testing 28,837 $ 14,191    
Development services 7,818 $ 2,501    
Topic 606 adoption        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Accounts receivable     4,907  
Accumulated deficit     $ 4,907  
Effect of Change | Topic 606 adoption        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Accounts receivable 994      
Accumulated deficit 994      
Precision oncology testing 994      
Development services 0      
Balances Without Adoption of ASC606        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Accounts receivable 29,983      
Accumulated deficit (302,215)      
Precision oncology testing 29,831      
Development services $ 7,818      
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Investment in Joint Venture (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
May 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Apr. 30, 2018
Schedule of Equity Method Investments [Line Items]          
Variable interest entity, assets   $ 47,000   $ 48,300  
Redeemable noncontrolling interest   46,500   $ 41,800  
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest   $ 4,700 $ 0    
Guardant Health AMEA, Inc          
Schedule of Equity Method Investments [Line Items]          
Payments to acquire interest in joint venture $ 9,000        
Equity method investment, shares purchased 40,000        
Equity method investment, ownership percentage 50.00%       50.00%
SoftBank | Guardant Health AMEA, Inc          
Schedule of Equity Method Investments [Line Items]          
Equity method investment, shares purchased 40,000        
Equity method investment, ownership percentage 50.00%        
Redeemable noncontrolling interest, redemption value $ 41,000        
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 46,884 $ 47,637
Less: accumulated depreciation and amortization (16,303) (16,634)
Property and equipment, net 30,581 31,003
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 23,742 23,440
Computer hardware    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 5,293 4,949
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 14,163 13,965
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,540 1,522
Computer software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 741 643
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,405 $ 3,118
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheet Components - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]      
Depreciation and amortization expense $ 2,100 $ 1,200  
Capital leases, balance sheet, assets, net 504   $ 504
Capital leases, balance sheet, assets, accumulated depreciation 324   $ 294
Amortization expense $ 30 $ 64  
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]    
Accrued royalty obligations $ 853 $ 707
Accrued legal expenses 2,400 814
Accrued tax liabilities 1,410 1,470
Accrued professional services 1,988 1,791
Purchases of property and equipment included in accrued expenses 137 343
Other 2,349 1,956
Total accrued expenses $ 9,137 $ 7,081
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements. Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 10,093 $ 25,796
Debt securities, short-term 313,069 278,417
Debt securities, long-term 25,916 77,563
Total assets 349,078 381,776
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 10,093 25,796
Debt securities, short-term 0 0
Debt securities, long-term 0 0
Total assets 10,093 25,796
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Debt securities, short-term 313,069 278,417
Debt securities, long-term 25,916 77,563
Total assets 338,985 355,980
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Debt securities, short-term 0 0
Debt securities, long-term 0 0
Total assets 0 0
Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 43,083 38,397
Debt securities, long-term 2,005 3,805
Corporate bonds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
Debt securities, long-term 0 0
Corporate bonds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 43,083 38,397
Debt securities, long-term 2,005 3,805
Corporate bonds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
Debt securities, long-term 0 0
U.S. government debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 264,992 235,016
Debt securities, long-term 23,911 73,758
U.S. government debt securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
Debt securities, long-term 0 0
U.S. government debt securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 264,992 235,016
Debt securities, long-term 23,911 73,758
U.S. government debt securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
Debt securities, long-term 0 0
U.S. government agency bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 4,994 5,004
U.S. government agency bonds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
U.S. government agency bonds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 4,994 5,004
U.S. government agency bonds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, short-term 0 0
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 10,093 25,796
Money market funds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 10,093 25,796
Money market funds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Money market funds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 0 $ 0
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details)
3 Months Ended
Mar. 31, 2019
Minimum  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Maturity period (years) 1 year
Maximum  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Maturity period (years) 1 year 2 months
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]    
Cash and cash equivalents $ 153,790 $ 140,544
Amortized cost, cash and cash equivalents and debt securities available-for-sale 348,675 381,858
Gross Unrealized Gain 481 235
Gross Unrealized Loss (78) (317)
Cash, Cash Equivalents and Debt Securities, Fair Value 349,078 381,776
Money market funds    
Debt Securities, Available-for-sale [Line Items]    
Cash and cash equivalents 10,093 25,796
Estimated Fair Value, Cash and Cash Equivalents 10,093 25,796
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost, debt securities, available-for-sale 45,065 42,273
Gross Unrealized Gain 26 0
Gross Unrealized Loss (3) (71)
Estimated Fair Value, Debt Securities 45,088 42,202
U.S. government debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost, debt securities, available-for-sale 288,522 308,775
Gross Unrealized Gain 455 235
Gross Unrealized Loss (74) (236)
Estimated Fair Value, Debt Securities 288,903 308,774
U.S. government agency bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost, debt securities, available-for-sale 4,995 5,014
Gross Unrealized Gain 0 0
Gross Unrealized Loss (1) (10)
Estimated Fair Value, Debt Securities $ 4,994 $ 5,004
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Patent License Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]        
Payment in connection with patent licensing agreement $ 9,700      
Capitalized license fees   $ 7,557   $ 7,800
Useful life (years)   7 years 9 months   8 years
Amortization of intangible assets   $ 243 $ 189  
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Schedule of Future Minimum Payments For Operating Leases (Details)
$ in Thousands
Mar. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Remainder of 2019 $ 3,693
2020 7,276
2021 8,161
2022 8,388
2023 9,023
2024 and thereafter 26,076
Total $ 62,617
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2018
patent
Nov. 30, 2017
patent
Mar. 31, 2019
USD ($)
party
Mar. 31, 2018
USD ($)
Other Commitments [Line Items]        
Operating leases, rent expense | $     $ 1,300 $ 1,100
Number of parties with patent license agreement | party     4  
Royalty expense | $     $ 633 $ 172
Percentage of precision oncology testing revenue     2.00% 1.00%
Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing        
Other Commitments [Line Items]        
Number of asserted patents   3    
Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc.        
Other Commitments [Line Items]        
Number of asserted patents 2      
Number of petitions filed 2      
Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing        
Other Commitments [Line Items]        
Number of asserted patents 4      
Number of petitions filed 6      
Other Income        
Other Commitments [Line Items]        
Amount awarded from other party | $       $ 4,250
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Schedule of Future Minimum Payments For Capital Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]    
Remainder of 2019 $ 107  
2020 108  
2021 36  
Total minimum capital lease payments 251  
Less: amount representing interest (55)  
Present value of net minimum capital lease payments 196  
Less: current installments of obligations under capital lease (96) $ (97)
Capital lease, net of current portion $ 100 $ 119
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Schedule of Future Royalty Payments (Details)
$ in Thousands
Mar. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Remainder of 2019 $ 1,052
2020 1,402
2021 1,402
2022 1,683
2023 1,683
2024 and thereafter 5,609
Total future minimum royalty payments 12,831
Less: amount representing interest (5,711)
Present value of future minimum royalty payments $ 7,120
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock (Details) - shares
Mar. 31, 2019
Dec. 31, 2018
Class of Stock [Line Items]    
Common stock, shares reserved for future issuance (in shares) 11,719,565 12,067,162
Stock options    
Class of Stock [Line Items]    
Common stock, shares reserved for future issuance (in shares) 7,378,068 7,588,405
Restricted stock units    
Class of Stock [Line Items]    
Common stock, shares reserved for future issuance (in shares) 102,498 0
2018 Incentive Award Plan    
Class of Stock [Line Items]    
Common stock, shares reserved for future issuance (in shares) 3,436,451 3,556,507
2018 Employee Stock Purchase Plan    
Class of Stock [Line Items]    
Common stock, shares reserved for future issuance (in shares) 802,548 922,250
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares canceled (shares) 508,847 812    
Weighted average grant date fair value, grants in period (in dollars per share)   $ 25.90 $ 3.77  
Stock based compensation not recognized, options   $ 16,600   $ 17,500
Stock based compensation not recognized, period for recognition (years)   2 years 5 months 27 days   2 years 8 months 21 days
Number of shares outstanding (in shares)   7,378,068   7,588,405
Number of shares granted (in shares)   18,370    
Stock-based compensation   $ 3,182 $ 1,277  
Weighted-average expected life   6 years 2 months 21 days    
Expected volatility   66.70%    
Risk-free interest rate   2.70%    
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Exercises in period, intrinsic value   $ 8,100 $ 1,300  
Shares authorized (in shares)   3,658,602    
Expected dividend yield   0.00% 0.00%  
2018 Employee Stock Purchase Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation not recognized, other than options   $ 646    
Stock based compensation not recognized, period for recognition (years)   4 months    
Stock-based compensation   $ 566    
Shares authorized (in shares)   922,250    
Maximum employee subscription rate, ESPP   10.00%    
ESPP purchase price of common stock (as a percent of the fair value of common stock)   85.00%    
Common stock issued under employee stock purchase plan (in shares)   119,702    
Weighted-average expected life   5 months 29 days    
Expected volatility   60.20%    
Risk-free interest rate   2.50%    
Expected dividend yield   0.00%    
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation not recognized, other than options   $ 4,200    
Stock based compensation not recognized, period for recognition (years)   3 years 7 months 24 days    
Nonemployee stock option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock subject to repurchase (in shares)   32,279   44,268
Stock subject to repurchase, per share (in dollars per share)   $ 4.66   $ 4.66
Cash proceeds received for unvested shares   $ 150   $ 206
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2018
Mar. 31, 2019
Dec. 31, 2018
Shares Available for Grant      
Beginning number of shares, available for grant (shares)   3,556,507  
Granted (shares)   (18,370)  
Canceled (shares) 508,847 812  
Ending number of shares, available for grant (shares)   3,436,451 3,556,507
Shares Subject to Options Outstanding      
Beginning number of shares, outstanding (shares)   7,588,405  
Granted (shares)   18,370  
Exercised (shares)   (146,318)  
Canceled (shares)   (82,389)  
Ending number of shares, outstanding (shares)   7,378,068 7,588,405
Options vested and exercisable, number of options (shares)   3,361,540  
Weighted-Average Exercise Price      
Beginning balance of options outstanding (in dollars per share)   $ 4.58  
Granted (unaudited) (in dollars per share)   41.25  
Exercised (unaudited) (in dollars per share)   3.49  
Canceled (unaudited) (in dollars per share)   4.77  
Ending balance of options outstanding (in dollars per share)   4.69 $ 4.58
Options vested and exercisable, weighted average exercise price per share (in dollars per share)   $ 3.61  
Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value      
Options outstanding, Weighted average remaining contractual term (in years)   8 years 14 days 8 years 3 months 6 days
Options outstanding, Aggregate intrinsic value   $ 531,281 $ 250,495
Options vested and exercisable, Weighted average remaining contractual term (in years)   7 years 4 months 17 days  
Options vested and exercisable, Aggregate intrinsic value   $ 245,680  
Restricted Stock Units      
Shares Available for Grant      
Granted (shares)   (120,835)  
Canceled (shares)   18,337  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 3,182 $ 1,277
Precision oncology testing    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 170 63
Research and development expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 1,210 204
Sales and marketing expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 826 374
General and administrative expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 976 $ 636
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Valuation of Stock Options (Details)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (years) 6 years 2 months 21 days  
Expected volatility 66.70%  
Risk-free interest rate 2.70%  
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected dividend yield 0.00% 0.00%
Stock options | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (years)   5 years 4 days
Expected volatility   81.60%
Risk-free interest rate   2.50%
Stock options | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (years)   10 years
Expected volatility   86.50%
Risk-free interest rate   2.70%
2018 Employee Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (years) 5 months 29 days  
Expected volatility 60.20%  
Risk-free interest rate 2.50%  
Expected dividend yield 0.00%  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Restricted Stock Activity (Details) - Restricted stock units
3 Months Ended
Mar. 31, 2019
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Beginning unvested balance (shares) | shares 0
Granted (shares) | shares 120,835
Canceled (shares) | shares (18,337)
Ending unvested balance (shares) | shares 102,498
Beginning balance of options outstanding (in dollars per share) | $ / shares $ 0.00
Granted (unaudited) (in dollars per share) | $ / shares 44.02
Canceled (unaudited) (in dollars per share) | $ / shares 41.30
Ending balance of options outstanding (in dollars per share) | $ / shares $ 44.50
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Earnings Per Share [Abstract]    
Net loss $ (21,351) $ (13,844)
Fair value adjustment of redeemable noncontrolling interest 4,700 0
Net loss attributable to Guardant Health, Inc. common stockholders $ (26,051) $ (13,844)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) $ (0.30) $ (1.16)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) 85,935 11,920
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 7,681 66,061
Convertible preferred stock (on an as if converted basis)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 58,265
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 7,503 7,457
Unvested restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 78 0
ESPP obligation    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 59 0
Stock warrants | Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 8
Stock warrants | Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 312
Common stock subject to repurchase    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 41 19
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Segment and Geographic Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Segment Reporting Information [Line Items]    
Total revenue $ 36,655 $ 16,692
United States    
Segment Reporting Information [Line Items]    
Total revenue 31,245 12,902
International    
Segment Reporting Information [Line Items]    
Total revenue $ 5,410 $ 3,790
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events (Details) - Bellweather Bio, Inc. - Subsequent Event
$ in Millions
1 Months Ended
Apr. 30, 2019
USD ($)
Subsequent Event [Line Items]  
Payments to acquire business $ 10.1
Contingent payment payable $ 20.0
XML 70 R9999.htm IDEA: XBRL DOCUMENT v3.19.1
Label Element Value
Accounting Standards Update 2014-09 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 4,907,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 4,907,000
Accounting Standards Update 2018-07 [Member] | Additional Paid-in Capital [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 1,266,000
EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 175 271 1 true 63 0 false 6 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://guardanthealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://guardanthealth.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 3 false false R4.htm 1001001 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 4 false false R5.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://guardanthealth.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 1003000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (unaudited) Sheet http://guardanthealth.com/role/ConsolidatedStatementsOfRedeemableNoncontrollingInterestAndStockholdersEquityUnaudited Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (unaudited) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://guardanthealth.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - Description of Business Sheet http://guardanthealth.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 2104100 - Disclosure - Summary of Significant Accounting Policies Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2107100 - Disclosure - Investment in Joint Venture Sheet http://guardanthealth.com/role/InvestmentInJointVenture Investment in Joint Venture Notes 10 false false R11.htm 2110100 - Disclosure - Condensed Consolidated Balance Sheet Components Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents Condensed Consolidated Balance Sheet Components Notes 11 false false R12.htm 2113100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities Sheet http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities Fair Value Measurements. Cash Equivalents and Marketable Securities Notes 12 false false R13.htm 2116100 - Disclosure - Patent License Agreement Sheet http://guardanthealth.com/role/PatentLicenseAgreement Patent License Agreement Notes 13 false false R14.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://guardanthealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2125100 - Disclosure - Common Stock Sheet http://guardanthealth.com/role/CommonStock Common Stock Notes 15 false false R16.htm 2134100 - Disclosure - Stock-Based Compensation Sheet http://guardanthealth.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 2137100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders Sheet http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders Notes 17 false false R18.htm 2140100 - Disclosure - Segment and Geographic Information Sheet http://guardanthealth.com/role/SegmentAndGeographicInformation Segment and Geographic Information Notes 18 false false R19.htm 2143100 - Disclosure - Related Party Transactions Sheet http://guardanthealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 2144100 - Disclosure - Subsequent Events Sheet http://guardanthealth.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 2304302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://guardanthealth.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 2310301 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables Condensed Consolidated Balance Sheet Components (Tables) Tables http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents 23 false false R24.htm 2313301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables) Sheet http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables) Tables http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecurities 24 false false R25.htm 2322301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://guardanthealth.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://guardanthealth.com/role/CommitmentsAndContingencies 25 false false R26.htm 2325301 - Disclosure - Common Stock (Tables) Sheet http://guardanthealth.com/role/CommonStockTables Common Stock (Tables) Tables http://guardanthealth.com/role/CommonStock 26 false false R27.htm 2334301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://guardanthealth.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://guardanthealth.com/role/StockBasedCompensation 27 false false R28.htm 2337301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables) Sheet http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersTables Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables) Tables http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholders 28 false false R29.htm 2340301 - Disclosure - Segment and Geographic Information (Tables) Sheet http://guardanthealth.com/role/SegmentAndGeographicInformationTables Segment and Geographic Information (Tables) Tables http://guardanthealth.com/role/SegmentAndGeographicInformation 29 false false R30.htm 2401401 - Disclosure - Description of Business (Details) Sheet http://guardanthealth.com/role/DescriptionOfBusinessDetails Description of Business (Details) Details http://guardanthealth.com/role/DescriptionOfBusiness 30 false false R31.htm 2404403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 31 false false R32.htm 2404404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) Details 32 false false R33.htm 2404405 - Disclosure - Summary of Significant Accounting Policies - Adoption of ACS 606 (Details) Sheet http://guardanthealth.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfAcs606Details Summary of Significant Accounting Policies - Adoption of ACS 606 (Details) Details 33 false false R34.htm 2407401 - Disclosure - Investment in Joint Venture (Details) Sheet http://guardanthealth.com/role/InvestmentInJointVentureDetails Investment in Joint Venture (Details) Details http://guardanthealth.com/role/InvestmentInJointVenture 34 false false R35.htm 2410402 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantAndEquipmentDetails Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) Details 35 false false R36.htm 2410403 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails Condensed Consolidated Balance Sheet Components - Narrative (Details) Details 36 false false R37.htm 2410404 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) Sheet http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) Details 37 false false R38.htm 2413402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) Sheet http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesMeasuredOnRecurringBasisDetails Fair Value Measurements. Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) Details 38 false false R39.htm 2413403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details) Sheet http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesNarrativeDetails Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details) Details http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesTables 39 false false R40.htm 2413404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) Sheet http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) Details 40 false false R41.htm 2416401 - Disclosure - Patent License Agreement (Details) Sheet http://guardanthealth.com/role/PatentLicenseAgreementDetails Patent License Agreement (Details) Details http://guardanthealth.com/role/PatentLicenseAgreement 41 false false R42.htm 2422402 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments For Operating Leases (Details) Sheet http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Payments For Operating Leases (Details) Details 42 false false R43.htm 2422403 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://guardanthealth.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 43 false false R44.htm 2422404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments For Capital Leases (Details) Sheet http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForCapitalLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Payments For Capital Leases (Details) Details 44 false false R45.htm 2422405 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details) Sheet http://guardanthealth.com/role/CommitmentsAndContingenciesScheduleOfFutureRoyaltyPaymentsDetails Commitments and Contingencies - Schedule of Future Royalty Payments (Details) Details 45 false false R46.htm 2425402 - Disclosure - Common Stock (Details) Sheet http://guardanthealth.com/role/CommonStockDetails Common Stock (Details) Details http://guardanthealth.com/role/CommonStockTables 46 false false R47.htm 2434402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 47 false false R48.htm 2434403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 48 false false R49.htm 2434404 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details) Sheet http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock Based Compensation Expense (Details) Details 49 false false R50.htm 2434405 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details) Sheet http://guardanthealth.com/role/StockBasedCompensationValuationOfStockOptionsDetails Stock-Based Compensation - Valuation of Stock Options (Details) Details 50 false false R51.htm 2434406 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details) Sheet http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails Stock-Based Compensation - Restricted Stock Activity (Details) Details 51 false false R52.htm 2437402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) Sheet http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfNetLossPerShareDetails Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) Details 52 false false R53.htm 2437403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) Sheet http://guardanthealth.com/role/NetLossPerShareAttributableToGuardantHealthIncCommonStockholdersScheduleOfAntidilutiveSecuritiesDetails Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) Details 53 false false R54.htm 2440402 - Disclosure - Segment and Geographic Information (Details) Sheet http://guardanthealth.com/role/SegmentAndGeographicInformationDetails Segment and Geographic Information (Details) Details http://guardanthealth.com/role/SegmentAndGeographicInformationTables 54 false false R55.htm 2444401 - Disclosure - Subsequent Events (Details) Sheet http://guardanthealth.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://guardanthealth.com/role/SubsequentEvents 55 false false R9999.htm Uncategorized Items - gh-20190331.xml Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - gh-20190331.xml Cover 56 false false All Reports Book All Reports gh-20190331.xml gh-20190331.xsd gh-20190331_cal.xml gh-20190331_def.xml gh-20190331_lab.xml gh-20190331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 76 0001628280-19-006594-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-19-006594-xbrl.zip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

USD9X;>11V&AXQAJ+[G"#H)@.4I>RQ3=]Q36'+WA:LE?5[:B8_',IR6.YW,BLXOKC$RFO;ORD&!7CR6CZ M6$FW0-,M@&B)^=S,;3+P/UFDMAC;-$$>BP32G&,\#C>3TS\:5Q?5[E MG7-NL['FS/1?4]Q^8GE$C(+ /$09#45 $! V6HXW9C"LT MA82]9LV_E:FM,0-?&E[G4]R)9O^LFC^A?_C;2^J''V6?QW?Y]2(.??LE>MM$ M_3"ZSW<4HTKM,N.8D%C-#1FH#='.(\%K9 P3*2?@!DCI\Y"J/(NNNF3QKF'N M+&I^N%$&K;9888UH+&8ID%4 U-+%U/'+8&)_)"@[0OZD':5?UZ;=?RQ-._6; M4\&!WU>.:$^#C!)M-'':8,D,%J'Q92V%%=V@&MOP;'--/QD M=G[?I!C1WH89T8IAI FU%#"+!13:U-(ZA2^M(N,Y5[Y.--(7_[;/T5=_%$%G M=Y-O'_-J'"EPN\\+:=Q'!JFB,$83&;$"8D2ALS4&R,FD?? A)EBT18FM5WRT M#_CY=@0^E/-5WMSG;]/)//AC03NSF+87\[$V"H!.T:]K\A;.5XL4]Z*:U?,E^O 35G=CYZ>X#TB\K;% M,*S?,-KRACU1LH8M,TPQP<0YBZB/=?(U]9XI@1RE0:?XY&OG9O4G/LO'?[TM MO_]RG4]67W?XP\N/.OQH,]I84G*+/"\?R1QFC %BH66>8HF5#:!!3(R T%'= MZSK0W4?8NAK+5N!L-LL?S0$5AG,=A^2GHVTY J^>R4"8>Z"1WC+,*0WF/M16 M"RT1*+>C^:$YX=FS&?:(<.\(=2[X:=A( M+(FW'&D,@U0RI1[X@#+5^I@<4G#MF!Y^,AN/IO^9CRH??K+-T=WS= :XLEH* MX!S'E ,C#1; 4LZ,9(2Y"RDQT =%TI#MA20K%C>GR9/G,ZYC^2R,53 _J1!" M"N-YX#L(T@&35)%T0,?]^R/*Z=AV1)4OU2BFOGU^N/]:3G?0X]DSF3.0(F$U MHPA02+"TF'LJM?7">N=3(F,#.I/?)252\.R(!BL!/^6WDRA7,8]AY!ULV/9H M!HBAV ( D4/482V!)LI! +E1'+&4ZR$&=%R]2U*T &NGW#!!Z&HT?1?<^#__ M3[XM!77GLYF%Q')C8M:2BR>-)?>$H+ ^(B^"89W"C@&=^NZ>'6FX=D0/LZBJ M9X;0?I]EU^,9I(Y(;T"LY$HU8$H):ZU# DA)=-(U1@,Z<-TE25J"MM-IQ$^F M>67"H&[+:O\D\NS)#&#LM(=!",0H%$H%,!AC4 "B)0-)N[H#.MS<_1R2 FNG MS/A\/YI.7^:F;V7&LR>S8"0Q)N-EDTQ0SZ%VFB"O*4$PB .2F\;P]<2<6V6Z_F\=[U)N4A10+[T' D/FD MVX*'=-2W!X>G/91[VA/WHTFUK)[P6SZ*AV>6Z>YF-+N+V_S?1]/X5U5<_S:J M_I$O+[7XG(\75?@Z\O,=5MF,^?',3Y,S*/N:9013Z3F@,MB7E&,B(/,:6!(I[DW:Z?SA??+NJ+[L# M>/A?>[.GSGV.K8NI02D7YFGA4$R60O'J2X %<1!A*#' C?:4NI'6YE_GC]BK M[P'ZJ Y?5C'[Z]!AL@:M,R.@0/'\)G&&H+!2857+KJP726;E&YLF&M.@[!KF MOM(V-P?AWA4!@U7JW/:#6P=:9!13;C$"CN.XQZQ@<+UJ^3Q020;F\&C4JL9? M+CJM(-P7@Y:N5-!-7"Y6A8B#(?SDA.6C$+.8V#;;_JN=Y["Z>$VF! D+M-': M\5@N7%NFW!K)L'(G70H^0*XF\^GE97GG4T5?I/ZM+/*'E?'C%\7U;.?!K_T- M,@;CPD&!AE@#A[@*7WXMG3-II9*&1[3S$*/L0!-]\0:;V1E5F1PKH!Q90'Q;HV%=(7^7[__&OY/:^**/^1_#O4 M-.-!0DT)=T0[I:@!E =HG:16(HU1RFF 86J!T7!EG5R#A:JVSR $D,,)[-Q M7Q<9<])0P1"BP2)GE#H 40TM-SSEQ/Z 8N"#966+NNGM6..F\L%+'^]1@/=- MCG8?TT]8+R S!&DI!:,8>/>C:;>':+OAQ4NKL /D M^V+=2UQ>?*7W936?_#/>0C&;Z]%L;\CPV*X"WCB6BI'>(B:Q"]^WIS4BSMA^ M3Q%>"!<[5L))179VS/PW934+(QRMOIS1ZP_HZ6"W\*ZEGC,;9 7 .QNDEI)# M[3VI$=!$I]#P>"?FC=/P/#H9R&0Y'J\NI,ZO?ZW*V>SWHLI'TRC2K\&TUA&! M?/]]$*WTGUD.- \.'Z<>4R(9)'2ST&@+U&6Y/X.85CO1S-!9'6\^Z)+5S_K/ M+)%>,8ZD4)0C: $$]8Q@)6F6UI-\'K3O>WB&3>X4!9W7J]J2'G"T9[6ECPPR MXRQ%'&!G +00:L-J#+!)NH?LZ!.JO53).J-_E8[_N2;8ITE63[^T(^;075UD MQ EOA'*2(.%!^",3H$: () 24QK0<=CSSH\M@7^2+Q4_@A<. 1(<0N^-W>^UXI:ZH"Q=;Z4@) PZXQ4'FV&KV2Q?ZNK]9/1U,MVE MHO# AS)8?4\U=B@EM;5W9((ZSYBC4&L3O@:KK)!K'#%3X$=*7&U,J5WY[3TK MH[?TUEH^_?!D3O)5_E^+O!@_'$IU/=PZ0T)Q1+@"AF =O!F$C*_E5A0UNI+I M#9*P/[[L8FQK.NF=B]O&?3#_M4'KS'KI*SK^0MJ:*O@CW M*0_&[F0\SZ^W#WW[3P_.>"G=9EJ'3S!\[,P8!X&RE'GW^-W[E )1 YP)VZ!, M>3;TW]K9$8.UQ0$Z:80$6$AH[3KE#5% DJY[&2"W^B%"L[,BQR'_!H]J(F0) M(<8@!X*JN,-6/\J7Y+,.,#G__$MM.WKXUX'.W=GIDH0U!T,O#6(!3T.)KS5# MC=,7=O@XF4]='N@\3A5O^Z =!T)CPBF0$" OJ0/&K&5ES"AR5$' M[8Y3R"47>-".8*B (!HI MBI30T$($-@@8E.*[#-#"'!PK6]3-&7;J-G_\CTE>A???/;S/O^?3YIMU>SK( MF#7 HF"_0^0)51Y+JFKI'9 IOL\ <2, MLM9;+HQ1'OK:C&<&HLO=QFN%($UV6%J"OG<:OBN^+>:S)2BP^5;>ZU:9U\PS M2H-;J C$GEN\"9AQ)M6EILZTRX%=3$O&^YR\0B?Q:MTJ$PYK%DR*\($:8X%$ ME*!:3JA9"J\&Z(VGX7U.7N&3>+5NE2FB 2">AT_%4\,8CG?8K>6,S+M"-'&<&:HAD)QY12IL=1:I@0)!W1?X0 ] MCC-H[S(/KV$3EAECB+>8,.J%0QQLK!<*+RS+X4S\.?EHVW':Z8NAST-/ZVO M]K!QZ_.91\0X81&"E%CI1+!UZDBJ"(M3RMG>(=N39V5>&YHX#\L"&.,CB?;8 M)%-64V]\6%NT)@H @65M1PE$9*:-ZOF3\@<_O:2R.%'V:=1<9OOV&]]]OM,0V*18SI, ME!1S2"!CNAXS8>9?KF&JKLMTU#MGRL[0[HLG,BN8H)Q+ )7P4%MK-%N/.ZS? MY$+8UV,GDK(+ MT_>Q&BO;P:U3G8_^/*SSI\]DAB(:[&?/A#4D( ")0(((*+C2P+H4DV) (9M6 M=)Z V[^V7/9YA\%HFDM A#(IW"# 2GXD*GDB2"[%^9VL;\I,7G^:;'\FO>1Y\#+;+E4#4$3$A" M%6-">4B9P\)*@9Q.<:J';.RTP9)VH>UIY7A7?,]G\[A>O"O^=SDIYG\+?WRR M!]7[@A!7K/G#;_G\KKQ^'%Q_SV]'4%?,PS!U[?%N>RCC1P>[15"GHM0<2$J/JH6/) M+VRKN&U]EFT!VQ$G5N/9>9#QY2.9@$P2H*DQC#ND!,"&UH-6#ES(3EZ2NLI6 MH#O)P_Q\L N9MOHC0=D1\BGWA7C?6O:G@99Z%MZJS3#(.X L5B?IQXOTJ31K1MO@REM*:[L M ->^\A8.SL;OC[JT_5 G&5=6*2"A2#KX/\/!(1VM=Y[CW MQ;Z/HX<5#*4:!PFJ_%T1E!)&OSUBOX5Z#7O(C&/QO)^$3 !JJ #.U?8K951= MB!_6)3'*/H _:?G;+N/GNP#5[..B&M^-9OF./)5&38-5X(+W@RRD!D!%XL!U M+0/$2?V^":MQ'YDDRCN+ M5;!#^8M?*M.GK*Z@[XM^G_+K/+^/%D,\ %H6\P!O>,EM M/?.NY(M/W7^+"M]U@V52?UFPB@EGP%!.,7%*""-JLY@J25,FPP$6!NR!EGVH MH2^*_FU43:(DF[$O8XBF+&;E='(]6MY:4%4/,<'QOEP4\U6VT1Z.GM9A9KVG MD#IO#69:0(4IK(.-3'&=4@=I@+5D>B!I+WH8UD3Z7*#D>?1Y=UFL/J]-^ _1 M!!H"$"6U(KA6Q"8P].B+SB^"H3UHH2]^?LB#%S4N[_/WY6RFYO-J\G6QS&W^ M4AZ2<@]-$WK-G+1&6B8U]B!"Q(&N(Q2<0GFQEZ)WQM;^E-%3"E40*(H2C.BE M+_=_OR^+SO!S_XZZ1-TBFVM$D U(90KR! MT"(:="2X$X!+ A%EPIM&DWH_4C9*J]S5)E-(6!&O5S3"4RF(8"[>LYDHYKD7>_T;->"^W,\703 ?>!_T.&WQ8HL80U\R=;&^95M MO"@SV#!MK77.:DRY90*R-:)>D*3J3V]IKFE,K)U[1&?01F_UQM)$TP_;.SAP MDT:';\VX$)XK1YR1SD DH6"\QME(DG+]Q@!9?RZ2OBQZ-AB%GO?#V9MLU+1I MQA#P$%GK12S+@:3'02UKB16C%[;E.@CN-.+SR2KJBY2F#)YV-9^$3_ECK>6E M/=G@%L*]+3,<+'9@*"344:VTD8CAE;P:&)84QCB:DF&@7\NSD/(4 KRZ7;!- MH'O;O[W_-BT?\GPYTJOE9LI!2NULDUFK/=4^: 4AKBV%3HA:1B=92AW< 68% M=$:EM@#N;_.@OH![.>+?B\E\]NGS[P>)M+==9A"/-S=1@332U%"DL*QEE88V M.J';UF;_FYZ9VH3Y+//2<3/26B[$%8HE?A50!%,E@-*ZEDM)D[*P';TI_Z;I MDPYN7Z3Y>ZQ;7,P/TN79^X =[6,AO"4I(W/\GPSP8A7K]<*8 E%Q[Y[US'NKE)5BU5$'@"]LP:$&[+WW[ M5$A[.SUR7'!H:Z#"6\(4 U1B#)745$&YF76M8KV2I0_#.46Y+T^ I./97T1Q MLR?=((;XXMD@DU4PWJ&B3!#$&D+@1B:%DRJ5#G#5:I$AJ5"^D>W#]PV.2+;U MBHRZ8 98"2D#0F'F$/%H\X$1DI)^/^A3(6]Y8_!4[;T1_A],D&ZE_\P 9 D& M7"D8] ;"Q*'7NV :V3 E799=US_EVN7\24I[VQ?PRWRR.5177-EIX6ZMC-&R906V5@)00SY@1"&LA[49>#5+JY [P M/'CK]&H7WMXVG_/)[5T8G@JKR^@V_["(T9VKFZ4$5XOY;#XJKM=W1C1CV6D= M9BSNMDE ,*.$!S2\ WJ-CC \J1C! +>S6R=?+ZB_$:?NS+<%M>FZ<;,L7>*( M4(QB#Y6B'C+/ &7*O+H4_CR'D [,>P=O>TGL,5/02Z:XU]P12@W12ENID;&< M0Z>2;H-Y2TYA8ZKL+CW7(>S]5T%,#3,?Q=BV7I9123WRWA &#>60Z."9QYT5 MPX47"J:=_P'I>WL\RU38BR:\#/^N&? M>[>BK^\?:8A\6 &8AD$9"$G/8N5EJRVRGME&-8=?(K"E#.FZ(NJ[PI1%D8^C MGOX^F=^-=LVWSRN1-FV=<1D\+^T=I\Q 2[1C3*VDP1"J2SL/W[:*RZX![\MD MW0_,R1]-!A0*[CT5'D$")$ <6%E+BS%(R?,>H"G9$;TZP?K\S/I]EM\LIN\G M-_O*?S1IGADI!;4&N0LK W\VEIV,>&^91_=E-9_\<^U. MO01G7TK1WH:9=Q8AXTSXN#3#!G*YO+MA*:USXL(V)3KF5ZM8]V3Q?LJGL2CI MQU$U?_A2C8K9:+G"G\_8W36@!F;NH::9L!PQJAEG& 6?PP@3_FJP0T''-JCG M? [NKJ$?Y^@>T4N& O\0EY0!3,(_B-#<""4 !<1 J%..& W0/&Z/&J^.47<% M>4\3P.?\-EKOJKC^-2]OJ]&WN\GX77%35O?+[LXV#ZS']2G_%B?5XK;!][^K M248AQ,$O@5))26.$@6DB"8.::**,/V.*WLLA'_>]-VB=:>PUCVP#WE!JL6*& M0$J1@Q(B;2YL_R:= B]#WJU#/(SO^MPQK38_;\ H08XP83&&0GNK08Q%6$>Q MQ,%B&\(V[LO!/U&%?EC_LGG!R,:]9= 9RX3@Q-!@O5+(D<,U-L$$O; *M.D4 MV;GCU17D)WJ0S2YPK<^\/DX!H^F^VUEW/9]!23"12"("C/"<.R386B8CT*7< MYMN+ULOV\>Z40RLAGXYP[_VJ.Y\/;C6E+*R-$!MIE7'!O/:U3 &["YF*6M)K MV3ZBQ[&DONA]'(\G50^1*+S^2^0)?\*3]8^SWS]O(<7C+S,1_@/BIH".UWH" MSVR\[',UWO#3E"S$H3$@76=E(GR])>R7Q>^S@Z?%GSR5462,X= +Q&-Z)-;$ MB[4H-$ !(FO) MF=0I>[L#8E"?YDB'\/=72J'\F(E91SY+%$0CBB-$.TEH B?V'I M/NTJ]54$]"1,AQ$&.7,R>YM1$$6QP((1B9VDS !A6(!>!740*S!H1.E!1$&. M2@T^JL?,*FX\XX0Q@:+G+X4/-E5,@X5,>-OHUI&W^]D?3Y6T:,B)L/HAQ3E?-B=M[]CL? \M7-TP&M-YA,.9O/EKG37^.0ZUO%&TP8:1UG7E J MH$?!S!0T[ED1))Q%6CNAI 9G/"/36##]5+ FTTMBSUFPYHV2#D)G#45$*NYC MIKW2'@,'7$I6Q0"GF;X(5IY326>=E#[$*KKQJ,6Y=VV&.DEI03!VC@'N >!2 M,PM]6&08-X0'%[E1Y9+.;9\-%Y\*J&)]Y-MEL' 65LZ7?%5_!)XLDTNVVHGI55V^YBLL!AE<>NA;LZ7,9E\90 MP<*_H'7"6L.5JV7185Z^+.J=@0,ODQ43T.\ME'@R-H_2%=KH;U.FBUO 0#"P!40!.R&YA(9()]:R2F-EK[> _6#4:U,Q MATFXY?CPA[+(CU@T#[3(O B3L83 .X4QD!!:57\VTO.D9(0!GH :!)7:5'5R&NY2A77^1C(<^;LOHU7N7FR^HFG\P7@2F3XF->3N$ M-WK:#K=[YE&!.66[ICG@@7,\[?WU*P%%R-$S^;$]^>4@T1SMM7I=V3-HW>/GTIEA^^3.9]JM>9/@4C(># M.:(5% P9AG6UZ:.LI3FA(@/,*#]*E6L6XIM7P\U"'QW2[5?I=[ /W3O8D2 ) M4"A=]Y+8<6ZU\H+N&?(Y^WL#+"P_1H5K M=;<=#VJF)LJF6TZ(+]\*Z@N(.$ M(RL@($@A8;B06YEJ#$A.N@)^UY4!079)4^$/?]\8'!UUFH[VQ-E'U;.I^7S-O M")X QI'2D-#H%4 O-.[*0'GY:&['T[WC]C@_;D7I3]7ZOGIRV*9]G;:\.:. MO2M01)$!SALIH9+,"Q=!WLI4:9YEJMP/D8>$W>#UX>^3/\O'Y\?=GNGSQ]5T M6:[]V/?1BVA#+I^+=*5N0_% M\O%42$%[+PV &^ASX8& ?O/IP:\#\6 M:?,L;2RTY4G4?WL AB!)//3>,@<,XTKYW3*K\LKHW,]/AX[G3>K1^W+UAU\6 MQ9MY-#N*U5.76G3HW4$CIXF#"#D3YR]%7)S"*IE;J+),L?LQ[K#1O$D-JN8. M6WXK'XKY0Q_KT/Z[ Y74K;<,59RC@'2(5#D^*$:T7H7V8U?S[F?40\:RU_RC MKW)^J.E3',C3]WLVTH,/#D9;8AQ3BDDFO"3* 2H)-L8)2(VO=36BI=GQIK*1 M:F$A X8S#(5"D*=T#%LY(@C'EJV]*]*UEHWT,KB&G8U4028=(8!RZ#B7#')G MJ[$(I,=6'Z1[#IS,1GJ9] =C6MY -E(JF6?0>.,T(%!(2 6H)(L9R;E$-$!> M7\FJ+K*17@;$;6?KBY(V0D"-L1,>2&%]%/]VK)RXL14/[94N%V7KNPR8PZZW4L'[<-.H=L\$1W_WZ.[O>;>=3M MY[7@7U_=WMU.;>_NY:5]""Q*'3O@C*9,2L>!@-44AHF3G9;__;HYF7Z:+)^& MOH%5F[I-:4W+P-Z^+;KWL0G# 6\0*M#7)'& MJ%19B-Z^3FW30!8/O:K5#[T((&VK*<0T,U@+Q071U:X:QDKF:%;]0'NYT:QY M\7FRB0.Y*UCWV-Z^C@W1*!04(VZ%8]0+#[$2$90M!@0XEA.5=G&H_L8H=/.' MNW)U"^N(5*O]3+[7]B5EU8_$\8Y8(A'FC@KB*TP\@#F[VDR#T#S3G4H& 4H0E@8!J2E3'@.[6Y*Y-)GJ-\XKR$,3_$:Q/?VM6\O@H1A Y0%2?("A?I0$[]Q7&F@AN>WC4%[NTKW2W8F9*E>H=: M,0.%,QSH.!M6F!B6E:+CXHL2=Y>N9WA[#5L]_.TV@]D]>/58'*&1&.A4RP!0 M"J$FVD/!+8>8&2-%'?6]!Z\601$2+4+HA%.41IT6:;/1(P*51(Z0D97B[8IT MK06O7@975Y;$FWF$46B4HQE*@%";, MJ /"(:^SDJ,,CY8]\&/1%A8]<^YLO.K)=@%YZJT1"@@FJ5)&*ZXDH=!@P3SF M.=L? ^1=(ZC78])5\KTJ5^:[93$M5_&5;V-/9HO/WS]$^["O=TFX"C M(L7>2@^\H0P*X:E0G"M%%)8^+Y'9S;#B4@07[4BWPQCC(K[KBYH_V.);,5M\ M3<+86N5U(HW/M0Y:0RX\CPZ*4#2EQ&$2,VQX=%J E3@GTFR X3#-LJH].7>V M^U+,XC,_QX[_?;+\HTCZ4)=9D\EZ?R6U&76[7:!T46QSRA0. MT,/HDB[7U0VY#(_^CP\VIR'WC!>G]V\1(L(#1APU",>N4RR D,1&K]-#"FJ9 M+?=#@R(XHY! "GN';/Q@/-:BDJ,B8&2S55>D:^W0X#*X!I[Q0AG!"9040&@4 M,(P"5HU%R[S*&L.C7@\<.)WQXB+I#\8;N8&,%]':B-ZC=4![8J+Y'>T/NY$L M HZ#K*2#P^/UE:SJ(N/%94#TE/'BTDP7V\T$KJ4!BG.*//G38KF.H'^_F,W\8IE^:=9* 8P4S=(L,4 \1O\Q/ZJ3%@U1O3_9E7 M!NR\,@HS+:RGB,1_6EY)6%C5:>!BV_<$AT+6EJK.96+;[6JQC3O_0:";6U?E M?C7TAI>-"]X/O\M'J:S!_*^>?3OGZ[+PR" M(NPUMI"0N))3YM.$M)$N8I+GK#U#W,[JWM(Z]J[@.6-"2F"A M,Q J*[&DE4R)Y3G)BP?GW0^%GNUIRU6@WHJBO$RW*,;WC?JB5$;T6G]N:.?Q;EYR])%M^*Y>1S41FI M[Y;EM$C3W*&3D;J:#W9ZKW/6L3VQ'IG']JUG0 M$!IOH7),<1C=&<7\3OX(+P)4C MQ%B").%>*ZT8J^Y#$)D70C#NG>S>%;$W$MR,,E:#[%T?+^I(,)92FNJ[&>^Y MLYX#X2LT.'(YN>_&Y.7=H$JVR8.;T6%70E8ILP\CC'EL$%..HVK M*'D"+BD*IAX!&\] M8@!H8(&WG D,J*MP<!C\TEL,45[8K>! V$(50C!$BJ MK,$LLM7,Q@!C.0;C"(\%AKFBM8_[#>KCR_FG([5[]=(@*=+2""E M!\8-U3) M*ED!\TCE5(,>X=;^X+4K#]Y>L\NO,P?>,\F_3NHM;,2-"B00)$)CR:E'4FAM MC/&6D@%GDM^_I%75"UB#_"'"JF.?_C@UY64_/*1J.5X09;2PF!F($&0;R5F@ M&1F9*]P5S2[,'=\X3ITM]+N![0I_O\JL^_N\?,HA]A7/#=9H;1TE AL85Q1) MJ=W)"DJ88PP/T 7MG=/M0]0]G?<%F23H%\L?;9Z]"()M'9OXZV,ZOL9!?T_Y MJZ]0@P[[$Z#!F!@*,=&I_B<3+I4\VV"#,1A)\K7!J,]PH>U>[0[[%>[QZVSQ MO2C6L\J[Y^7T2_Q%&EVRWS<46ZV>'S?K9Y;QU-!;@[&$< @]\'&M5IA9)D@E M9\3@R HR]JY"?0/8JTNX&TV4PYX=>2\Z=IAM1#H+%0=4,R4T8=@IJ)(U3;V$ MQ-3*T]"/JSBLHF,:8:N)9#;*SE"JL*)J*T?'++X7';N*=*T5';L,KJY6_NN* MCD%+(,$0 QX[K@"-PN3;L7A+>$ZD]0"IUP,'3A8=NTSZ@SE$OX&B8UYS 1CD MT01R%"&73EG7DF61-69LO+Z255T4';L,B*XH_L*>W5AY9PN/'6T3I$\EWI2C MC%(@((QK$JK&R!W)R5B56KY&^2F9M8OWW1/O%;X)F4ALO"03*Q0\VG2A5?8]KZ4B. ML:]&;-&,W%K%?/+G>"K:_Z93YY -/CC63\KE.F)Q[]AJ MET*RK9CTLR\-T?>(DX:E!#BL&8U<@Y7/"JGR;AQ+;Q^T;"H"MFD,![\DG!KP M/Q:S^)A9^?3]_>2IE2M2]=\>F#.*C0NP,&E"ANE;-0>HFTPQ!6,I?, MW6\^#5*!&H#R)M6GFCAL^:U\*.8/?:Q!^^\.UEAFM?*:X?BWYD8Q5IFU'6"H0]UB80Y;$DT5-' @+.@>(.I7$B""4FI--TW!U, M#MEPOU;YA@3;DZKV'4':J,8J#(W'<;)6F"L*%(N3-X+.V)29D=?*2M')*,\& M? 0 V^X5C"ZZSZN -R@:G0,\K%MP62#?%I/KY%I5\:H?EY%2V2U4M-_ M/Y>K]37K,Z&31UH$1ZS7WENIJ2#"8DW!;GR$@IQ$TL/GS(40+]H0:9^421^C M]W4VS/%LVZ"YP$@#2X@QF%*54L)78^8JJ]CM &F4C7P-)N7(]SRG/G])/)$ M;UGR^4O0Q6SVGV(2[8&E+A=OYM/_/GH(>^+7 7NN$='80ZCI6K&4V/942IV5 MF?Y&F' EC7V:\P8!0BZGGT/IJC%#AD43]-(;T>>9<)=>> MN',V$/G@[P,QD@(&L8KN-M8"*2)(-3;#T<@,E@8P/LV:JZ3:$V-^J1,I=*1) MX(1*CCU02B* TD45A[K4^PYUS1H9W%T%I!$RI%H'NHX9U#^;=8E9.RQ[S M"_[8E1J;_L<;!:F44Y1#)GATP3762L?Y0!L$C2"(U H.:.84)A+4.L5N9Z3OB[@\/1=OYN53.9FI MKU]CS]= ;XK,F>?'YQ1?^*UPGSX5TZ>5B-54,WDIN:71/C]2+6( 2=91UXV=6SV\0'?Q]\VM@2 M,*[TU@CD!.385F.3THPMA*D9G%^G$&A LEVQYGTR7N;%@YLL4\&$U=E=XL,- M@J%"$.R<0(02)05 Q%2C2\,<%V\R$?YA]6M I%T1YO*I^,QR=]T#@[$(1W=! M(0>$%IISXEPEG:BT.?4R![A#T],ZV DVPV7NV37TVD<&X2B#!+'H7?LH$RLL MWNDVIG!DV:3:IE$V:Z]"I2O>VC+V-HIY6NCBZ3]%,=].!G][+A\F\=LW\\UP M=/%IL4R9D-2G".F'Q==RR@ [NZ W\?@ )%1&:FHX]*FXM3'1^5M+3B-*Q,B6 M__8)MN@=HZ[8;2:SZ?,Z*>SO\XCWR8'5YO3U#PV:&PVBV>\%% 00BA37E92( M&5MH5>=,[@R9KOBK'O[UO'I:G[+ZQ?+7XC][VV/+Q3Q^G&[K$)Q)V7O)@@&2+ _^U_-4"P+N;O_QRJG]EQK! MB?D/#UY:P SRAFCJ-70$ ;0S.B3/<=0'>-^_IX6V#+/RX3%^1GS8+- H@%,L8+2,BTX8QHAOQNIUYUFO>\B!U*7Y#@\L3:!0U_G M.7$(&P$5#[;X5$[+4[P[WSAH3XBPAD49&H0$X,[NUBC(44Y [@#=XQZYUS@6 M5]UUW H@2>;=LIB6JQ3W-)\N9HO/WS\4JV1S'.!3O88!2*.9Y1@9)RP B NR MLTB XSE;+6-R8J_G4BLXY/+(QH^SQ=?D0OU6++^5T^*0"7>V35"26V"-IQ9R M;[S&@.T\+T MN5MFC;(G'X)!!7'^.EDNU_(:6_2F80(P9IPQ"C@(4'3XC$)0 M44L]HJ['Z,W]$JZS.*C%!H 7M5KG#[\NTNQT\+_7I(YC+*OZDZ>"Z!I_6-4&Q$S5\>\%DW&<"S$B)!=6.$4*@U&E.WLB" M 1FGZ''QLT\R99T37 ;3+9T3>"^9F_9MTS*]S!WP=, !;&( :T1@8(J3"MQB9,5MC- M +?'![2R-0%'9UL-/\AG"Z6K21TI.+8TA:UQX77D M=9-"[YMB%ZP%O]0(%&OR-0'"5)4 >XV0A)0:05AE$B/K)1[7P>2 UNT>4>Q* M'WZ??RQGL^+AKXBDU?EPLN.- A:(Q4G#<,FCUF-E)*FVH)!$>&2N;#\$6;2$ MQEA"R@@TEEN)G>+"$Q_=-E(M:!AC,+(;5X/@8..H=&;)=\$9"20$B("5;L-&T8K :JU(F)ZAQ@)[V(!C8)""#(-\V5"K. MZHO/\_+_BH=KV?C#@P+SGF%$):+<0"*U=7HG#8I9#CT':% .GYZY"'7&UU=! M@6\_O3JE+N?3\NNL>+,-(OSK@/(4=Z]^:'"82Z%)LN7D9E@)RA^,RZ!"7Q'JD*?"*(0T]JW<4T,Y(]615KE(F MU!=]_[[YLTY>WGH/"-90"8"G2B('H',LF@65!+3%(PL7:8(*KU-RMR'GSK8] M5L7;3V[U5#Y&%^741M[+'P:BG;64<^TP5D0IJ2C8C0:0G.V- ;J6+; F2YY7 M!9[]/I\\/Y31$5V7.B\?HR7V4,Q7Q8,OYY.X6$UFNX"$U?E9)N^!P0(L.=14 MQ=%:9;B/GO!VO @C/K(T&PWRIU.Y7\6S_WVK?U/3/>/!S8JUU56+5'5;!TZ= M4-HK2:74@G+&+:U&XBD=V2VE9AG4DI"[6K3\8EE$*W6SN1N[NV?81Q=@_<_9 M&M,:\UCV,P,"RC*%HS.*J%+<6"U8)2.+?$XB@P$Z7RTLA5V)OKO$:ZLOL>/I MKQ2J]6TR*]97W:.8RFF/(& B$I2D&0E M7V,_!4D[E'Z'NZ[3(NW&)4#?EZL_3$2P?$J?3F^Q'FL5F%<*0J.YAE0Y:JVG MLAIG7$=RUF3^<["L,>%V=X:Y.VRMO]@>;Y2N;CC+B0?0$X8,H.ERSW:4<9 Y M,1[BIZ!08[+M.%&5C\(Y=#AP":LN>5 @UG@&,/$HSL#2"D!QM2&#"/4Y0>/R M)V%:B_*^RO4TB]73:O'I6#Z.6@[H9<\(1$HE.%L7\*+$:NM$I5-QN3=9P;I@ MU#1J6];=S5^K(KXK67][J3SKZ&$L'E-WUPB^79\DQM&\6=N+Y;?BW6PR/^]# M7O&TP!SUV@+F@>31;C#6:%+))7Z7=4#T<^SUMR_USJYY;L/:WA7+]:#J&V=G M6@8G,4?*0<\AUT)!26!E'6"->%8.F'&?"+0CX:X8=2*]PZ4'WI<^*DAAD7:2 M1.N31BE([+2I)&(MRLJ,/.XSA(Y$/JC8E_W[&*]V:<:6ZLP9YAE5S.OHLADN M+&% "H6,89 056L?KZ,]RW/IR@XW"%H"#X%T D(-E8E7P#T.JRIUR+3+LN;;0 MBQ2POQD%PK >_V^'';E0+AJ499N,^'7R&"?O%UT\FJ?DY.^#M, #):.NI+K, MRD)-=34FX-A(BLSE KIH7I37[0INWZA.Y=9Z]:/@!=7:80NTXLX"#H635;^\ MDB.Y*MT0-HN&Q)@%KZX#KZYJ=A#-N%#1\,2&0RDU)U6_,!1L),FM6H/W.C%F MP6OJP+O]4;#8(.,%8L#%T4$C'/*[?LFQA!>V!N]U8LR"U]:!UU;]4L)8QZP0 MZ4" ,PX1J?HE*1I)[%]K\%XGQM["4O3WE"/F3*:G$ZV"T=@+2)GFC*5+9-SQ MRI+%CC@WCLF^87.^><'V1J#4W[,9"4^T"L@;0*UV1&!JI,PAWCATQ-HM/MS!'74V ML\S*DG-G02>36;':AO?]6IQ/.WCP]U$=L6#2$"8IQCB.">/*O2#>D9P[!S?! MH6NA?AT]TH!PNR+.CW4=ZQ8Q_J%)2#<4B;UDJ&U9(YN(Z]6KT*OWG[: MV.KI3Q^'L%C6"1.\XFD!*!8-+HTD=HA 1BPD?"L;BZT9V99-$R0Y4J&P/:%W MYAOMP@!/52:;/Y@O*?'8ZLW\0%*PU24\;>9%P4MB,/)(*B10!! QIBII&JQR M8E8&:$ZW2.%>\*BQ\&W_(_WQ<;(J_N>__A]02P$"% ,4 " "0BZI.HV2> MM5YT 0!;DQ4 #P @ $ 9V@M,C Q.3 S,S$N>&UL4$L! M A0#% @ D(NJ3DQLI%UV#P 5:L \ ( !BW0! &=H M+3(P,3DP,S,Q+GAS9%!+ 0(4 Q0 ( )"+JDZ15HV2)"$ ))F 0 3 M " 2Z$ 0!G:"TR,#$Y,#,S,5]C86PN>&UL4$L! A0#% @ MD(NJ3K!4S!NT0@ @U(# !, ( !@Z4! &=H+3(P,3DP,S,Q M7V1E9BYX;6Q02P$"% ,4 " "0BZI.:NU.)M>Z !_OPD $P M @ %HZ $ 9V@M,C Q.3 S,S%?;&%B+GAM;%!+ 0(4 Q0 ( )"+JDX- MACY,CG$ +^^!0 3 " 7"C @!G:"TR,#$Y,#,S,5]P&UL4$L%!@ & 8 ?@$ "\5 P $! end